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Recombinant AAV Gene Therapy and Delivery for  
Alzheimer’s Disease 
 
Nikisha Christine Carty 
ABSTRACT 
 
 
Alzheimer’s disease (AD), first characterized in the early 20th century, is a 
common form of dementia which can occur as a result of genetic mutations in the 
genes encoding presenilin 1, presenilin 2, or amyloid precursor protein (APP).  
These genetic alterations can accelerate the pathological characteristics of AD, 
including the formation of extracellular neuritic plaques composed of amyloid 
beta peptides and the formation of intracellular neurofibrillary tangles consisting 
of hyperphosphorylated tau protein.  Ultimately, AD results in gross neuron loss 
in the brain which is evidenced clinically as a progressive decline in mental 
capacity.  A strong body of scientific evidence has previously demonstrated that 
the driving factor in the pathogenesis of AD is potentially the accumulation of Aβ 
peptides in the brain.  Thus, reduction of Aβ deposition is a major therapeutic 
strategy in the treatment of AD.  Recently it has been suggested that Aβ 
accumulation in the brain is modulated, not only by Aβ production, but also by its 
degradation.  Several important studies have demonstrated that Aβ degradation 
is modulated by several endogenous zinc metalloproteases shown to have 
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amyloid degrading capabilities.   These endogenous proteases include neprilysin 
(NEP),  endothelin converting enzyme (ECE), insulin degrading enzyme (IDE) 
and matrix metalloprotease 9 (MMP9).  In this investigation we study the effects 
of upregulating expression of several of these proteases through administration 
of recombinant adeno-associated viral vector (rAAV) containing both 
endogenous and synthetic genes for ECE and NEP on amyloid deposition in 
amyloid precursor protein (APP) plus presenilin-1 (PS1) transgenic mice.  rAAV 
administration directly into the brain resulted in increased expression of ECE and 
NEP and a substantial decrease in amyloid pathology.  We were able to 
significantly increase the area of viral distribution by using novel delivery 
methods resulting in increased gene expression and distribution. 
These data support great potential of gene therapy as a method of 
treatment for neurological diseases.  Optimization of gene transfer methods 
aimed at a particular cell type and brain region in the CNS can be accomplished 
using AAV serotype specificity and novel delivery techniques leading to 
successful gene transduction thus providing a promising therapeutic avenue 
through which to treat AD.
 1
 
 
INTRODUCTION 
 
ALZHEIMER’S DISEASE 
 
Alzheimer’s disease (AD) is a debilitating and devastating 
neurodegenerative disorder that leads to a progressive decline in memory, the 
ability to learn and reason, and loss of overall brain function ultimately resulting in 
death.  AD is the most common form of senile dementia (a group of conditions 
that gradually destroy brain cells leading to progressive decline in mental 
capacity) affecting approximately 4.5 million individuals in the United States 
consequently causing a great financial burden on the U.S. economy.  The 
estimated annual costs of caring for individuals with Alzheimer’s disease are at 
least $100 billion, according to the Alzheimer’s Association and the National 
Institute on Aging.  The molecular mechanisms underlying Alzheimer’s disease 
(AD) have been extensively investigated.  AD can occur as a result of genetic 
autosomal-dominant mutations in the genes encoding presenilin 1, presenilin 2, 
or amyloid precursor protein (APP) (Levy et al., 1990), (Goate et al., 1991), 
(Hardy et al., 1992),(Scheuner et al.,1996).  Interestingly, these autosomal 
dominant genetic mutations only account for 1-2% of AD cases which are 
inherited and commonly referred to as early onset Alzheimer’s disease or familial 
AD (FAD)(Fidani and Goate, 1992).  The cause of AD accounting for the majority 
of the cases remains unknown, although Apolipoprotein E4 is a known risk factor. 
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These genetic alterations have been found to accelerate the pathological 
characteristics of AD which include the formation of extracellular amyloid plaques 
and the formation of intracellular neurofibrillary tangles consisting of 
hyperphosphorylated tau.  The accumulation of these amyloid  plaques are not 
only a crucial factor in the pathology of AD (Selkoe, 2001), (Bard et al., 2003), 
but have been argued to contribute to the distinctive clinical symptoms of AD 
such as progressive cognitive decline, loss of memory and decreased mental 
capacity (Cummings et al., 1996a), (Nicoll et al., 2003), (Masliah et al., 2005).  
The genetic mutations that result in AD pathology all cause alterations in the 
normal processing of the amyloid precursor protein (APP) by altering the 
proteolytic cleavage sites which cause the production and release of Aβ peptides 
in the brain.  Accumulation of these peptides leads to the formation of 
extracellular deposits commonly referred to as neuritic plaques (Cummings et al., 
1996b), (Selkoe, 2001).  Another hallmark pathological feature of AD are 
intraneuronal neurofibrillary tangles which can occur independent of the neuritic 
plaque.  The tau aggregates which compose these tangles are nonmembrane 
bound fibers arranged as pairs of helical filaments.  Although the mechanism by 
which neuritic plaques and neurofibrillary tangles can eventually lead to neuron 
loss is debated among researchers, it has been repeatedly demonstrated that 
reducing amyloid deposits in the brain can significantly improve cognitive deficits 
(Janus et al., 2000), (Morgan et al., 2000), (Dodart et al., 2002).  Consequently, 
elucidating novel methods of decreasing or preventing amyloid accumulation has 
been a primary focus in the treatment of Alzheimer’s disease.  
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AMYLOID PRECURSOR PROTEIN (APP) AND PRESENILIN 1 AND 2  
The genetic etiology of AD provides important evidence supporting the 
“Amyloid Cascade Hypothesis” first put forth by John Hardy in 1991 (Hardy and 
Allsop, 1991), (Hardy and Selkoe, 2002).  Specifically, all genetic mutations that 
cause early onset or familial AD alter the production of Aβ in the brain (Kimberly 
et al., 2000).   The amyloid precursor protein (APP) gene was the first AD 
susceptibility gene to be identified (George-Hyslop, 2000).  The βAPP gene 
encodes for a transmembrane glycoprotein that contains 770 amino acids, but 
has several isoforms which vary in length (George-Hyslop, 2000).  The 
extracellular domain of the protein is the critical portion that normally undergoes 
processing through a series of proteolytic cleavages.  These cleavage pathways 
involve an α-secretase, β-secretase, and γ-secretase that give rise to several 
different peptides.   The normal processing of the APP molecule only involves the 
α-secretase cleavage which readily cleaves the βAPP695 isoform of APP 
between the Lys687 and Leu688 residues in the extracellular domain.  This 
cleavage is subsequently followed by a γ-secretase cleavage which yields a 
soluble APP molecule and a smaller P3 fragment.  The abnormal processing of 
APP involves a β-secretase cleavage followed by a γ-secretase cleavage 
yielding Aβ peptide species Aβ1-40 and Aβ1-42 (Selkoe, 1998), (Sinha and 
Lieberburg, 1999), (George-Hyslop, 2000).  Cells that contain the APP mutation 
readily produce larger amounts of the Aβ 1-42 peptide, the pathogenic species 
which is slightly more hydrophobic causing it to aggregate, as opposed to the 
Aβ1-40 species (Wang et al., 1999).  This results in a change in the ratio of the 
 4
particular species which are normally produced by the cell, causing the peptides 
to abnormally accumulate forming plaques which are primarily made up the Aß 1-
42 peptide and deposited within the brain paranchyma (Cummings et al., 1992), 
(Suzuki et al., 1994), (Cummings et al., 1996b), (Skovronsky et al., 1998).  The 
aberrant accumulation of Aβ peptides in the brain has been recognized as an 
essential factor in the pathology of Alzheimer’s disease (AD).  Due to the fact that 
γ-secretase catalyzes the final step in the production of Aβ peptides and because 
it determines the final length of the Aβ peptide variants, understanding this 
protease has become an important target not only in the molecular genetics of 
AD but has emerged as an important target in the development of potential AD 
therapy.    
The continued study of the molecular genetics of AD eventually revealed 
the genes known as presenilin 1 (PS1) and presenilin 2 (PS2) (57 and 55 kDa 
polypeptides, respectively) which were initially discovered in 1995.  The 
presenilins play an integral role in the molecular mechanisms leading to the 
development of Alzheimer’s disease (Anwar et al., 1996), (Hutton et al., 1996), 
(Hutton and Hardy, 1997), (Dewji and Singer, 1998), (Siman et al., 2000).  
Several different functions have been credited to presenilin including a role in 
promoting or reducing a neurons susceptibility to apoptosis, regulating 
intracellular calcium signaling, trafficking of membrane proteins, processing of 
the APP molecule, and involvement in the cleavage of other substrates (Ray et 
al., 1999), (Siman et al., 2000), (Brunkan and Goate, 2005), (Dewji, 2005).  The 
presenilin 1 mutations account for the earliest and most aggressive forms of AD, 
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while presenilin 2 mutations have a later and more variable age of onset 
(George-Hyslop, 2000), (Ishii et al., 2001).  Over one hundred different mutations 
have been reported in the PS1 gene, most of which are missense mutations, and 
approximately 6 mutations found in PS2.  The presenilins have been found to be 
in part expressed at the cell surface with the majority of the protein being 
expressed in the intracellular compartment.  Reports have also indicated that 
PS1 and PS2 are expressed in the endoplasmic reticulum and the golgi 
apparatus as well as in nuclear membranes (Dewji, 2005). Ultimately, the 
presenilin mutations lead to an increased production of cerebral Aβ1-42 peptides 
and a 1.5 to 3 fold increase in Aβ42 containing plaques in human brain tissue of 
FAD human tissue as opposed to sporadic cases of AD (Lamere et al., 1996).   
The finding that presenilin mutations cause specific increases in Aβ1-42 
production lead to the idea that mutant PS must play a role in the modulation of 
γ-secretase activity and are essential for the γ-secretase cleavage of βAPP (Ray 
et al., 1999).  Results from transgenic mouse models with PS mutations and APP 
mutations clearly indicate that PS mutations not only increase production and 
deposition of Aβ species in the brain but also imply that presenilin may act as the 
γ-secretase enzyme or an essential cofactor for the γ-secretase cleavage of 
βAPP (Duff et al., 1996), (Ishii et al., 2001), (Brunkan and Goate, 2005).  Despite 
the breakthrough discovery of genes responsible for early onset AD this accounts 
for only 1-2% of all AD cases and therefore investigation to identify AD 
susceptibility genes have become an area of intense research.    
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TRANSGENIC MOUSE MODELS OF AMYLOID DEPOSITION 
Almost ten years after the discovery of the FAD mutations in the APP 
gene and the introduction of transgenic technology, researchers have used 
knowledge of the numerous mutations on APP, PS1, and PS2 to create murine 
models that have lead to an increased understanding of AD pathogenesis.  The 
first generation of an AD transgenic mouse model was based on the over 
expression of the wild type human (hAPP) cDNAs and in most cases these 
efforts failed to produce mice with the hallmark pathogenicity found in human AD 
cases with the exception of the NSEAPP (APP751) mouse produced by Quon et. 
al. in 1991.  Investigators eventually discovered that the overexpression of the 
hAPP in addition to either the Swedish mutation (APPK670N,M671L) or the London 
mutation (APPV717F) was sufficient to produce enough Aβ peptides to cause 
significant amount of amyloid deposition (Quon et al., 1991), (Higgins and 
Jacobsen, 2003).  This gave rise to the PDAPP mouse first presented by Games 
et. al. in 1995 that contains the London mutation (APPV717F) under control of the 
platelet derived growth factor promoter (PDGF).  The Tg2576 mouse first 
described by Hsiao et. al. in 1996 contains the APP695 isoform with the Swedish 
mutation (APPK670N, M671L) under the prion protein promoter (PrP) which ensures 
high CNS expression (Hsiao et al., 1996, Higgins and Jacobsen, 2003).  These 
mice exhibit a similar positive correlation between increased age and amyloid 
deposition as well as selective distribution of amyloid within specific brain regions 
such as cortex and hippocampus.  
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Another single transgenic mouse model of amyloid deposition (APP23 
mouse) was developed by Novartis and described by Sturchler-Pierrat et. al., in 
1997 and contains the hAPP751 isoform with the Swedish mutation under the 
control of the Thy-1 promotor to enhance neuronal expression.  These mice also 
emulate the PDAPP and Tg2576 mice in their region specific development of 
amyloid deposits but unlike the two previous transgenic models the APP23 
mouse has been shown to demonstrate neurodegeneration in the CA1 region of 
the hippocampus which seems to correlate with increased plaque load (between 
14-18 months of age) (Calhoun et al., 1998), (Higgins and Jacobsen, 2003).  In 
more recent years double transgenic mouse models of AD which express both 
mutant APP and human presenilin with FAD mutations have been successfully 
created (Higgins and Jacobsen, 2003).  These mice have significantly enhanced 
production of the Aβ1-42 peptide and also begin to develop amyloid deposits at a 
much earlier age compared to their single transgenic counterparts (Borchelt et 
al., 1997), (Holcomb et al., 1998).  The PSAPP mouse overexpresses the PS1 
gene with the M146L mutation (Duff et al., 1996) and the Swedish mutation 
(Hsiao et al., 1996) and show significantly increased plaque pathology, beginning 
around 3 months of age, which is associated with gliosis (Holcomb et al., 1998).  
Interestingly, transgenic mice that express only FAD presenilin mutations alone 
show no signs of amyloid deposition (Duff et al., 1996).  The CRND8 transgenic 
model expresses a double mutated form of the APP695 (APPV717F and APPK670N, 
M671L) under the PrP promoter.  This model also results in accelerated plaque 
deposition which is clearly evident at 3 months of age.  PDAPP mice have also 
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been shown to exhibit some behavioral deficits as early as three months of age 
even before the development of amyloid plaque deposits could be detected 
(Higgins and Jacobsen, 2003).  The Tg2576 transgenic model differ from the 
PDAPP animals in that they begin to develop cognitive deficits between 9-10 
months of age and this correlates more closely with the development of amyloid 
deposits in the brain (Hsiao et al., 1996).  In early 2002 Westerman and 
collegues proposed that cognitive deficits more likely are the result of increases 
in soluble forms of Aβ (or small protofibrils of Aβ) rather than plaque deposition 
(Westerman et al., 2002).  More recent reports argue that large Aβ aggregates 
may in fact play a neuroprotective role providing a mehcanims in which smaller 
soluble Aβ moieties are sequestered into larger insoluble aggregates preventing 
them from causing destruction.  Specifically, the soluble oligomeric Aβ 
assemblies have been implicated as the driving factor in AD pathogenisis as they 
exhibit potent toxicity in their capacity to significantly decrease LTP, contribute to 
learning and memory deficits in vivo and induce neuronal cell death in vitro 
(Lambert et al., 1998), (El-Agnaf et al., 2000), (Klein, 2002; Glabe, 2005), 
(Malaplate-Armand et al., 2006), (Townsend et al., 2006), (Cerpa et al., 2008), 
(Varvel et al., 2008) 
 
 
ZINC METALLOPROTEASES/ENDOGENOUS Aβ DEGRADING ENZYMES 
 
In recent years a growing number of endogenous proteases have been 
found to have Aβ degrading capabilities in the brain and other tissues both in vivo 
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and in vitro.  Several of these enzymes are members of zinc metalloprotease 
family and include neprilysin (NEP), insulin degrading enzyme (IDE; insulysin), 
endothelin converting enzymes (ECE-1 and ECE-2), and angiotensin converting 
enzyme (ACE).  Recently, a number of other proteases have been shown to 
degrade Aβ in vitro, including matrix metalloproteases 2, 3, and 9, and, the serine 
protease, plasmin but the degree to which they may be involved in the normal 
catabolism of Aβ remains uncertain (Yan et al., 2006), (Turner and Nalivaeva, 
2007).  Down regulation of these enzymes within the brain could potentially 
contribute to Aβ accumulation and lead to development of AD. 
NEP, a 92-kDa glycosylated ectoenzyme, was originally found as a kidney 
enzyme and is capable of degrading multiple peptide hormones (Iwata et al., 
2000a). Also known as enkephalinase, it is capable of cleaving enkephalins and 
termination of peptidergic neurotransmission.  It is membrane bound and its 
active site is oriented outside the cell.  NEP has a very large range of regulatory 
activity as it is capable of degrading numerous bioactive peptides including opioid 
peptides, tackykinins, substance P, atrial natriuretic peptides, chemotactic 
peptides and adrenocorticotropin hormone (ACTH) (Matsas et al., 1984a), 
(Turner et al., 1996).  NEP is expressed in the CNS and in the periphery 
particularly in epithelial cells of the intestines, kidney and lungs (Fulcher et al., 
1982), (Matsas et al., 1984b), (Kenny et al., 1985).  In the CNS NEP is 
expressed in neurons, mainly pyramidal neurons, and glial cells types (Turner et 
al., 2003).  Therefore, NEP is involved in regulation of several different 
physiological processes, such as cardiovascular activity, cell migration and 
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proliferation, inflammation, and neuropeptide regulation (Turner, 2003).   NEP, is 
a highly conserved protein and the NEP gene in located on chromosome 3 
spaning more the 80 kb (Roques et al., 1993) in humans.   Several homologues 
of NEP have also been identified most of which remain uncharacterized (Turner 
and Nalivaeva, 2007), (Nalivaeva et al., 2008).  Although, one homologue named 
NEP2 (also known as Sep and NL1) has been shown to also degrade Aβ, unlike 
NEP it is expressed only in specific neuronal populations in the brain and in the 
spinal cord.  Furthermore, NEP2 is expressed in a membrane bound form in the 
endoplasmic reticulum and a soluble secreted form but very little is known 
regarding its function or whether it plays a role in Aβ metabolism. 
Iwata et. al., in 2000 first demonstrated the ability of NEP to degrade Aβ 
peptides in the brain parenchyma and also illustrated that suppressing NEP 
would lead to an increase in Aβ deposition (Iwata et al., 2000).  In 2002 Iwata et. 
al.. also demonstrated that NEP activity decreased with age in regions where Aβ 
accumulated such as the cortex and hippocampus, however in areas such as the 
striatum where Aβ did not accumulate NEP was increased (Yasojima et al., 
2001b).  Evidence from transgenic animal models demonstrate that NEP 
deficient mice show a significant increase in amyloid deposition as opposed to 
their wild type counterparts clearly indicating that NEP activity plays a significant 
role in endogenous Aβ degradation (Iwata et al., 2002), (Iwata et al., 2004), (Marr 
et al., 2004).    
Another important Aß degrading enzyme is known as endothelin 
converting enzyme (ECE).  ECE, like NEP is a membrane bound 
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metalloprotease approximately 87 kd in size and exists in several isoforms 
including ECE-1a, ECE-1b, ECE-1c, and ECE-2.  ECE-1 has been found 
localized in the Golgi and vesicles.  Its primary function is to catalyze the 
conversion of big endothelin (big ET) into vasoactive endothelins(Eckman et al., 
2003).  ECE-1 has also been reported to hydrolyse other biologically active 
peptides including bradykinin, neurotensin and substance P.  ECE is a 
homologue protein of NEP, yet an important structural difference between the 
two is that ECE-1 exists as a disulfide linked dimer.  ECE-1 is expressed in 
endothelial cells as well as several other cell types including neurons and glia 
within the brain that are particularly relevant to AD disease pathology.  Although 
several other isoforms of ECE exist, ECE-1c is the predominantly expressed 
mRNA in humans.  Each isoform has distinct subcellular localizations; specifically 
ECE-1a, ECE-1c, and ECE1d are primarily localized at the cell surface, while 
ECE-1b is found in the intracellular compartment.  To date there are no 
significant differences in the catalytic properties of the different isoforms (Turner 
et al., 2004).  The Aβ degrading capabilities of ECE were discovered when 
Eckman et. al. observed that the metalloprotease inhibitor, phosphoramidon, 
caused a rapid accumulation of Aβ in a cell line which expressed ECE and did 
not cause this increase in cells not expressing ECE (Eckman and Eckman, 
2005).  Subsequent studies revealed that when ECE was overexpressed in the 
cell lines the Aβ accumulation was reduced by approximately 90%.  In vivo data 
from ECE (+/-) transgenic mice which show about 27% reductions in ECE-1 
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activity also show significant increases in both Aβ40 and Aβ42 levels in the brain 
(Eckman and Eckman, 2005).   
In addition to NEP and ECE, IDE (insulysin) has been suggested as 
another Aβ degrading enzyme that may play an important role in the dynamic 
process of Aβ degradation in the brain.  Unlike NEP and ECE-1, IDE is primarily 
localized in the cytosol but it can also be located, at low levels, in peroxisomes as 
well as in the plasma membrane and in a secreted form in the extracellular 
compartment (Turner et al., 2004).  IDE is expressed in the human CNS in 
cortical and subcortical neurons as well as in endothelial cells, pericytes and 
smooth muscle cells (Morelli et al., 2004).  In vitro, IDE is capable of degrading a 
variety of substrates including insulin and its role in Aβ degradation in the brain 
was first proposed by Kurochkin et. al., (Kurochkin and Goto, 1994), (Kurochkin, 
2001), (Turner et al., 2004), (Farris et al., 2005).  Several studies support the 
importance of IDE activity in Aβ catabolism, including a correlation study 
presented by Perez et. al. in 2000 revealed that IDE activity which correlated with 
a decrease in soluble Aβ peptide degradation in the AD brain compared to 
normal aged matched control brains (Perez et al., 1999).  Furthermore, in 
transgenic mice with IDE (-/-) deficiencies results in almost a 50% decrease in Aβ 
degradation in not only the brain but in primary neuron cultures as well; while the 
overexpression of IDE significantly reduces brain Aβ levels in APP mice (Farris et 
al., 2003), (Leissring et al., 2003), (Farris et al., 2005).           
The in vivo data from multiple studies involving NEP, ECE, and IDE 
transgenic mice provides clear evidence that the activity of these specific 
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proteases are essential for the regulation of Aβ accumulation in the brain.  
Therefore, the regulation of these proteases through novel methods such as 
gene therapy provides a unique avenue through which novel therapeutic 
treatments can be explored. 
 
GENE THERAPY AND VIRAL VECTORS 
 
Gene therapy has a fairly short and controversial history and was first 
envisioned as a potentially viable scientific tool for the treatment of hereditary 
single-gene defects.  Beginning in the late 1970’s and 80’s gene therapy made 
its unofficial clinical debut with two unapproved clinical trails.  In the first trials, 
two young boys with arginase deficiency syndrome were treated using in vivo 
gene therapy with a wild-type Shope papilloma virus in an effort to replace the 
missing enzyme with the viral arginase.  Another trial involved the use of ex vivo 
gene therapy in which a bone marrow transplant was performed using bone 
marrow treated with a β-globin-containing plasmid in order to treat two patients 
with β-thalassemia.  The results were neither efficacious nor deleterious (Scollay, 
2001).  During the 1990’s the use of gene therapy in approved gene therapy 
trials steadily increased and by the mid 2000 nearly 4000 patients have been 
treated with gene therapy in more than 500 trials (Scollay, 2001).  The majority of 
the trials in the 1990’s were unsuccessful and in 1999 the first published death 
resulting from gene therapy using an adenovirus vector was highly publicized 
lending to a bad public perception of gene therapy and it’s potential as a viable 
therapeutic avenue in the treatment of disease and revealing the need to further 
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understand the viral vector interactions with the human immune system.  
Fortunately, by 2000 the first successful procedures were conducted in three 
individuals suffering from severe combined immunodeficiency (SCID), (Scollay, 
2001).  This progress was the result of improvements in understanding different 
types of viral vectors and in our understanding of genetics and the biology of 
transducing cells.   
  There are several different mechanisms by which gene therapy can be 
achieved and an important factor in the success of the method involves the type 
of vehicle used to delivery the therapeutic gene to the target tissue (Thomas et 
al., 2003).  Viral vectors utilized in the first gene therapy attempts were extremely 
inefficient and did not persist in the host cells and the transgene expression was 
in most cases for a short time.  A thorough understanding of the molecular basis 
of how viruses and viral vectors interact with the host has been a major focal 
point in the area of gene therapy.  As a result over the past few years, several 
vectors have been developed aimed at improved efficiency, specificity, and 
safety which have also resulted in successful treatments (Thomas et al., 2003).  
The diversity of diseases that gene therapy research has aimed at targeting is 
expanding from the initial hereditary single gene defect treatment to include 
acquired diseases such as cancer, cardiovascular disease, infectious disease 
and neurodegenerative disease (Mandel and Burger, 2004).  This means that no 
one vector method will be the most efficacious for all disease categories. Thus 
understanding and utilizing unique characteristics of different viral vector types is 
essential for the success of gene transfer and persistence of the transgene.   
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There are five major categories of viral vectors which can be categorized 
into two main groups (Thomas et al., 2003).  The groups include viruses whose 
genome integrates into the host cellular genome known as oncoretroviruses or 
those which persist apart from the cellular host genome as an episome, or 
extrachomosomal unit, within the cell nucleus.  Retroviruses, such as human T 
cell leukemia virus, sarcoma virus and HIV, are a class of viruses that can create 
double-stranded DNA copies of their RNA genomes. These copies of its genome 
can be integrated into the chromosomes of host cells.  Lentivirus is characterized 
by a long incubation period.  Human immunodeficiency virus (HIV) is an example 
of a lentivirus.  Adenoviruses are a class of viruses with double-stranded DNA 
genomes that cause respiratory, intestinal, and eye infections in humans.  The 
virus that causes the common cold is an adenovirus.  Adeno-associated viruses 
are a class of small non-pathogenic human parvovirus, single-stranded DNA 
viruses that can insert their genetic material which can persist as an episomal 
plasmid.  Finally, herpes simplex viruses are a class of double-stranded DNA 
viruses that infect a particular cell type, specifically neurons.  Herpes simplex 
virus type 1 is a common human pathogen that causes cold sores (Thomas et 
al., 2003).  There are advantages and disadvantages to each type of vector 
which determines it’s suitability for specific treatments.  Particularly, vectors such 
as adeno-associated virus (AAV), adenovirus and herpes virus, which have non-
integrating vectors, usually have a persistent transgene expression only in non 
proliferating cells whereas retroviruses with integrating genomes have persistent 
transgene expression in dividing cells.  The size of the viral vehicle can also be a 
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determining factor mediating the type of gene that can be expressed.  The table 
below, published by Thomas et. al.. in 2003 summarized the advantages and 
disadvantages of the five different viral vectors (Thomas et al., 2003).    
Adeno-associated viruses are members of the parvoviridae family and are 
subsequently a member of the helper virus genus which indicates that they need 
a helper virus, in most cases adenovirus or herpes simplex virus, in order to 
support successful infection and replication.  When the helper virus is absent 
AAVs will generate a latent infection within the cell and in 90% of cases this 
means the AAV genome will persist as an episomal unit (Thomas et al., 2003), 
(Tenenbaum et al., 2004a), (Wu et al., 2006).   
 
 ADENO-ASSOCIATED VIRAL VECTORS AND SEROLOGY 
AAVs are one of the smallest viruses, approximately 25 nm in diameter, 
and their DNA genome is less than 5 kb which contains two large open reading 
frames with inverted terminals repeats located at either end (Samulski et al., 
1982), (Tenenbaum et al., 1994), (Tenenbaum et al., 2004b), (Wu et al., 2006).  
AAVs must accomplish several major steps to achieve successful gene 
expression which include attachment to the cell surface receptors, endocytosis, 
trafficking to the nucleus, uncoating of virus which releases viral genome, and 
finally conversion of the genome to double stranded DNA which is transcribed in 
the nucleus.  The efficiencies of rAAV transduction intricately depend on the 
successful implementation of each step.  AAV vectors arrive in a variety of 
flavors otherwise known as serotypes.  The AAV serotype refers to the efficiency 
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by which the specific AAV can infect a particular cell type through attachment to 
specific cell surface receptors.  A new AAV serotype is defined by the inability of 
an antibody that is reactive to the viral capsid protein of one serotype in 
neutralizing those of another serotype (Choi et al., 2005).  Through the 
modifications to the viral genome and the capsids rAAV can be designed to be 
more efficient at transducing specific cells or tissue types to optimize gene 
therapy (Choi et al., 2005). 
AAV2 serotype was the first to be cloned into bacterial plasmids by 
Samulski et. al. in 1982 and to date it is the most characterized of all the 
serotypes of which a total of 10 have been discovered, and has been shown to 
effectively transducer neurons in the CNS in a number of animal studies 
(Samulski et al., 1982), (Fu et al., 2003), (Burger et al., 2004), (Tenenbaum et al., 
2004b).  AAV5 was originally discovered in a human clinical sample in 1984 as a 
contaminant in adenovirus stock and it contains ITRs (inverted terminal repeats) 
that are not unlike the structures of AAV2 ITRs and is the most divergent of all of 
the serotypes (Choi et al., 2005), (Wu et al., 2006).  AAV1 and AAV3 were also 
initially found as contaminants of simian adenovirus 15, while AAV6 was 
identified as a contaminant of adenovirus type 5 by Rutledge et. al. in 1998.  
AAV7 and AAV8 were originally isolated from rhesus monkey tissue in 2002 by 
Gao et. al..  AAV9, like AAV5, was originally discovered in human tissue, while 
AAV10 and AAV11 are the most recently identified serotypes and initially were 
isolated from cynomolgus monkey tissue in 2004 by Mori et. al. but they are not 
well characterized (Mori et al., 2004), (Wu et al., 2006).    
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The fairly recent identification of different AAV serotypes had advanced 
the study of rAAV vectors which has quickly become a major dominant focus in 
the field of gene therapy.  There are a number of studies aimed at characterizing 
the different AAV serotypes with respect to transduction efficiency, tissue 
tropism, cell surface receptors, intracellular processing, and capsid structure.  
AAV2 vectors are the most extensively characterized and due to their well 
established safety profile and range of infectivity, approximately 20 clinical trails 
have been conducted using the AAV2 vector serotypes in numerous patients 
(Wu et al., 2007).  In order to effectively study transduction efficiencies of 
different serotypes of AAV vectors in different tissue types, scientists have 
utilized the “cross-packaging” strategy which essentially enables an unbiased 
direct comparison of the transduction rates without influence of ITRs on 
transgene expression (Grieger and Samulski, 2005), (Wu et al., 2007).  To 
accomplish this the Cap genes of different serotypes are placed downstream of 
the AAV2 Rep genes which ultimately allows the generation of serotypes specific 
capsids while the packaged genomes within the capsids are identical, these are 
also referred to as hybrid viruses (Rabinowitz et al., 2002), (Rabinowitz et al., 
2004), (Wu et al., 2006).  In addition to transcapsidation first described by 
Rabinowitz et. al. in 2002 there are several other techniques to accomplish the 
formation of a hybrid virus armed with specific modifications to enhance 
efficiency of gene uptake, transfer, and expression in a specified therapeutic 
avenue.  These include absorption modifications where the capsid surface is 
modified to carry a foreign antibody that will bind to the cell surface receptor of 
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interest to increase absorption efficiency.  Mosaic capsids are another method to 
increase transduction efficiency.  This technique involves creating a mixture of 
viral capsid proteins from different serotypes at various ratios in order to combine 
tissue tropisms of interest (Xiao et al., 1999), (Rabinowitz and Samulski, 2000).  
Finally, chimeric capsids can also provide a means of increasing transduction of 
a particular specificity and this technique involves the packaging of capsid 
proteins with foreign peptide sequences, such as a hemagglutinin (HA) tag fused 
at either the N or C terminus of the capsid coding sequence to alter tissue 
tropism (Yang et al., 1999), (Bowles et al., 2003), (Wu et al., 2006).  
Although the data regarding AAV serotype specific tissue tropism is 
subject to different interpretation due to variations in vector titer, promoters, 
transgenes between studies, in general the transduction efficiencies for most of 
the AAV serotypes have been determined.  In the CNS serotype characterization 
studies have revealed that AAV1, and 5 have higher transduction efficiencies 
than AAV2 throughout the all regions and cell types of the CNS (Alisky et al., 
2000), (Burger et al., 2004), (Burger et al., 2005) while AAV4 will efficiently 
transduce specific cell types such as astrocytes within the subventricular zone 
(Davidson et al., 2000), (Weber et al., 2003), (Wu et al., 2006).  Studies by Wolfe 
et. al. also reveal that AAV7, 8, 9 and Rh10 expressing cDNA for lysosomal 
enzyme are also capable of transducing neurons within specific regions in the 
mouse brain.  AAV9 and AAVRh10 appeared to have the highest transduction 
efficiencies and were found to undergo vector genome transport through axonal 
transport pathways (Cearley and Wolfe, 2006).  
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Despite the rapidly growing body of knowledge in the field of AAV vector 
serology there is still much to be done.  In addition to the 10 AAV serotypes that 
have been found over 100 AAV variants have also been discovered and with the 
technological advances in engineering hybrid vectors, including mosaic AAVs, 
chimeric AAVs, absorbtion modifications and transcapsidation AAV vectors 
appear to have a promising future in the field of gene therapy.   
(AAV serotypes 6-11 are not currently commercially available).     
         
 ENHANCING DISTRIBUTION OF GENE PRODUCT 
 
AAV vectors are a novel mean by which transgenes can be delivered to 
potentially treat several types of degenerative brain diseases.  Unfortunately, one 
of the major disadvantages of a single intracranial injection into the brain 
parenchyma using simple diffusion does not allow for efficient uptake of the 
transgene or significant distribution of the AAV macromolecules to significantly 
large areas of the affected regions within the brain.   Convection enhanced 
delivery (CED), first described by Bobo et al in 1994, is a method of delivering 
clinically relevant volumes of therapeutic agents to significantly larger areas of 
the brain in a direct intracranial injection procedure in comparison to simple 
diffusion methods (Bobo et al., 1994).  The CED technique is designed to utilize 
the phenomenon of bulk flow and positive pressure to distribute macromolecules 
to a large area within solid tissue.  The CED technique was originally proposed 
by scientists in the early 1990s as a method of delivering drugs directly to the 
parenchyma that would not normally cross the blood brain barrier and that 
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consisted of large macromolcules too large to diffuse throughout the tissue 
(Raghavan et al., 2006).  Due to the lack of approved drugs that can be directly 
intracranially administered to the brain and the difficulty in predicting methods 
that ensure delivery of the therapeutic agent to its target site in spite of its use in 
clinical trails CED remains an experimental procedure and research of CED 
delivery devices is under current investigation by several researchers 
(Bankiewicz et al., 2000), (Raghavan et al., 2006). 
This CED method has been investigated in gene therapy studies as a way 
to increase the distribution of AAV vectors in the brain.  Studies conducted by 
Bankiewicz et. al. in 2000 revealed that CED can significantly increase in gene 
transfer and distribution of AAV expressing AADC in the striatum of MPTP-
treated monkeys.  The AAV vector was found to be safely distributed throughout 
the entire region of the striatum compared to the simple injection method where 
the distribution was severely limited (Bankiewicz et al., 2000).  Similar results 
were replicated in the rat brain by Cunningham et. al. in 2000 with AAV2 
expressing thymidine kinase (TK) where the CED method showed robust gene 
transfer and increased distribution area within the putamen.  CED injections in 
the striatum were found distributed the AAV-TK throughout the striatum after a 
single injection into this region and TK immunoreactive cells were also found 
outside the striatum, in the globus pallidus, subthalamic nucleus, thalamus, and 
substantia nigra (Hadaczek et al., 2006). 
One of the mechanistic limitations of the CED method as well as the 
simple injection method is the reflux of the injected material from the injection 
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hole upon the removal of the cannula.  In 2005 Krauze et. al. developed a reflux 
free step cannula design which effectively eliminates reflux by placing silicone 
coated tubing within the cannula creating a step that prevents the backflow of 
fluid (Krauze et al., 2005b), (Krauze et al., 2005a).  The optimization of more 
efficient cannula designs coupled with the encouraging results from studies 
showing enhanced gene transfer and distribution emphasizes the therapeutic 
potential of the CED method in helping overcome some of the mechanical 
disadvantages of gene delivery in regards to gene therapy (Krauze et al., 2005a). 
The use of osmotic agents such as mannitol is an addition method that 
can be used to increase the area of distribution of macromolecules throughout 
the CNS.  Mannitol is a blood brain barrier interruptive reagent and is also known 
to temporarily increase vascular pressure subsequently reducing intracranial 
pressure.  High concentrations of mannitol intravenously infused are currently 
used in patients with traumatic brain disease to reduce intracranial pressure.  
This osmotic agent pulls fluid from the CNS by increasing vascular osmotic 
pressure.  Several studies have also shown that with intra-arterial infusion of 
mannitol the blood brain barrier can be opened to enhance the distribution of 
chemotherapeutics throughout the CNS in both rats and humans (Nilaver et al., 
1995), (Rapoport, 2001), (Fu et al., 2003).   
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Short title: rAAV delivery of ECE reduces Aβ in APP + PS1 mice. 
 
 
ABSTRACT 
Reduction of Aβ deposition is a major therapeutic strategy in Alzheimer's 
disease (AD).  The concentration of Aβ in the brain is modulated, not only by Aβ 
production, but also by its degradation.  One protease involved in the 
degradation of Aβ peptides is endothelin converting enzyme (ECE).  In the 
current study, we investigated the effects of an intracranial administration of a 
recombinant adeno-associated viral vector (rAAV) containing the ECE-1 
synthetic gene on amyloid deposition in amyloid precursor protein (APP) plus 
presenilin-1 (PS1) transgenic mice.  The recombinant AAV vector was injected 
unilaterally into the right anterior cortex and hippocampus of six-month-old mice 
while control mice received an AAV vector expressing GFP.  
Immunohistochemistry for the haemagglutinin tag appended to ECE revealed 
strong expression in areas surrounding the injection sites but minimal expression 
in the contralateral regions.  Immunohistochemistry for Aß decreased in the 
anterior cortex and hippocampus of mice receiving ECE synthetic gene.  Further, 
decreases in Congo red positive deposits were also observed in both regions.  
These results indicate that increasing the expression of β-amyloid degrading 
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enzymes through gene therapy is a promising therapeutic avenue through which 
to treat AD. 
 
Key Words: Alzheimer’s disease; Beta Amyloid, Gene Therapy, Viral Vector, 
Amyloid Degrading Enzyme, Zinc Metalloprotease. 
 
 
INTRODUCTION 
AD is the most common form of senile dementia (a group of conditions 
that gradually destroy brain cells leading to progressive decline in mental 
capacity) affecting approximately 4.5 million individuals in the United States.  The 
molecular mechanisms underlying AD have been extensively investigated (Hardy 
and Selkoe, 2002).  Although the mechanism by which neuritic plaques and 
neurofibrillary tangles can eventually lead to neuron loss is debated, it has been 
repeatedly demonstrated that reducing amyloid deposits in the brain can 
significantly improve cognitive deficits in amyloid depositing  transgenic mice 
(Janus et al., 2000),(Morgan et al., 2000),(Westerman et al., 2002),(Wilcock et 
al., 2006).  Consequently, elucidating novel methods of decreasing or preventing 
amyloid accumulation has been a primary focus in the treatment of AD.  
In recent years several endogenous proteases have been found which 
degrade Aβ in the brain and other tissues both in vivo and in vitro.  These zinc 
metalloproteases, include neprilysin (NEP), insulin degrading enzyme (IDE; 
insulysin), and endothelin converting enzymes (ECE-1 and ECE-2).  Other 
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proteases that appear to play a role in Aß metabolism include matrix 
metalloproteinase-9 (Yan et al., 2006), cathepsin B (Mueller-Steiner et al., 2006) 
and plasmin (Turner et al., 2004).  The overall accumulation of Aβ in the brain is 
attributed to an imbalance between its production and degradation/clearance.  
Down-regulation of these degrading enzymes within the brain during aging could 
potentially contribute to Aβ accumulation eventually leading to development of 
AD (Caccamo et al., 2005),(Yasojima et al., 2001).   
Several current studies have implicated ECE as an important enzyme in 
the degradation of Aβ and preventing its accumulation (Eckman and Eckman, 
2005).  ECE is a membrane-bound metalloprotease with an N-terminal cytosolic 
domain and an extracellular catalytic domain.  ECE-1 is expressed in endothelial 
cells in all organs as well as other cell types including neurons, glia and 
neuroendocrine cells.  Two different genes encoding for ECE-1 and ECE-2 have 
been identified, however ECE-1 is predominately expressed.  ECE was 
discovered for its ability to catalyze the conversion of big endothelin into 
vasoactive endothelins (Shimada et al., 1996), (Eckman et al., 2003), (Leissring 
et al., 2002), (Muller et al., 2003),(Hunter and Turner, 2006).  ECE-1 has now 
been reported to hydrolyse other biologically active peptides including bradykinin, 
neurotensin and substance P.  In humans, ECE-1 exists as four different 
isoforms including ECE-1a, ECE-1b, ECE-1c,and ECE-1d (Muller et al., 2003), 
(Hunter and Turner, 2006), (Turner et al., 2004), (Jackson et al., 2006).  
Expression patterns have shown that these isoforms have distinct subcellular 
localizations with slight variations depending on the species and cell type (Muller 
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et al., 2003), (Hunter and Turner, 2006).  To date, there are no significant 
differences reported in the catalytic properties of the different isoforms (Turner et 
al., 2004).  The Aβ degrading capability of ECE was discovered when Eckman 
(Eckman and Eckman, 2005) observed that the ECE inhibitor, phosphoramidon, 
caused a rapid accumulation of Aβ in a cell line expressing ECE but not in cells 
lacking ECE expression.  Subsequent studies revealed that overexpression of 
ECE in cell lines reduced Aβ accumulation by approximately 90%.  In vivo data 
from ECE (+/-) transgenic mice, which show 25% reductions in ECE-1 activity, 
also show significant increases in both Aβ40 and Aβ42 levels in the brain 
(Eckman and Eckman, 2005).  Moreover, intraventricular injections of 
phosphoramidon, increase Aß in wild type and APP transgenic mice (Eckman et 
al., 2006). These studies indicate a clear correlation between ECE-1 activity and 
Aβ load in the brain. 
In the present study we investigated the effects of upregulating the ECE-1 
enzyme by using a rAAV vector, serotype 5, on Aβ load in the brain.  rAAV 
vectors are desirable candidates for gene therapy in the central nervous system 
because AAV is a nonpathogenic virus; it has low immunogenicity and it is 
deficient for replication due to the removal of all the viral encoded genes.  
Further, rAAV vectors have been shown to be very efficient in infecting neuronal 
cells and maintaining long term expression (Burger et al., 2005), (Mandel et al., 
2006).  We observed a significant reduction in the levels of Aβ in the mice 
injected with the ECE virus which shows that this method may offer a promising 
therapeutic avenue through which to treat AD.  
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RESULTS 
The ECE-1 synthetic gene within the rAAV was under the control of the 
hybrid chicken β-actin cytomegalovirus (CBA) promoter and was tagged with 
haemagglutinin (HA) peptide sequence for detection within the brain and 
discrimination from endogenous ECE.  Prior to virus production the rAAV vector 
was tested in HEK 293 cells to evaluate the expression cassette.  Cell lysate and 
conditioned media from transfected and untransfected cells were examined by 
Western blot analysis to determine ECE expression.  Untransfected cell lysate 
and media were negative for ECE-HA protein expression.  ECE-HA protein 
expression was only detected in the cell lyate fraction and not the media (Fig 1b).   
  The rAAV ECE-HA vector was tested for enzyme activity in vivo.  
Nontransgenic mice (n=12) aged 9 months were injected bilaterally into the right 
and left hippocampus.  Group one received the rAAV-ECE-HA treatment and the 
second group served as the control group and received no treatment (n=6 per 
group).  All injections were performed as described in Methods with each site of 
injection receiving a total volume of 2 μl of the vector at a concentration of 1 x 
1012 vg/ml.  Six weeks post injection the animals were sacrificed and frozen 
hippocampal tissue from the animals was homogenized and separated into 
membrane and soluble fractions by centrifugation.  The ECE specific activity was 
determined as the nmole of MOCA/ min/µg protein.  Within the homogenate and 
in the membrane fractions of the homogenized tissue, animals receiving the ECE 
treatment had significantly higher ECE-like specific activity than the control 
animals (Fig 2). Error bars indicate ± standard error of the mean value from 
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triplicates for each sample (specific activity/min/μg protein) for each treatment 
group (n=6 per group). 
  rAAV was initially injected unilaterally into the right hippocampus and right 
anterior cortical regions of six month old APP + PS1 mice.  Each injection site 
received 2μl volume and a concentration of 1 x 1012 vg/ml of material at a flow 
rate of 0.5 μl/min.  The expression of ECE was evaluated six weeks following 
treatment.  Immunostaining of the tissue with an anti-HA antibody revealed ECE-
HA expression in most animals.  The expression patterns for the ECE protein 
were confined to the areas surrounding the injection site.  ECE-HA was detected 
in CA4 neurons in the hilus and CA3 neurons of the hippocampus pyramidal cell 
layer.  In the dentate molecular layer, a number of round cells, possibly, 
oligodendrocytes or astrocytes also expressed the label (Fig. 3b).  In animals 
receiving the rAAV-GFP control vector there was no positive HA staining in the 
hippocampus, but the GFP expression pattern was comparable to that of the 
ECE vector (Fig 4).  In animals receiving the rAAV expressing ECE-HA there 
were low levels of positive staining in the contra-lateral dentate gyrus (Fig. 3a). 
When the cortical regions were analyzed for expression, there was a large 
amount of ECE-HA expression which was also detected over a larger area of the 
cortex.  ECE positive expression was concentrated in the anterior cortex (Fig 3c), 
but was observed also in the striatum, corpus callosum and septum along the 
midline (Fig 3d) in the ipsilateral and contralateral hemispheres.  In animals 
receiving rAAV-GFP, GFP was detected in a similar expression patterns as ECE-
HA.   GFP positive cells were limited to the areas immediately surrounding the 
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injection site in both the cortex and the hippocampus and no GFP positive cells 
were seen in the contralateral hemisphere (Fig. 4b, 4d and 4f respectively).  This 
data suggests that the rAAV vector serotype 5 is effective at transducing 
neuronal cell types in vivo and expressing significant amounts of recombinant 
ECE-1.    
Our next goal was to evaluate the effects of a single intracranial 
administration of the rAAV-ECE-HA vector in APP + PS1 transgenic mice, to 
determine the effect of over expression of the ECE protein on amyloid deposition.  
rAAV was injected unilaterally into the right anterior cortex and hippocampus of 
six month old mice while the left untreated hemisphere.  The control group was 
treated with rAAV containing GFP.  Total Aβ load was ascertained six weeks 
after intracranial injections by immunohistochemical methods using a polyclonal 
anti-Aβ antiserum which primarily recognizes the N-terminal domain of Aß, and 
thus labels both Aβ1-40 and Aβ1-42 (gift of Gottschall, PE, Univ of Arkansas).   The 
regional Aβ distribution and density in APP + PS1 transgenic mice were similar to 
those reported by Gordon et al. (Gordon et al., 2002).  Immunohistochemistry 
revealed darkly stained compact plaques and more lightly stained diffuse plaque 
deposits in the APP + PS1 animal tissue.  Plaque deposition was distributed 
throughout the cortical regions as well as in the hippocampus (although most 
concentrated in the molecular layers of the dentate gyrus and the CA1 region, 
surrounding the hippocampal fissure).  Animals injected with the control rAAV-
GFP showed Aβ immunohistochemical staining patterns throughout the cortex 
and hippocampus comparable to those of untreated APP + PS1 transgenic mice 
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of the same age (Fig 5a and 5b).  A notable decrease in the amount of 
hippocampal Aβ staining was observed in animals injected with the rAAV 
expressing ECE-HA six weeks after the time of injection when compared to 
animals injected with the control rAAV-GFP vector (Fig. 5c, 5d).  The reductions 
in Aβ deposition were limited to the areas surrounding the cortical and 
hippocampal injection sites.  ANOVA analysis of total Aß was significantly 
decreased by 50% in mice receiving rAAV-ECE-HA in both the hippocampus and 
the anterior cortex (Fig. 5e).    
Congophilic plaque load was also analyzed following intracranial injections 
of rAAV-ECE-HA vector.  The area of congophilic labeling was substantially less 
than Aβ immunochemistry, staining only compacted fibrillar Aβ deposits, as 
expected (Gordon et al., 2002).   Figures 6c and 6d indicate that the positive 
congophilic staining for the mice receiving the ECE vector was visibly less, 
especially in the hippocampus, compared to the control animals.  The reductions 
in congophilic deposition were limited to the site of injection in cortex and 
hippocampus.  Quantification of the Congo red staining by ANOVA analysis 
revealed that animals receiving the rAAV expressing ECE-HA  showed significant 
reductions in the hippocampus (62%) as well as significant reductions in the 
anterior cortex (46%; Fig 6e).   
 
DISCUSSION 
There have been several gene therapy approaches examined for the 
treatment of Alzheimer’s disease. Initial experiments were based on the 
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observation that application of neuronal growth factors mediated neuroprotection 
and reduced the loss of cholinergic neurons in experimental lesion models (Hefti 
and Weiner, 1986);(Williams et al., 1986).  Therefore,  NGF (nerve growth factor) 
genes have been delivered to the brain using  recombinant viral vectors, such as 
AAV and lentivirus, or delivered via an ex vivo approach, with transformed 
fibroblasts or neuronal stem cells (Tuszynski, 2007),(Cenciarelli et al., 2006). 
These studies have shown rescue of cholinergic neurons and are being further 
examined as a potential therapy. However, it is unlikely that NGF would cure AD 
because the widespread neuronal loss that occurs in the later stages of the 
disease would not be compensated by the early rescue of cholinergic neurons. 
NGF rescue of neurons is currently being examined in clinical trials because it 
offers a substantial decline in the rate of neuronal loss and could slow the 
progression of symptoms of Alzheimer’s.   Other growth factors that are also of 
potential interest in AD include brain-derived neurotrophic factor and 
neurotrophin-4/5 to address the neuronal loss in the cortex and hippocampus.  
A second approach to treat Alzheimer’s pathology involves the reduction 
of Aβ through immunization. It was observed that immunization against Aβ would 
result in a significant reduction in Aβ deposits and improve learning and memory 
deficits (Morgan et al., 2000),(Janus et al., 2000).  Peripheral passive 
immunization against Aβ with antibody injections has been successful in mouse 
models and more recently viral vectors have been used as a gene therapy 
approach to deliver Aβ antibodies (Fukuchi et al., 2006), (Levites et al., 2006). 
This approach has demonstrated some promising reduction (25-50%) in the 
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levels of Aβ deposition.  AAV vectors have also been used as an Aβ vaccine, 
with the over expression of Abeta42. This method has shown reduction in Aβ 
deposition and some reduction in cognitive impairment in Alzheimer Tg mice 
(Mouri et al., 2007), (Hara et al., 2004), (Zhang et al., 2003).  
It has been demonstrated that the apolipoprotein E (apoE) gene is a major 
risk factor for late-onset AD with the ApoE2 allele decreasing and the ApoE4 
allele increasing the morbid risk for developing AD. Therefore to develop a gene 
therapy approach to Alzheimer’s, Dodart et al. (2005) over expressed ApoE2 
using a lentiviral vector. The authors observed a dramatically reduced 
hippocampal Aβ burden in Tg mice. It is as yet unclear how ApoE2 is reducing 
the Aβ but it may be increasing the Aβ clearance (Dodart et al., 2005).  
A final gene therapy approach for the treatment of Alzheimer’s has been 
the over expression of Aβ degrading enzymes such as neprilysin.  Either using a 
direct transduction of neurons using a viral vector or an ex vivo approach with 
transformed fibroblasts, the increase in NEP expression has been shown to 
significantly reduce the overall Aβ load on Alzheimer Tg mice (Marr et al., 2003), 
(Iwata et al., 2004),(Hong et al., 2006), (Hemming et al., 2007).  In this report we 
are examining another Aβ degrading enzyme, ECE, for its ability to reduce the 
Aβ load on Alzheimer APP + PS1 mice using rAAV for increased neuronal 
expression of ECE.   
Recombinant AAV has become widely used for the transduction of 
neuronal cells. AAV is nonpathogenic, has low immunogenicity, lacks all viral 
genes and is capable of long term expression in neurons. This makes rAAV a 
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good candidate for the use as a gene therapy vector for neurological disorders 
(Mandel et al., 2006), (Burger et al., 2005). Further, rAAV is currently being 
examined in a number of neurological clinical trials (Mandel and Burger, 2004). 
Here we are using rAAV for the over expression of the ECE protease which had 
been previously shown to cleave Aβ peptide (Eckman and Eckman, 2005). We 
believed that the over expression of ECE using rAAV would enable the clearance 
of Aβ deposition within the mouse brain and ameliorate the pathogenesis of 
Alzheimer’s.  
rAAV serotype-5 ECE-HA vector was injected unilaterally into the mouse 
hippocampus and anterior cortex.  Examination of the expression profile of the 
expressed ECE has shown that the rAAV of ECE can transduce several different 
neuronal cell types within the mouse brain, and possible other cell types in the 
dentate molecular layer. This is consistent with the previously published 
serological specificity of this vector (Alisky et al., 2000), (Burger et al., 
2004),(Choi et al., 2005).  The expression profile of ECE was similar to that 
observed with our rAAV5 vector expressing GFP. 
No noticeable toxic effects were seen in mice receiving the ECE-HA 
vector compared to control animals.  No neuron loss or gross morphometric 
changes were observed in fixed brain tissue nor were there any signs of general 
toxicity as evidence by abnormal behavior in the mice.  Only one animal died 
throughout the course of the study but this did not appear to be a result of toxicity 
from the over expression of the ECE protein. All animals were weighed before 
treatment and immediately before sacrifice and no significant changes in weight 
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were noted indicating that up regulation of ECE does not appear to have adverse 
effects or cause general toxicity in the mouse model, yet further investigation 
must be done to confirm its safety profile.  ECE has many endogenous peptides 
including opioid peptides, tachykinin, atrial naturetic peptides, and other small 
regulatory vasoactive peptides.  It is uncertain whether interactions between 
other potential substrates in the brain may limit the ability of ECE to degrade Aβ 
or cause potential problems by reducing the levels of these other peptides.  
Previous studies have revealed that in the AD brain as well as in the animal 
model of AD, ECE (in addition to other Aβ degrading enzymes) are down 
regulated specifically in areas that are prone to plaque formation (Iwata et al., 
2002), (Yono et al., 2004).  Therefore, up-regulation of ECE to restore normal 
levels of this endogenous protease should have minimal adverse effects.  In 
addition, ECE has been shown to have higher affinity for larger peptides such as 
bradykinin, substance P, and neurotensin, hydrolyzing them at amino acid 
hydrophobic residues (Johnson et al., 1999), (Lo et al., 1999).  Monitoring 
changes in these peptides between control and treatment groups may help 
identify other potential toxic effects resulting from increases in ECE that could 
occur in this model.  
Our results from the over expression of ECE suggest that the up-
regulation of ECE through rAAV vectors can provide a viable method to decrease 
total amyloid deposition in the brain. The activity level determined using an ECE 
specific assay demonstrated that we achieved a several fold fold increase in ECE 
activity in homogenates, most of which was membrane associated. This increase 
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in ECE activity was able to significantly reduce total Aβ deposition in the anterior 
cortex and hippocampal sites of injection (Fig. 5).  Similarly, when Congo red 
stained compacted deposits were measured; the ECE-HA vector significantly 
reduced staining (Fig. 6).  We were able to achieve a 50% reduction in the total 
Aβ present in the cortex and hippocampal regions.  Similarly, we reduced the 
congophilic compact plaque load to ~50% of that of the controls.  We have yet to 
determine if this reduction in the Aβ levels in the mice with the ECE will lead to 
significant improvement in behavioral tests such as the Morris water maze. We 
are currently testing more injections of ECE to see if we can create a significant 
reduction of whole brain Aβ levels and ameliorate the memory deficits that are 
observed in the APP + PS1 mice.  Our data are consistent with reports that ECE 
can degrade Aß in vitro, and that partial knockdown of the ECE gene leads to 
more rapid accumulation of Aß (Eckman et al., 2001), (Eckman et al., 2003).  
The present work adds to the evidence that ECE plays an important role in Aß 
deposition by demonstrating that local over expression of the enzyme activity can 
dramatically reduce the deposition of amyloid in the brains of APP + PS1 
transgenic mice.  Thus, regulation of ECE may be used as therapeutic target for 
the treatment of Alzheimer's disease.  
 
MATERIALS AND METHODS 
Generation of ECE Constructs and rAAV Production  
The ECE-1 coding sequence (GI:4503442) was cloned using polymerase chain 
reaction (PCR) from a GenePool cDNA library obtained from Invitrogen. The 
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primers used for the full length ECE were 
GAGGAATTCACCGGTCCACCATGCGGGGCGTGTGGCCGCCCCCGGTGTC 
and GAGATCGATTACCAGACTTCACACTTGTGAGGCGG.  The PCR product 
was cloned into pBluescript and sequenced to confirm sequence identity.  The 
ECE was then cloned into the vector called pTR5-MCS at the Eco RI and Cla I 
cloning sites. This vector contains the AAV terminal repeats for AAV virus 
production and the CBA promoter for ECE mRNA transcription. A Hemagglutinin 
(HA) tag was added to the C-terminus of ECE synthetic gene using the following 
oligonucleotide 
GTGTGAAGTCTGGATGGCTTCTAGCTATCTTATGACGTGCCTGACTATGCCA
TGTAA and its complement.  The recombinant viruses were generated and 
purified using the method of Zolotukhin et al. (2002). Infectious rAAV particles 
are expressed as vector genomes (v/g)/mL. Vector genomes were quantitated 
using the dot plot protocol, with a probe for the CBA promoter, as described by 
(Zolotukhin et al., 2002).  
Western Blot Analysis 
Protein samples were boiled in Lamaelli sample buffer prior to loading on a 10% 
polyacrylamide gel. The proteins on the gel were transferred to Millipore 
Nitrocellulose membrane and probed with anti-HA antibody (Santa Cruz) and 
antimouse-HRP conjugate (Amersham). Millipore Immobilon detection reagent 
was used to visualize bands. 
Transgenic Mice 
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APP + PS1 mice (Holcomb et al., 1998) were acquired from the breeding 
colonies at the University of South Florida.  Multiple mice were housed together 
whenever possible until the time of the experiment. Mice were then singly- 
housed 1 week before surgical procedures until the time of sacrifice.  Study 
animals were given water and food ad libitum and maintained on a twelve hour 
light/dark cycle and standard vivarium conditions.  Two cohorts of mice were 
used, the first cohort consisted of APP + PS1 mice aged 6 months (n =16) and 
the second cohort consisted of nontransgenic mice aged 9 months (n =12).  
Animals in each cohort were assigned to two groups.  Group one received a 
control vector expressing GFP (first cohort n=8; second cohort n=6).  Group two 
received AAV vector expressing the membrane bound endothelin converting 
enzyme sequence (first cohort n =8; second cohort n=6).  All groups were 
sacrificed after six weeks post intracranial injection.   
Surgical Procedure 
Immediately before surgery mice were weighed then anesthetized using 
isoflurane.  Surgery was performed using a stereotaxic apparatus.  The cranium 
was exposed using an incision through the skin along the median sagittal plane, 
and two holes were drilled through the cranium over the right cortex injection site 
and the right hippocampal injection site.  Previously determined coordinates for 
burr holes, taken from bregma were as follows; frontal cortex, anteroposterior, -
1.5 mm; lateral, -2.0 mm, vertical, 3.0 mm, hippocampus, anteroposterior, -
2.7mm; lateral -2.5 mm, vertical, 3.0 mm.  Burr holes were drilled using a dental 
drill bit (SSW HP-3, SSWhite Burs Inc., Lakewood, NJ).  Injections of 2 μl of total 
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volume of each of the viral vectors in sterile PBS at a concentration of 1 X 1012 
vg/ml were dispensed into hippocampus and cortex over a period of 4 min using 
a 26 gauge needle attached to a 10 μl syringe (Hamilton Co., Reno, NV).  The 
incision was then cleaned and closed with surgical staples.  Animals were 
recovered within 10 minutes and housed singly until time of sacrifice. 
Immunohistochemistry  
Six weeks post surgery, mice were weighed, overdosed with pentobarbital 
(200 mg/kg;) and perfused with 25 ml of 0.9% normal saline solution then 50 ml 
of freshly prepared 4% paraformaldehyde.  Brains were collected from the 
animals immediately following perfusion and immersion fixed in 4% 
paraformaldehyde for 24 h.  Mouse brains were cryoprotected in successive 
incubations in 10%, 20%, 30% solutions of sucrose; 24 h in each solution.   
Subsequently, brains were frozen on a cold stage and sectioned in the horizontal 
plane (25 μm thickness) on a sliding microtome and stored in Dulbecco’s 
phosphate buffered saline (DPBS) with 0.2% sodium azide solution at 4 ˚C. 
Six sections 100 μm apart spanning the site of injection were chosen and 
free-floating immunochemical and histological analysis was performed to 
determine ECE expression using anti-HA biotinylated rabbit polyclonal antibody 
at a concentration of 1:1000 (Roche, Indianapolis, IN), total Aβ using a rabbit 
primary anti-Aß serum at a concentration 1:10,000 and a secondary anti-rabbit 
antibody (Serotec, Raleigh, NC).  Another series of sections were mounted on 
slides and stained with Congo red to assess compact congophilic positive plaque 
load.  Immunohistochemical procedural methods are analogous to those 
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described by Gordon et al. 2002, for each marker.  Six to eight sections from 
each animal were placed in multisample staining tray and endogenous 
peroxidase was blocked (10% methanol, 3% H202, in PBS).  Tissue samples were 
permeabilized (with 0.2% lysine, 1% Triton X-100 in PBS solution), and 
incubated overnight in appropriate primary antibody.  Sections were washed in 
PBS then incubated in corresponding biotinylated secondary antibody (Vector 
Laboratories, Burlingame, CA).  The tissue was again washed after a 2 h 
incubation period and then incubated with Vectastin® Elite® ABC kit (Vector 
Laboratories, Burlingame, CA) for enzyme conjugation.  Finally, sections were 
stained using 0.05% diaminobenzidine and 0.3% H202.  For anti-HA 0.5% 
nickelous ammonium sulfate was added for color enhancement.  Tissue sections 
were then mounted onto slides, dehydrated, and cover slipped.  Each 
immunochemical assay omitted some sections from primary antibody incubation 
period to evaluate nonspecific reaction of the secondary antibody.  
Congo red histology was performed using sections that were premounted 
on slides then air dried for a minimum of 24 hours.  The sections were rehydrated 
for 30 seconds before beginning staining protocol.  For Congo red, hydrated 
sections were incubated in an freshly prepared alkaline alcoholic saturated 
sodium chloride solution (2.5mM NaOH in 80% alcohol) for 20 min, then 
incubated in 0.2% congo red in alkaline alcoholic saturated sodium chloride 
solution for 30 minutes.  Slides with sections were rinsed through three changes 
of 100% ethanol, and cleared through three changes of xylene and finally 
coverslipped with DPX.  Histological sections from control animals treated with 
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rAAV expressing GFP were mounted on slides and dehydrated through a series 
of increasing concentrations of ethanol.  The mounted sections were then 
cleared in three changes of histoclear and coverslipped with DPX.   
Stained sections were imaged using an Evolution MP digital camera 
mounted on an Olympus BX51 microscope at 100X final magnification (10 X 
objective).  Six horizontal brain sections (100µm apart; every 4th section) were 
taken from each animal and four nonoverlapping images near the site of injection 
from each of these sections were captured (24 measurements per mouse).  All 
images were taken from the same location in all animals.  Quantification of 
positive staining product surrounding and including the injection sites in the right 
anterior cortex and the right hippocampus and the corresponding regions in the 
left hemisphere were determined using Image-Pro® Plus (Media Cybernetics®, 
Silver Springs, MD).  Quantifications of the right regions, ispilateral to the 
injection site, were calculated and ANOVA statistical analysis was performed 
using StatView® version 5.0.1 (SAS Institute, Raleigh, NC).   
Enzyme Activity Assay 
ECE activity was characterized and adapted from a previous fluorometric 
assay method (Johnson and Ahn, 2000) for a 96 well plate format with slight 
modifications. Six weeks post injection brain tissue was removed then dissected 
immediately following sacrifice and frozen at -80 ºC.  The tissue from each 
animal was rapidly thawed and homogenized with the Ultra-Turrax T8 motor- 
driven homogenizer (IKA-Labortechnik, Germany)  in solubilizing buffer 
containing 20 mM Tris-HCl, pH 7.4, 250 mM sucrose immediately prior to 
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assaying (Iwata et al., 2002).  Samples were then centrifuged at 100,000 x g, 4 
ºC for 45 min using an Avanti J-30I Centrifuge (Beckman Instruments, Inc., Palo 
Alto, CA) to obtain a soluble fraction and a membrane fraction.  The membrane 
fraction was resuspended in buffer containing 20 mM Tris-HCl, 250 mM sucrose, 
pH 7.4.  Protein concentration was determined from the homogenate, membrane 
fraction and soluble fractions from each sample using a general BCA assay 
(Pierce).  Aliquots of the cell lysate (5 μg) were incubated with 10 μM (final) of 
the fluorogenic peptide (MOCA- Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-
OH), (R&D Systems) in MES buffer (sodium phosphate pH 6.8 containing 0.1M 
NaCl).  MOCA- Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH  is efficiently 
quenched by resonance energy transfer to the dinitrophenyl group and the 
continuous fluorescent intensity is increased upon internal cleavage of the 
peptide (ECE-1 cleavage between the Ala-Phe bond). The increased 
fluorescence produced from cleavage of the substrate was measured using a 
Molecular Devices fMax spectrofluorometer plate reader (MDS Analytical 
Technologies, Sunnyvale, CA) with a 60 min time point to normalize independent 
experiments.  A standard curve of (7-methoxycoumarin-4-yl) acetyl (MOCA) was 
analyzed along with each assay and used to convert the relative fluorescence 
units (RFU) to the moles of MOCA produced by the respective cell lysates.  
Parallel assay reactions of all samples (in triplicate) were carried out in the 
presence of an ECE specific inhibitor (SM19712, Sigma Aldrich) at a 
concentration of 20 μM (Umekawa et al., 2000), (Matsumura et al., 2000).  ECE 
specific activity was considered to be the difference in RFU between samples 
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including SM19712 from the total activity samples (no SM19712).  Values were 
calculated and expressed as nanomoles MCA/min/μg protein. 
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FIGURE 1: (A) DIAGRAM OF ECE CONSTRUCT AND (B) WESTERN 
ANALYSIS OF ECE EXPRESSION IN HEK 293 CELLS. (A) Diagrammatic 
representation of the rAAV construct expressing the ECE synthetic gene under 
the control of the chicken β-actin (CBA) promoter. (B) Western analysis of ECE 
expressed in 293 cells using an anti-HA antibody. Lane 1, 293 cell lysate; lane 2, 
ECE transfected cell lysate, lane 3, conditioned media from untransfected cells, 
lane 4 media from cells transfected with ECE. 
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FIGURE 2: ECE ENZYMATIC ACTIVITY OBTAINED FROM MOUSE 
HIPPOCAMPAL REGIONS AFTER INJECTION OF rAAV VIRUS 
EXPRESSING ECE PROTEIN. ECE-like specific activity is higher in the 
membrane fraction and homogenate of the hippocampal tissue in the ECE 
treatment group compared to the control group.  The star (*) indicates 
significance with a p-value < 0.05.  Error bars indicate ± standard error of the 
mean value from triplicates for each sample (specific activity/min/μg protein) for 
each treatment group (n=6 per group). 
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FIGURE 3: EXAMINATION OF ECE EXPRESSION USING ANTI-HA 
IMMUNOREACTIVITY IN THE HIPPOCAMPUS AND ANTERIOR CORTEX. 
Panel A shows slight ECE expression in granule cells of the dentate gyrus of the 
left contra lateral hippocampus following intracranial administration of ECE into 
the right hippocampus. Panel B shows strong ECE expression detected at the 
site of vector injection.   Panel C shows strong ECE expression in the anterior 
cortex.  Panel D shows slight ECE expression along the midline and some 
expression in the lateral septum of left (contra lateral) side following intracranial 
administration of ECE into the right anterior cortex.  fi = fimbtria; LS = lateral 
septum; CC = corpus callosum;  dg = dentate gyrus; CA1 = Cajal Area 1; CA3 = 
Cajal area 3; Magnification = 40X and Scale bar = 120 μm 
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FIGURE 4: ECE AND GFP EXPRESSION PROFILES IN MICE BRAINS 
FOLLOWING rAAV ADMINISTRATION.  Panels A shows strong ECE 
expression in the right anterior cortex following intracranial administration of ECE 
vector.  Panel B shows GFP expression in the anterior cortex following 
intracranial administration of control GFP vector.  Panel C shows ECE 
expression in pyramidal cells in CA2 region of the right hippocampus.  Panel D 
shows GFP expression in the CA3 region of the hippocampus.  Panel E shows 
slight ECE expression in CA4 neurons of the dentate gyrus of the left contra 
lateral hippocampus.  Panel F shows no positive expression in the left uninjected 
hippocampus following intracranial injection of GFP vector into the right 
hippocampus. Scale bar = 50μm (panels A, C, E). Scale bar = 25 μm (panels B, 
D, F). 
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FIGURE 5: TOTAL AMYLOID LOAD IS REDUCED FOLLOWING 
INTRACRANIAL ADMINISTRATION OF rAAV-ECE-HA VECTOR.  Panels A 
and B show Aβ immunostaining in the right cortex and hippocampus respectively 
of animals receiving intracranial injection of control vector, GFP.  Panels C and D 
show Aβ immunostaining in right cortex and hippocampal regions respectively of 
mice receiving intracranial injection of ECE.  Scale bar = 120μm. Panel G shows 
the percent area of positive staining, normalized to the control, for both cortex 
(left) and hippocampus (right) after AAV-ECE injection. The asterisk (*) indicates 
significant reduction compared with control values with p-values < 0.05.  
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FIGURE 6: CONGOPHILIC COMPACT PLAQUE LOAD IS REDUCED 
FOLLOWING INTRACRANIAL ADMINISTRATION OF ECE-HA rAAV 
VECTOR. Panels A and B show total congophilic staining in the right cortex and 
hippocampus respectively of animals receiving intracranial injection of control 
vector, GFP. Panels C and D show congophilic positive staining in right cortex 
and hippocampal regions respectively of mice receiving intracranial injection of 
ECE. Magnification = 40X, scale bar = 120μm.  Panel E shows the percent area 
of positive staining, normalized to the control, for the cortical (right) and 
hippocampal (left) injected regions.  The star (*) indicates significance with a p-
value < 0.05. 
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ABSTRACT 
      The accumulation of β-amyloid (Aß) peptides in the brain has been 
recognized as an instigating factor in Alzheimer’s disease (AD) pathology.  
Recently, it has been argued that clearance of Aβ is partially dependent upon 
several endogenous zinc metalloproteases.  Gene therapy using adeno-
associated viral (AAV) vectors are an effective means of delivering transgenes 
encoding for these specific proteases which include neprilysin, endothelin 
converting enzyme, and insulin degrading enzyme to regions in the brain affected 
by AD pathology.  In this study the convection enhanced delivery method using 
the step-design cannula (Bankiewicz, 2005) was used to deliver recombinant 
AAV (rAAV) vectors expressing either a native, membrane bound form of human 
neprilysin gene (NEP-n) or an engineered, secreted form of the neprilysin  gene 
(NEP-s) into the right hippocampus and right frontal cortical regions of the mouse 
brain. The control group was treated with an rAAV vector expressing a mutant 
neprilysin gene (NEP-m) with a single amino acid substitution in the active site 
rendering it inactive. Six weeks after injection, immunohistochemistry for NEP 
revealed strong expression throughout the hippocampus in animals treated with 
the NEP-n and NEP-m vectors.  Animals treated with the NEP-s showed 
expression in a smaller portion of the hippocampus compared to the NEP-n 
treated group.  Immunohistochemistry for total Aß was significantly decreased in 
animals receiving the NEP-n and NEP-s viral vectors when compared to control 
animals in both the hippocampus and cortex.  Congo red staining followed a 
similar trend revealing significant decreases in the hippocampal fissure and CA1 
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regions and the cortex for NEP-n and NEP-s treatment groups compared to mice 
given control treatments.  These data suggest that increasing the expression of 
certain endogenous β-amyloid degrading enzymes through gene therapy using 
the CED step cannula provides and efficient means of increasing transgene 
distribution and ultimately may provide a promising therapeutic avenue through 
which to treat AD. 
 
 
INTRODUCTION 
Alzheimer’s disease (AD) is the most common form of senile dementia 
that can occur sporadically or as a result of genetic mutations in the genes 
encoding presenilin 1, presenilin 2, or amyloid precursor protein (APP).  These 
mutations result in the overproduction of Aß peptides which ultimately lead to the 
formation of extracellular amyloid plaques and intracellular neurofibrillary tangles 
consisting of hyperphosphorylated tau.  The AD cases with these autosomal 
dominant mutations, commonly referred to as early onset AD or familial AD 
(FAD) (Fidani and Goate1992), account for only 1-2% of all AD cases. 
Interestingly, the more common late onset AD cases do not seem to over 
produce Aβ peptide species suggesting that there is a deficit in the clearance 
mechanisms which are normally involved in regulation of Aβ levels in the brain.  
Therefore, the accumulation of Aβ in late onset AD is attributed to an imbalance 
between its production and degradation/clearance. 
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Several endogenous proteases have been shown to degrade Aβ in the 
brain and other tissues both in vivo and in vitro.  This family of zinc 
metalloproteases, include neprilysin (NEP), insulin degrading enzyme (IDE; 
insulysin), and endothelin converting enzymes (ECE-1 and ECE-2).  Other 
proteases that appear to play a role in Aß metabolism include matrix 
metalloproteinase-9 (Yan et al., 2006) and cathepsin B (Mueller-Steiner et al., 
2006) and plasmin (Turner et al., 2002).  Down-regulation of these degrading 
enzymes within the brain during aging could potentially contribute to Aβ 
accumulation eventually leading to development of AD pathology (Caccamo et 
al., 2005); (Yasojima et al., 2001).  
NEP is a membrane bound a 92-kDa glycosylated ectoenzyme whose 
active site is oriented outside the cell.  NEP belongs to the M13 sub family of 
neutral endopeptidases, and has a range of regulatory activities as it degrades 
numerous bioactive peptides (Turner et al., 2000), (Iwata et al., 2000a).  Iwata et. 
al. in 2000 first demonstrated the ability of NEP to degrade Aβ peptides in the 
brain parenchyma and also illustrated that suppressing NEP would lead to an 
increase in Aβ deposition (Iwata et al., 2000a).  NEP activity decreases with age 
in amyloid depositing regions, such as the cortex and hippocampus, yet 
remained unchanged in areas such as the striatum (Iwata et al., 2002), 
(Yasojima et al., 2001).  NEP deficient mice showed a significant increase in 
amyloid deposition as opposed to their wild type counterparts indicating that NEP 
activity plays significantly impacts  Aβ pathology (Iwata et al., 2000c), (Marr et al., 
2004). 
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Recently, viral vector gene therapy has emerged as a viable approach to 
the delivery of potentially therapeutic genes.  Several vectors and serotypes have 
been developed with improved efficiency, specificity, and safety (Thomas et al., 
2003).  In the present study we investigate the effects of upregulating the NEP 
enzyme by using a recombinant adeno-associated viral (rAAV) vector, serotype 
5, on Aβ load in the brain using a novel convection enhanced delivery 
administration technique to further increase area of distribution and potentially 
increase transduction efficiency of the transgene (a limitation of viral vector gene 
therapy). rAAVs are parvoviruses that require a helper virus, typically Adenovirus 
or herpes simplex virus, in order to support viral replication (Berns and Parrish, 
1996).  rAAV vectors are desirable candidates for gene therapy in the central 
nervous system because AAV is a nonpathogenic virus; it has low 
immunogenicity and it is deficient for replication due to the removal of all the viral 
encoded genes.  Further, rAAV serotype 5 vectors are very efficient in infecting 
neuronal cells and maintaining long term expression (Burger et al., 2005), 
(Mandel et al., 2006).  Therefore we have chosen to examine the efficacy of a 
rAAV serotype 5 vector to deliver the recombinant expressed NEP cDNA. The 
rAAV vectors used in this study express either a membrane bound native form of 
the NEP cDNA, or a modified form of the NEP cDNA that is secreted into the 
extracellular compartment.  We observed a significant reduction in the levels of 
Aβ in the mice injected with the NEP viruses, both the native NEP and the 
secreted NEP appeared to reduce the levels of Aβ load significantly compared to 
the mutated NEP in both the hippocampus and the anterior cortex.  
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MATERIALS AND METHODS 
Generation of NEP Gene Constructs and rAAV Production:  
The NEP gene (GI:4503442) was cloned using polymerase chain reaction (PCR) 
from a GenePool cDNA library obtained from Invitrogen. The primers used for the 
full length NEP were 
GAGGAATTCACCGGTCCACCATGCGGGGCGTGTGGCCGCCCCCGGTGTC 
(contains an Eco RI and Age I restriction sites, 5' primer) and 
GAGATCGATTACCAGACTTCACACTTGTGAGGCGG (contains a Cla I and Ale 
I restriction sites, 3' primer). The PCR product was cloned into pBluescript and 
sequenced to confirm sequence identity.  The NEP was then cloned into the 
vector called pTR5-MCS at the Eco RI and Cla I cloning sites. This vector 
contains the AAV terminal repeats for AAV virus production and the CBA 
promoter for NEP mRNA transcription. A Hemagglutinin (HA) tag was added to 
the C-terminus of NEP gene at the Ale I restriction site. The following 
oligonucleotides 
GTGTGAAGTCTGGATGGCTTCTAGCTATCTTATGACGTGCCTGACTATGCCA
TGTAA and its compliment were annealed and ligated to the vector. Generating 
the soluble truncated form of NEP (232-2313 bp): The 5' primer that was used for 
this PCR was 
GAGGAATTCACCGGTGCAGGACTGGTGGCCTGCTTGGGCAGC, and the 3' 
primer was the same as above. The PCR product was cloned as described for 
the full length NEP including the addition of a HA-tag. To add the secretion signal 
sequence the following oligonucleotide and its compliment were annealed and 
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ligated at the Age I site of the construct 
[CCGGTCCACCATGAAGTTATGGGATGTCGTGGCTGTCTGCCTGGTGCTGC
TCCACACCGGCGTCCG]. The sequence was confirmed to be in frame with the 
NEP gene coding frame. This signal peptide sequence was derived from the 
GDNF gene.  The NEP-m was generated via site directed mutagenesis of the 
NEP-n construct. The codon for glutamic acid 585, GAA, was changed to encode 
for valine, GTA. The recombinant viruses were generated and purified using the 
method of Zolotukhin et al. (2002). Infectious rAAV particles are expressed as 
vector genomes (v/g)/mL. Vector genomes were quantitated using the dot plot 
protocol, with a probe for the CBA promoter, as described by (Zolotukhin et al., 
2002).  
Transgenic Mice 
 APP + PS1 mice (Holcomb et al., 1998) were acquired from the breeding 
colonies at the University of South Florida.  Multiple mice were housed together 
whenever possible until the time of the experiment; mice were then singly- 
housed 1 week before surgical procedures until the time of sacrifice.  Study 
animals were given water and food ad libitum and maintained on a twelve hour 
light/dark cycle and standard vivarium conditions.  Mice in this colony have been 
interbred for the last 8 years and have had the retinal degeneration mutation 
(rd1) removed by selective breeding. 
In study 1, two cohorts of mice were used, the first cohort consisted of 
APP + PS1 mice aged 6 months (n =32) and a second cohort 6 mo old APP + 
PS1 mice (n =18) were treated at separate times.  Animals in each cohort were 
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assigned to one of three groups.  Group one received a control vector expressing 
mutated NEP (first cohort n=9; second cohort n=6).  Group two received rAAV 
vector expressing native neprilysin transgene (first cohort n =12; second cohort 
n=6).  Group three received the rAAV vector expressing the secreted neprilysin 
transgene (first cohort n = 11; second cohort n=6).  All groups were sacrificed 
after six weeks post intracranial injection at 7.5 mo of age.   
In study 2, APP + PS1 mice were 15 months of age at the time of 
treatment and were assigned to one of two groups.  Group 1 received the NEP-s 
rAAV vector while group two received the control vector which was rAAV 
expressing GFP. Mice were sacrificed at 20 mo of age. 
Surgical Procedure 
Study 1 
Immediately before surgery mice were weighed then anesthetized using 
isoflurane.  Surgery was performed using a stereotaxic apparatus.  The cranium 
was exposed using an incision through the skin along the median sagittal plane, 
and two holes were drilled through the cranium over the right anterior cortex 
injection site and the right hippocampal injection site.  Previously determined 
coordinates for burr holes, taken from bregma were as follows; anterior cortex, 
anteroposterior, 1.5mm; lateral, -2.0mm, vertical, 3.0mm, hippocampus, 
anteroposterior, -2.7mm; lateral -2.5mm, vertical, 3.0mm.  Burr holes were drilled 
using a dental drill bit (SSW HP-3, SSWhite Burs Inc., Lakewood, NJ).  Injections 
of 2μl of total volume of each of the viral vectors in sterile PBS at a concentration 
of 1.5 X 1011 vg/ml were dispensed into hippocampus and cortex over a period of 
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2 min. using a 27 gauge step design cannula needle (see below) attached to a 
10 μl syringe (Hamilton Co., Reno, NV).  The incision was then cleaned and 
closed with surgical staples.  Animals were recovered within 10 minutes and 
housed singly until time of sacrifice. 
Step Design Cannula 
The step design cannula was used for all intracranial surgeries.  Fused 
silica tubing (polymicro technologies, Pheonix, AZ) was inserted into a 27 gauge 
Hamilton blunt ended needle and fixed in place with super glue (Krauze et al., 
2005).  The end of the silica tubing was cut leaving 1mm of tubing protruding 
from the end of the Hamilton needle. 
Study 2 
Immediately before surgery fifteen month old mice were weighed then 
anesthetized using isoflurane.  Surgery was performed in a similar manner 
mentioned previously.  Four holes were drilled through the cranium over the right 
and left cortex injection site and the right and left hippocampal injection sites with 
predetermined coordinates listed previously.  NEP rAAV vectors were 
administered intracranially using a 26 gauge beveled Hamiliton needle (Hamilton 
Co., Reno NV).  Injections of 2 μl were given over a four min period at a rate of 
0.5µl/min.   
Immunohistochemistry  
In study 1, 6 weeks post surgery; mice were weighed, overdosed with 
pentobarbital (200 mg/kg) and perfused with 25 ml of 0.9% normal saline solution 
then 50 ml of freshly prepared 4% paraformaldehyde.  Brains were collected from 
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the animals immediately following perfusion and immersion fixed in 4% 
paraformaldehyde for 24 hrs.  Mouse brains were cryoprotected in successive 
incubations in 10%, 20%, 30% solutions of sucrose; 24hrs in each solution.   
Subsequently, brains were frozen on a cold stage and sectioned in the horizontal 
plane (25 μm thickness) on a sliding microtome and stored in Dulbecco’s 
phosphate buffered saline (DPBS) with 0.2% sodium azide solution at 4˚C. 
Eight sections 100 μm apart spanning the site of injection were chosen 
and free-floating immunochemical and histological analysis was performed to 
determine transgene expression using anti-HA biotinylated rabbit polyclonal 
antibody at a concentration of 1:1000 (Roche, Indianapolis, IN), total Aβ using a 
rabbit primary anti-Aß serum at a concentration 1:10,000 and a secondary anti-
rabbit antibody (Serotec, Raleigh, NC).  Another series of sections were mounted 
on slides and stained with Congo red to assess compact congophilic positive 
plaque load.  Immunohistochemical procedural methods are analogous to those 
described by Gordon et al. 2002, for each marker.  Six to eight sections from 
each animal were placed in multisample staining tray and endogenous 
peroxidase was blocked (10% methanol, 3% H202, in PBS).  Tissue samples were 
permeabilized (with 0.2% lysine, 1% Triton X-100 in PBS solution), and 
incubated overnight in appropriate primary antibody.  Sections were washed in 
PBS then incubated in corresponding biotinylated secondary antibody (Vector 
Laboratories, Burlingame, CA).  The tissue was again washed after a 2 h 
incubation period and incubated with Vectastin® Elite® ABC kit (Vector 
Laboratories, Burlingame, CA) for enzyme conjugation.  Finally, sections were 
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stained using 0.05% diaminobenzidine and 0.3% H202.  For anti-HA 0.5% 
nickelous ammonium sulfate was added for color enhancement.  Tissue sections 
were then mounted onto slides, dehydrated, and coverslipped.  Each 
immunochemical assay omitted some sections from primary antibody incubation 
period to evaluate nonspecific reaction of the secondary antibody.  
Congo red histology was performed using sections that were premounted 
on slides then air dried for a minimum of 24 hours.  The sections were rehydrated 
for 30 seconds before beginning the staining protocol.  For Congo red, hydrated 
sections were incubated in an freshly prepared alkaline alcoholic saturated 
sodium chloride solution (2.5mM NaOH in 80% alcohol) for 20 min, then 
incubated in 0.2% Congo red in alkaline alcoholic saturated sodium chloride 
solution for 30 minutes.  Slides with sections were rinsed through three changes 
of 100% ethanol, and cleared through three changes of xylene and finally 
coverslipped with DPX.  Histological sections from control animals treated with 
rAAV expressing GFP were mounted on slides and dehydrated through a series 
of increasing concentrations of ethanol.  The mounted sections were then 
cleared in three changes of histoclear and coverslipped with DPX.   
Stained sections were imaged using an Evolution MP digital camera 
mounted on an Olympus BX51 microscope at 100X final magnification (10 X 
objective).  Eight horizontal brain sections (100µm apart; every 4th section) were 
taken from each animal and four nonoverlapping images near the site of injection 
from each of these sections were captured (32 measurements per mouse).  All 
images were taken from the same location in all animals.  Quantification of 
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positive staining product surrounding and including the injection sites in the right 
frontal cortex and the right hippocampus and the corresponding regions in the left 
hemisphere were determined using Image-Pro® Plus (Media Cybernetics®, 
Silver Springs, MD.  Quantification of percent area of positive stain for cortex and 
hippocampus for both right and left hemispheres was determined. Data were 
analyzed using ANOVA statistical analysis followed by Fisher’s LSD test for 
individual means differences as recommended by the computer software 
program StatView® version 5.0.1 (SAS Institute, Raleigh, NC).   
Enzyme Activity Assay 
NEP activity of the three different NEP constructs was characterized and 
adapted from a previous fluorometric assay method (Johnson and Ahn, 2000) 
and the NEP ELISA kit (R&D Systems) for a 96 well plate format with slight 
modifications.  HEK 293 cells were transfected with NEP-n, NEP-m, and NEP-s 
plasmids and control cells were transfected with a GFP plasmid using 
lipofectamine 2000 per invitrogen protocol.  Cells were harvested after 72 hrs. 
and samples were centrifuged at 1,000 x g 4º C for 45 min. using  Beckman J6-
HC Centrifuge (Beckman Instruments, Inc., Palo Alto, CA)   to obtain cell media 
fraction and a cell pellet containing the membrane fraction.  The membrane 
fraction was resuspended in M-PER mammalian protein extraction reagent buffer 
(Thermo Scientific, Rockford, IL) to obtain a cell lysate.  Protein concentration 
was determined from the cell media and cell lysate containing the membrane 
fractions from each sample using a general BCA assay (Per Pierce Protocol).  
Aliquots of the cell media and membrane fractions were (100 μg) were incubated 
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in NEP ELISA plate containing NEP capture antibody.  The plate was washed 
with PBS buffer then incubated with 20 μM (final) of the fluorogenic peptide 
(MOCA- Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH), (R&D Systems) in 
Tris-HCL buffer (sodium phosphate pH 7.4 containing 0.1M NaCl) MOCA- Arg-
Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH  is efficiently quenched by 
resonance energy transfer to the dinitrophenyl group and the continuous 
fluorescent intensity is increased upon internal cleavage of the peptide (NEP 
cleavage between the Ala-Phe bond). The increased fluorescence produced from 
cleavage of the substrate was measured using a Molecular Devices fMax 
spectrofluorometer plate reader (MDS Analytical Technologies, Sunnyvale, CA) 
with a 60 min time point to normalize independent experiments.  A standard 
curve of (7-methoxycoumarin-4-yl) acetyl (MOCA) was analyzed along with each 
assay.  Values were calculated and expressed as RFU/ min/ ml protein.  Data 
were analyzed using ANOVA statistical analysis test. 
 
RESULTS 
Three rAAV vectors expressing different versions of human NEP were 
developed.  cDNAs were packaged in AAV vectors to generate either the native, 
membrane bound, form of the enzyme (denoted NEP-n), a secreted form of the 
enzyme (denoted NEP-s) or an enzymatically-deficient mutant enzyme (denoted 
NEP-m).  The secreted form of the enzyme contained a signal peptide in place of 
the transmembrane domain of the native enzyme to direct the enzyme's 
secretion into the extracellular compartment (Fig 1).  The gene sequences are 
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under the control of the hybrid chicken β-actin cytomegalovirus (CBA) promoter 
sequence and were tagged with haemagglutinin (HA) peptide sequence for 
detection within the brain and discrimination from endogenous NEP.  The control 
group received the rAAV expressing NEP-m cDNA, which contains a single point 
mutation in the active site, E585V, rendering the expressed enzyme inactive.   
 Prior to virus production the NEP constructs were tested in HEK 293 cells to 
evaluate the expression cassettes and the effectiveness of the signaling peptide 
in directing secretion of the NEP-s gene product.  Cell lysate and conditioned 
media from transfected and untransfected cells were examined by Western blot 
analysis to determine NEP expression.  Untransfected cell lysate and media 
were negative for NEP protein expression. NEP-n and NEP-m protein expression 
was only detected in the cell lysate fraction and not the media. In contrast, NEP-s 
protein was detected in both the cell lysate and the media indicating that the 
signaling peptide did effectively direct secretion of the NEP protein.   
 rAAV vectors for NEP-m, NEP-n and NEP-s were injected unilaterally into the 
right hippocampus and right anterior cortical regions of six month old APP + PS1 
mice. Animals received 2 μl of virus at a flow rate of 2.5 μl/min and at a 
concentration of 1.5 x 1011 vg/mL.  The transgene expression of NEP was 
evaluated six weeks after injection.  Gene expression in the mice which received 
either the NEP-n or the NEP-s was compared to control animals which received 
NEP-m or were untreated.  
  Immunostaining of the tissue with an anti-haemagglutinin (HA) antibody 
revealed NEP expression in all animals for NEP-n, NEP-m and NEP-s.  The gene 
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expression patterns filled virtually all of the hippocampus.  The staining for NEP-n 
and NEP-m was greater in intensity than the staining for NEP-s.  NEP-n was 
detected in CA4 neurons in the hilus and CA2 and CA3 neurons of the 
hippocampus pyramidal cell layer (Fig. 2A).    Some expression of NEP-n was 
even noticeable in the entorhinal cortex.  Interestingly, it appears that the cell 
bodies in the dentate granule cell layer were not stained as intensely as the 
corresponding neuropil, suggesting some dendritic localization of the transfected 
protein.  NEP-s was detected in cell bodies of CA4 neurons in the hilus, some 
CA3 neurons as well as a few cells in the molecular layers of hippocampus.  
NEP-s expression was of noticeably less intense and limited in area of 
distribution compared to that of NEP-n and NEP-m expression (Fig 2C).  It is 
uncertain the degree to which this reflects reduced expression, or diffusion of the 
soluble enzyme in vivo or during tissue processing. NEP-m staining pattern was 
very similar to the pattern with NEP-n (Fig. 2B) revealing expression throughout 
the hippocampus in the dentate gyrus as well as in all CA regions.   
When the cortical regions were analyzed for expression, there was again 
a greater amount of NEP-n and NEP-m expression than NEP-s (greater intensity 
of HA staining; Fig 3).  NEP-n as well as NEP-m positive expression was 
concentrated in the anterior cortex (Fig 3A and B), but was observed also in the 
striatum and corpus callosum and to small extent in the contralateral hemisphere.  
Again, NEP-m and NEP-n expression profiles were very similar, with expression 
largely confined to the neuropil and little staining of the neuronal somata.  NEP-s 
cortical HA staining was less intense than that of NEP-n HA staining and was 
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confined to largely to somatic areas of neurons, conceivably in vesicular 
compartments in preparation for secretion (Fig. 3C).   Overall, intensity of HA 
immunohistochemical staining in the cortical region of the brain appeared less 
intense than in the hippocampus possibly indicating a lower level of the gene 
expression of NEP in this region.  Hippocampal and anterior cortical regions of 
uninjected animals showed no noticeable HA staining (Fig 2D and 3D).  
The rAAV NEP-s, NEP-m and NEP-n vector constructs were tested for 
enzyme activity in vitro using HEK 293 cells.  Cells were transfected using NEP-
n, NEP-m and NEP-s plasmids and control cells were transfected with the GFP 
plasmid.  All cells were harvested 72 hrs after transfection using lipofectamine 
2000.   The NEP specific activity was determined as RFU/min/ml protein.  HEK 
293 cells transfected with NEP-n had significantly higher NEP specific activity in 
the cell lysate containing the membrane fraction than the cells transfected with 
the NEP-m, NEP-s and the control GFP transfected cells (Fig 4).  NEP specific 
activity of the lysate from NEP-s transfected cells was also significantly greater 
than NEP-m and GFP transfected cell lysates.  In addition, the NEP-s specific 
activity in the cell media was significantly greater than the NEP-n, NEP-m, and 
GFP transfected cells (Fig 4).           
Our next goal was to evaluate the effects of a single intracranial 
administration of a rAAV vector containing either the secreted or native form of 
the NEP gene in APP + PS1 transgenic mice to determine the effect of over 
expression of the transgene on amyloid deposition.  In study 1 rAAV vectors 
were injected unilaterally into the right anterior cortex and hippocampus of six 
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month old mice.  The control group was treated with rAAV containing a NEP-m 
gene.  Total Aβ load was ascertained six weeks after intracranial injections by 
immunohistochemical methods.   The regional Aβ distribution and density in APP 
+ PS1 transgenic mice that were control animals were similar to aged matched 
untreated animals reported by us previously (Gordon et al., 2002).  
Immunohistochemistry for Aβ revealed both darkly stained compact plaques and 
more lightly stained diffuse plaque deposits in the APP+PS1 animal tissue (Fig 
5A and 5D).  Plaque deposition was distributed throughout the cortical regions as 
well as in the hippocampus (although most concentrated in the molecular layers 
of the dentate gyrus and the CA1 region, surrounding the hippocampal fissure).  
Animals injected with the control rAAV-NEP-m showed Aβ immunohistochemical 
staining patterns throughout the cortex and hippocampus comparable to those of 
untreated APP transgenic mice of the same age.  A notable decrease in the 
amount of hippocampal Aβ staining was observed in animals injected with either 
the rAAV expressing NEP-n or NEP-s six weeks after the time of injection when 
compared to animals injected with the control rAVV-NEP-m vector (Fig. 5A-5F).  
The reductions in Aβ deposition were not only limited to the areas surrounding 
the cortical and hippocampal injection sites.  Significant reductions were also 
notable in corresponding areas contralateral to the site of injection (although only 
a few cells showed very faint positive HA staining in the contralateral anterior 
cortex and hippocaompus).  ANOVA analysis of total Aß in the ipsilateral 
hemisphere revealed significant decreases of, 78% and 65% in the anterior 
cortex and hippocampus respectively, in mice receiving NEP-n injections.  
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Decreases in total Aβ were also observed in mice receiving the NEP-s rAAV with 
significant declines of 60% in the anterior cortex and 56% in the hippocampus 
(Fig. 6A).  Quantification of total Aß in the contralateral hemisphere showed 
significant reductions of 56% and 36% in the anterior cortex and hippocampus 
respectively, of mice receiving NEP-n.  Similarly, significant decreases of 53% 
and 44% in total Aβ of the contralateral anterior cortex and contralateral 
hippocampus respectively, were seen in mice receiving NEP-s (Fig. 6B).      
Congophilic plaque load was analyzed following intracranial injections of 
rAAV vectors.  The density of congophilic labeling was substantially less than Aβ 
immunohistochemistry, staining only fibrillar Aβ deposits as expected (Gordon et 
al., 2002).  Animals injected with the control rAAV-NEP-m showed positive 
congophilic staining patterns throughout the cortex and hippocampus 
comparable to those of untreated APP transgenic mice of the same age (Fig. 7A 
and 7D).   Figures 6B and 6E show that the presence of congophilic staining for 
the mice receiving the NEP-n vector was visibly less, especially in the 
hippocampus, compared to both the control animals and the animals that 
received the NEP-s vector (Fig 7C and 7F).   ANOVA analysis revealed that 
animals receiving the NEP-n rAAV showed significant reductions in the 
hippocampal region (56%) and in the anterior cortex (56%; Fig 8A) ipsilateral to 
the site of injection.  rAAV expressing NEP-s also had significant decreases in 
the compact plaque load in both the hippocampus (51%) and cortical regions 
(57%;Fig 8A).  When compact plaque load was calculated in the contralateral 
hemisphere and compared to the control group, significant decreases were 
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observed only in the hippocampus (49%) of animals receiving the NEP-s vector 
treatment (Fig 8B).  Animals receiving the NEP-n showed a decreased trend but 
no statistical difference in congophilic staining from the NEP-m.  No significant 
decreases of Congo red staining were noted in the contralateral anterior cortex of 
animals receiving either treatment (Fig 8B). 
Study 2 
In study 1 we demonstrated that either NEP-s or NEP-n could reduce 
amyloid accumulation when tested in a prevention type of study. Study 2 was 
designed to test NEP-s, which appeared slightly superior to NEP-n at sites 
distant from the injection, in mice with large amounts of preexisting amyloid 
deposits, what some would term a therapeutic type of study design. Aged APP + 
PS1 transgenic mice (15 months of age) were injected into hippocampus and 
anterior cortex bilaterally.  Tissues were collected 5 mo later when mice were 20 
mo old.  
 Total Aβ load was reduced following intracranial administration of rAAV-
NEP-s in aged mice.  Panels A and C of fig. 10 show positive 
immunohistochemical staining of total Aβ in the hippocampus and cortex 
respectively of aged APP+PS1 mice treated with rAAV-NEP-s.  Panels B and D 
of Fig. 9 showed positive Aβ staining in the hippocampus and cortical regions of 
untreated aged mice.  Panel E shows quantification of Aß immunostaining of 
NEP-s treated and untreated 20 mo old APP+PS1 mice. Total Aβ was reduced 
significantly in the left anterior cortex as well as in the left and right hippocampus 
following treatment with the NEP-s vector compared to control untreated animals.  
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Total congophilic staining is reduced following intracranial administration of 
rAAV-NEP-s in aged 20 month old mice.  Panels A and C of Fig. 11 show total 
positive congophilic staining in the hippocampus and cortex respectively of 
APP+PS1 mice treated with rAAV-NEP-s.  Panels B and D of Fig. 11 show 
positive congophilic staining of the hippocampus and cortex respectively of 
untreated 20 month old mice.  Panel E of Fig. 11 shows quantification of 
congophilic staining in NEP-s and untreated 20 Mo old APP+PS1 mice. Total 
congophilic staining was significantly reduced in the left and right anterior cortex 
as well as the left and right hippocampal regions in animals receiving treatment 
with the NEP-s vector compared to untreated control animals.  
 
DISCUSSION 
Several recent findings have clearly implicated the important role of 
endogenous proteases such as neprilysin in the catabolism of Aβ peptides in the 
brain.  Also known as enkephalinase and CD10, it is capable of cleaving 
enkephalins and terminating peptidergic neurotransmission.   In addition to NEP, 
other endogenous Aβ degrading proteases maintain a conserved catalytic 
domain which includes a zinc binding motif, HEXXH (Turner et al., 2000).  Other 
proteases in addition to the zinc metalloproteases that appear to play a role in Aß 
metabolism include matrix metalloproteinase-9 (Yan et al., 2006) and cathepsin 
B (Mueller-Steiner et al., 2006) and plasmin (Turner et al., 2001).  Down-
regulation of these degrading enzymes within the brain during aging could 
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potentially contribute to Aβ accumulation eventually leading to development of 
AD pathology (Caccamo et al., 2005), (Yasojima et al., 2001).  
 Deficiency in the expression of NEP and other metallopeptidases in the 
aged brain and in animal knockout models correlates with plaque accumulation in 
a region specific manner (Iwata et al., 2000), (Eckman et al., 2001), (Fukami et 
al., 2002), (Yasojima et al., 2001b), (Farris et al., 2004), (Saito et al., 2003), 
(Caccamo et al., 2005), (Miners et al., 2006).   Enzyme kinetic studies using 
specific NEP inhibitors have shown that neprilysin can efficiently degrade 
numerous peptides on the N-terminus of hydrophobic amino acid residues, which 
is essential for the efficient catabolism of the Aβ peptide (Marie-Claire et al., 
1997), (Shimada et al., 1996), (Hoang et al., 1997), (Turner et al., 2001), 
(Leissring et al., 2003), (Hersh, 2003).    Furthermore, in vivo studies show that 
an increase in the enzyme activity of amyloid degrading enzymes specifically 
neprilysin, endothelin converting enzyme, and insulin degrading enzyme, have a 
significant effect on both intracellular and extracellular Aβ levels in the brain 
(Hama et al., 2001), (Zou et al., 2006), (Eckman et al., 2006), (Guan et al., 2008).  
Most recently, Farris et al., demonstrated that when the expression of 
endogenous NEP is partially or completely inhibited both Aβ deposition and 
cerebral amyloid angiopathy are significantly exacerbated (Farris et al., 2007b).  
Subsequently, peptidases have become popular targets for Alzheimer’s disease 
therapies.  
 Previously, we examined the effects of the overexpression of ECE-1 gene 
on amyloid load in the APP + PS1 mouse model (Carty et al., 2006).  In the 
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current study, we examine the effectiveness of rAAV to deliver NEP into 
hippocampus and anterior cortex of the mouse brain to determine its effects on 
amyloid burden.  In particular, we are interested in developing a delivery method 
that increases the dissemination of therapeutic levels of NEP protein.  Previous 
studies involving gene therapy approaches for the treatment of Alzheimer’s 
pathology have used viral vectors to reduce Aβ deposition by overexpressing Aβ 
degrading enzymes, including NEP, ECE and IDE and more recently Cathepsin 
B, a cysteine protease also implicated in the lysosomal degratory pathway of Aβ 
peptides (Marr et al., 2003), (Iwata et al., 2004), (Mueller-Steiner et al., 2006).  A 
comparison of gene transfer studies indicate that overexpression of neprilysin 
appears to have the most pronounced effect on plaque load in the brain (Farris et 
al., 2007a), (Eckman et al., 2003), (Hersh et al 2008), (Spencer et al., 2008).  
Marr et al (2003) used lentiviral vector and were successful in reducing amyloid 
levels in APP Tg mice but only moderately peptides (Marr et al., 2003).  In 
addition, others have shown that the transgenic overexpression of NEP and IDE 
crossed with transgenic APP mice significantly reduces amyloid accumulation in 
the brain (Leissring et al., 2003), (Poirier et al., 2006), (Meilandt et al 2009). 
Iwata et al.used AAV, as in this study, to express NEP-n and were also 
successful in reducing Aβ levels in the hippocampus of Tg2576 mice.  
In this paper, we further explore the use of different rAAV expressing 
different forms of the NEP gene.  Particularly, we examine a secreted form of the 
NEP in addition to using the CED delivery method to increase distribution and 
ultimately total area of gene expression. We also determine the effect of both the 
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native and secreted versions of NEP expression in the anterior cortex and 
hippocampus comparing the relative distribution and differences in NEP gene 
expression in specific cell types in the brain.  Unlike previous gene transfer 
studies with these proteases we use the double transgenic APP + PSI mouse 
model which have a very aggressive amyloid deposition profile and exhibit 
memory deficits at a younger age than single transgenic amyloid depositing 
models.  Recombinant AAV has become widely used for the transduction of 
neuronal cells. rAAV is nonpathogenic, has low immunogenicity, lacks all viral 
genes and is capable of long term expression in neurons. This profile makes 
rAAV a good candidate for the use as a gene therapy vector for neurological 
disorders (Mandel et al 2006), (Mandel and Burger 2004).  One limitation with a 
gene therapy approach for a disease such as Alzheimer’s is that the therapeutic 
protein must be delivered to the whole brain.  Unfortunately, the intracranial 
injections into the brain parenchyma using simple diffusion does not allow for 
efficient uptake of the transgene or significant dispersion of the AAV vectors to 
significantly large areas of the affected regions within the brain.  Thus if only a 
small area of the brain is transduced by the viral vector, multiple injections would 
be required to cover the entire brain. Therefore, in an attempt to overcome this 
problem we engineered the NEP gene to contain a signal peptide sequence in 
the hopes of creating a nucleus from which the expressed protein could diffuse to 
greater regions of the brain; thus eliminating the requirement for a large number 
of injections.  Additionally we implemented a novel infusion technique using the 
CED method allowing us to obtain a larger area of distribution of the rAAV 
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vectors upon delivery with a single injection in the brain parachyma both in the 
hippocampus and cortical regions of the brain.  CED is a method of delivering 
clinically relevant volumes of therapeutic agents to significantly larger areas of 
the brain in comparison to simple diffusion methods.  The CED technique is 
designed to utilize the phenomenon of bulk flow and positive pressure to 
distribute macromolecules to a large area within solid tissue.  Macromolecules 
can therefore be administered to significantly larger areas of specific brain 
regions by utilizing the advantage of fluid convection within and throughout the 
interstitial space in the brain (Leiberman et al. 1995, Sanftner et al 2005).  The 
greatest area of distribution is therefore achieved by using an increased and 
optimal pressure gradient, flow rate, and volume of liquid material (Sanftner et 
al., 2005). One of the mechanistic limitations of the CED method as well as the 
simple injection method is the reflux of the injected material up the injection tract.  
In 2002 Krauze et. al. developed a reflux free step cannula design which 
effectively minimizes reflux by placing silicone coated tubing within the stainless 
steel blunt end cannula creating a step that prevents the backflow of fluid.  The 
optimization of more efficient cannula designs coupled with the encouraging 
results from studies showing enhanced gene transfer and distribution 
emphasizes the therapeutic potential of the CED method in helping overcome 
some of the mechanical disadvantages of gene delivery in regards to gene 
therapy (Krauze et al., 2005b). 
  Implementing these techniques, rAAV serotype-5 NEP vectors were 
injected unilaterally into the mouse hippocampus and anterior cortex.  
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Examination of the expression profile, using anti-HA immunohistochemisty, of the 
expressed NEP reveals that the rAAV constructs of both NEP-m and NEP-n can 
transduce several different neuronal and glial cell types within the mouse brain.  
Interestingly, it appears that the cell bodies in the dentate molecular layer were 
not stained as intensely as the corresponding axonal projections of these cells 
which were very darkly stained.  This may suggest that the expressed NEP is 
processed in the endoplasmic reticulum and golgi apparatus of the cell body, 
then transported along the axon via vesicles to the synaptic terminal.  These 
results are consistent with data published in 2006 by Huang et al. describing the 
normal neuronal metabolism of NEP (Huang et al, 2006) and by Iwata expressing 
NEP-n with rAAV (Iwata et al 2004).  The expression profiles are also consistent 
with the previously published serological specificity of the AAV vectors (Alisky et 
al., 2000),(Burger et al., 2004),(Choi et al., 2005).  The AAV 5 serotype has 
previously been shown to effectively transduce non-dividing neuronal cells as 
well as glial cells in the mouse brain.   
The NEP-s expression profile revealed less intensity of HA staining when 
compared to the NEP-m and NEP-n staining patterns.  Cells within the hilus of 
the molecular layer were stained as were as cells in the CA3 region of the 
hippocampus.  We believe that more diffuse staining of the NEP-s construct does 
not necessarily mean that this vector had lower transduction efficiency. It is likely 
due to the diffusion of the NEP protease throughout the extracellular milieu, 
making it more difficult to detect using anti-HA immunohistochemisty compared 
to the membrane bound NEP-n protease.  However, another explanation for the 
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decreased staining of the NEP-s protease may be that once the NEP-s is 
secreted the NEP protein or at least the HA-tag is more prone to degradation by 
other extracellular proteases.  We plan to conduct further investigation of the 
expression and activity profile using in vitro studies to delineate the metabolism 
of both the NEP-n and NEP-s proteases.  Additionally, the NEP-s staining was 
more intense in the cortical regions compared to the hippocampus which may 
indicate that the signal peptide is processed more effectively in the cortex 
compared to the hippocampus.  Despite the differences in staining intensity of 
the different NEP proteins our in vitro data confirmed that both NEP-n and NEP-s 
proteases shown activity, while the NEP-m version did not.  Additionally, only the 
NEP-s protein showed enzyme activity once secreted into the cell media. We 
also plan to re-examine the levels of soluble protease activity in the cortex 
compared to the hippocampus of injected animal to see if this is the case in vivo.   
Our results demonstrate that the up-regulation of NEP through rAAV 
vectors can provide a viable method to decrease the total amyloid deposition in 
the brain of amyloid depositing Tg mice.  NEP-n and NEP-s were able to 
significantly reduce total Aβ deposition in the anterior cortex and hippocampus at 
the site of injection.  Similarly, both NEP-n and NEP-s significantly reduced the 
level of congophilic deposits.  Interestingly, when the area of positive staining for 
Aβ was analyzed in the hippocampus and cortical regions of the contralateral 
hemisphere, both the NEP-s and NEP-n rAAV were able to decrease total Aβ (in 
anterior cortex) load compared to the control group.  Only NEP-s treated animals 
showed significant reductions in total Aβ load in the contralateral hippocampus 
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compared to control animals.  However, examination of the congophilic deposits 
on the contralateral anterior cortex showed no reduction.  Interestingly, on the 
contralateral hippocampal side there was a 40-50% reduction of congophilic 
staining, but only the reduction with NEP-s was statistically significant compared 
to the control group.  The reduction on the contralateral hemisphere observed 
here is likely due to retrograde transport of the rAAV and anterograde transport 
of the NEP protein.  Retrograde transport of rAAV has previously been reported 
(Burger et al 2004).  The lower number of neuronal connections between the 
ipsilateral and contralateral sides in the anterior cortex compared to those 
present in the hippocampus could explain why there is a reduction in congophilic 
staining in the contralateral hippocampus and not the contralateral anterior 
cortex.  Further, since the contralateral anterior cortex showed reduction of total 
Aβ load but not congophilic staining it would seem to suggest that a critical 
amount of NEP expression is required in order to reduce the insoluble Aβ plaque 
formation.   
As previously mentioned our findings showed that by implementing the 
use of a secreted form of the NEP protease in addition to using the CED method 
for intracranial administration, we were able to successfully improve the area of 
gene expression to further reduce amyloid load in the brain.  An alternative 
method which would potentially overcome the limitations of a direct intracranial 
injection is to attempt to express the NEP protease in a peripheral fashion.   
Previous studies using anti-amyloid vaccines have clearly demonstrated 
that effective therapy does not have to cross the blood brain barrier to have a 
 83
significant effect on amyloid load in the brain.  It is well established that both 
passive and active Aβ immunotherapy can effectively decrease amyloid load 
from the brain as well as improve cognitive impairment in transgenic animals 
(Morgan et al., 2000), (Janus et al., 2000), (Dodart et al., 2002), (Masliah et al., 
2005), (Wilcock et al., 2004),(Solomon, 2005),(Maier et al., 2006).  The 
mechanism underlying this phenomenon referred to as the ‘peripheral sink’ 
hypothesis asserts that amyloid is in a state of equilibrium throughout the body.   
Therefore, sequestering and removing amyloid in the periphery will change the 
equilibrium such that amyloid will move from the brain into the periphery 
(DeMattos et al., 2002), (Matsuoka et al., 2003), (Lemere et al., 2003), (Deane et 
al., 2005).  Most recently, ex vivo gene transfer studies using cell mediated over 
expression of amyloid degrading peptidases have shown initial success and may 
provide a useful alternative to passive immunotherapy.  Hemming et al in 2007 
showed that over expression of secreted neprilysin in primary fibroblasts 
reintroduced peripherally into transgenic APP mice showed a robust reduction in 
plaque load (Hemming et al., 2007).  Additionally, other methods implementing 
cell mediated gene expression using both leukocytes and erthrocytes have been 
used enhance Aβ degradation in the periphery and in the CNS (Guan et al., 
2008), Lui et al 2008).   
We also wanted to examine the effect of increasing NEP expression in 
aged animals where there is already significant deposition of Aβ.  Evidence has 
shown that rAAV viral vectors can successfully transfect neurons in the CNS and 
result in sustained and stable long term gene expression in the brain (McCown et 
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al., 1996), (McCown, 2005), (Royo et al., 2008), (Spencer et al., 2008).  Our 
results demonstrate that the rAAV NEP-s vector was able to significantly reduce 
both total Aβ load and fibrillar Aβ in aged animals.  These data are consistant 
with evidence from Spencer et al (2008).  As expected, the NEP-s showed strong 
expression in the brain 5 months following treatment in older animals 20 months 
of age (treatment was at 15 mo. of age) demonstrating persistence and stability 
of the transgene expression.  Upon observation of congophilic positive plaque 
load in 20 mo. old animals compared to plaque load in 15 mo.old animals it 
appears that treatment with NEP in the old animals with a large amount of 
preexisting plaques simply halts the progression of plaque build up rather than 
actively removing compact plaques established well before treatment onset. 
Further investigation must be done to verify the aforementioned observation.  
Gordon et al. in 2001 showed that congophilic positive staining, primarily 
composed of Aβ40, increases until about 12 months of age in the double 
transgenic APP+PS1 mouse and remains relatively stable up until 18 months of 
age (Gordon et al, 2001).   
Although we have yet to perform a detailed examination, initial 
observations showed no noticeable toxic effects in mice receiving the NEP 
vectors.  No neuron loss or gross morphometric changes were observed in fixed 
brain tissue.  No significant changes in total body weight were noted, indicating 
that up regulation of NEP did not appear to have adverse effects or cause 
general toxicity in the mouse model during our study period.  NEP has been 
shown to have other endogenous peptide substrates, including atrial natriuretic 
 85
peptide, substance P, endothelin and enkephalin.  It is uncertain whether 
interactions between NEP and these other potential substrates in the brain may 
cause potential problems although one recent study suggests that high levels of 
enkephalins can contribute to memory and cognitive deficits in amyloid producing 
mice, further implicating the importance of NEP activity in AD (Meilandt et al., 
2008).  Monitoring changes in these NEP peptide substrates between control and 
treatment groups may help identify any potentially harmful side effects resulting 
from increases in NEP activity.  Previous studies have revealed that in the AD 
brain as well as in the animal model of AD, NEP are down regulated specifically 
in areas that are prone to plaque formation (Yasojima et al., 2001a), (Fukami et 
al 2002).  Therefore, up-regulation of NEP to restore normal levels of this 
endogenous protease should have minimal adverse effects.  In future studies, we 
could regulate the levels of NEP expression by using an inducible promoter 
system which would enable the levels of NEP to be managed as required per 
individual and potentially reduce unwanted side effects of continuous high levels 
of NEP expression.  Future studies which implement a combination of peripheral 
and central gene transfer studies can also have additive effect on total amyloid 
load in the brain.  Another therapeutic gene therapy technique could implement a 
cell mediated gene transfer technique in an in vivo fashion.  Rivest et al in 2008 
demonstrated that injection of lentivirus expressing the TLR2 gene resulted in 
successful expression of the gene in bone marrow cells.  Additionally, these cells 
successfully migrated to the CNS of amyloid depositing transgenic mice ensuing 
in a decrease in amyloid pathology  (Richard et al., 2008).  These findings further 
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demonstrate that viral vectors and cell mediated therapy can be combined to 
provide a novel therapeutic technique in the treatment of neurological disease. 
We have yet to determine if this reduction in the Aβ levels with our NEP-n 
or NEP-s rAAV vectors will lead to significant improvement in behavioral tests 
such as the Morris water maze in both the young and old populations of 
transgenic mice.  However, these data are consistent with reports that NEP can 
degrade Aß in vitro, and that partial knockdown of the NEP gene leads to more 
rapid accumulation of Aß (Farris et al., 2007), (Eckman et al., 2003).  The 
present work adds to the evidence that NEP plays an important role in Aß 
deposition by demonstrating that local overexpression NEP enzyme activity can 
dramatically reduce the deposition of amyloid in the brains of APP transgenic 
mice.  Thus, regulation of NEP through methods such as gene therapy may be 
used as a potential therapeutic target for the treatment of Alzheimer's disease 
warranting further study into the use of gene therapy techniques in a combinatory 
fashion to increase effectiveness while reducing adverse events. 
 
 
Acknowledgments. Supported by The Johnnie Byrd Center for Alzheimer's 
Research, NIH grants AG-25509, AG 15490, AG 18478, AG 04418, AG 25711 
 
 
 
 
 87
FIGURE 1:  DIAGRAMMATIC REPRESENTATION OF rAAV CONSTRUCTS 
EXPRESSING THE NEP GENE UNDER THE CONTROL OF THE CHICKEN β-
ACTIN (CBA) PROMOTER. Note the C-terminal fusion HA tag in both 
sequences and the secretion signaling peptide in the NEPHA-s construct.  Panel 
A shows a gene map of the recombinant AAV NEP-n and NEP-s constructs 
under control of the hybrid CBA chicken β-actin promoter. A hemagluttinin tag 
has been appended to the NEP encoding sequence to allow for easy detection. 
 
 
 
 
 
 
 
 
 
 
 
HA tag HA tag 
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FIGURE 2:  EXAMINATION OF NEP EXPRESSION IN TRANSDUCED CELLS 
OF THE HIPPOCAMPUS CONTRALATERAL AND IPSILATERAL TO VECTOR 
INJECTION.  Strong NEP-n and NEP-m expression is detected using anti-HA 
immunostaining in the right hippocampus following intracranial administration of 
NEP-n and NEP-m vector (panels A and B, respectively).  Panel C shows less 
intense diffuse NEP-s expression in granule cells of the dentate gyrus in the right 
hippocampus following intracranial administration of NEP-s.  Panels D shows no 
positive staining in the uninjected hippocampus of an untreated age matched 
animal.  Magnification = 40X for all panels. dg = dentate gyrus; CA1 = Cajal Area 
1; CA3 = Cajal area 3. 
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FIGURE 3: EXAMINATION OF EXPRESSION LEVELS OF NEP AFTER 
INTRACRANIAL ADMINISTRATION OF rAAV VECTORS INTO THE RIGHT 
ANTERIOR CORTEX OF MICE.  Panels E and F show strong NEP-n and NEP-
m expression as detected by anti-HA immunostaining in the anterior cortex and 
striatum ipsilateral to the injection site.  Panel G shows slightly less intense 
diffuse NEP-s expression in the anterior cortex and striatum ipsilateral to the 
injection site.  Panels H shows no positive staining in the uninjected cortex of 
untreated aged matched animals. Str = striatum; CC = corpus callosum; CX= 
cortex.  Magnification = 40X. 
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FIGURE 4:   QUANTIFICATION OF NEP SPECIFIC ACTIVITY IN HEK293 
TRANSFECTED CELLS. Neprilysin specific activity is significantly higher in the 
HEK293 cells transfected with NEP-n in the cell lysate (membrane fraction) 
compared to NEP-m, NEP-s, and GFP transfected cell lysates.  NEP-s 
transfected cell lysates (cell media fraction) showed significantly higher NEP 
activity compared to NEP-n, NEP-m and GFP expressing cells.  The asterisk (*) 
indicates significance with a p-value < 0.05. The number (#) indicates 
significance with a p-value < 0.001.  Note differences in Y axis scaling for each 
panel. 
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FIGURE 5:  TOTAL AMYLOID LOAD IS REDUCED FOLLOWING 
INTRACRANIAL ADMINISTRATION OF NEP-s OR NEP-n rAAV VECTORS. 
Aβ immunostaining is observed in mice throughout both hippocampus (panels A, 
B and C) and anterior cortex (panel D, E and F).  Aβ staining in the ipsilateral 
hippocampus of animals receiving intracranial injection NEP-n (panel B) or NEP 
–s (panel C) is reduced compared to control vector NEP-m (panel A). Aβ staining 
in the right anterior cortex of mice receiving intracranial injection of NEP-s (panel 
D) or NEP-n (panel F) is reduced compared to control vector NEP-m (panel B). 
Scale bar = 120μm.  
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FIGURE 6:   QUANTIFICATION TOTAL AMYLOID LOAD IN THE 
HIPPOCAMPUS AND CORTICAL REGIONS FOLLOWING INTRACRANIAL 
ADMINISTRATION OF rAAV.   Panel A shows percent area of positive staining 
for total Abeta load of the right cortex and hippocampus ipsilateral to the injection 
site.  Panel B shows quantification left cortical and hippocampal percent area of 
positive staining for total abeta load of the contralateral hemisphere to the 
injection site. The star (*) indicates significance with a p-value < 0.05; (**) 
indicates p-value <.001. 
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FIGURE 7: CONGOPHILIC COMPACT PLAQUE LOAD IS REDUCED 
FOLLOWING INTRACRANIAL ADMINISTRATION OF NEP rAAV VECTORS.  
Total congophilic staining is observed in mice throughout both hippocampus 
(panels A, B and C) and anterior cortex (panel D, E and F).  Positive congophilic 
staining in the ipsilateral hippocampus of animals receiving intracranial injection 
NEP-n (panel B) or NEP-s (panel C) is reduced compared to control vector NEP-
m (panel A). Congophilic staining in the right anterior cortex of mice receiving 
intracranial injection of NEP-s (panel D) or NEP-n (panel F) is reduced compared 
to control vector NEP-m (panel B). Scale bar = 120μm.  
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FIGURE 8:  QUANTIFICATION OF TOTAL CONGOPHILIC LOAD IN THE 
HIPPOCAMPUS AND CORTEX FOLLOWING INTRACRANIAL 
ADMINISTRATION OF rAAV.  Panel A shows quantification of percent area of 
positive staining for total congophilic staining of the cortex and hippocampus 
ipsilateral to the injection site in the hippocampus and cortex.  Panel B shows 
quantification of percent area of positive stain of total congophilic staining in the 
contralateral hemisphere to the injection site. The star (*) indicates significance 
with a p-value < 0.05 
 
Total Congo Contralateral
B 
A
Total Congo ispilateral
 95
FIGURE 9:  DISTRIBUTION OF NEP EXPRESSION 20 WEEKS AFTER  rAAV 
NEP-S ADMINISTRATION IN AGED APP + PS1 MICE AT 15 MONTHS. Brains 
sections were immunostained for NEP with an antibody recognizing both rodent 
and human NEP.  Panels A, C, and E show NEP expression from mice treated 
with rAAV-NEP-s.  Panels B, D, and E show no NEP expression from control 
animals treated with rAAV-GFP. 
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FIGURE 10: TOTAL ABETA LOAD IS REDUCED FOLLOWING 
INTRACRANIAL ADMINISTRATION OF rAAV NEP-S IN AGED MICE. Panels 
A and C show positive immunohistochemical staining of total abeta in the 
hippocampus and cortex respectively of APP+PS1 mice treated with rAAV-NEP-
s.  Panels B and D show positive abeta staining of the hippocampus and cortex 
of untreated mice.  Panel E shows quantification of Aß immunostaining in NEP-s 
and untreated 20 Mo old APP+PS1 mice. Mice were injected at 15 mo of age in 
hippocampus and cortex of both hemispheres. RCX = right anterior cortex, LCX= 
left anterior cortex, RHPC = right hippocampus, LHPC=left ippocampus. Y axis is 
Aß load (percent area occupied by reaction product). ** P < 0.01  
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FIGURE 11: TOTAL CONGOPHILIC STAINING IS REDUCED FOLLOWING 
INTRACRANIAL ADMINISTRATION OF rAAV NEP-s IN AGED MICE. Panels A 
and C show positive immunohistochemical staining of total congo in the 
hippocampus and cortex respectively of APP+PS1 mice treated with rAAV-NEP-
s.  Panels B and D show positive abeta staining of the hippocampus and cortex 
of untreated mice.  Panel E shows quantification of Aß immunostaining in NEP-s 
and untreated 20 Mo old APP+PS1 mice. Mice were injected at 15 mo of age in 
hippocampus and cortex of both hemispheres. RCX = right anterior cortex, LCX= 
left anterior cortex, RHPC = right hippocampus, LHPC=left hippocampus. Y axis 
is Aß load (percent area occupied by reaction product). ** P < 0.01  
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ABSTRACT 
The use of recombinant adeno-associated viral (rAAV) vectors as a 
means of gene delivery to the central nervous system has emerged as a viable 
method of gene therapy for the treatment of several types of degenerative brain 
diseases. A major disadvantage of typical intracranial injections into the brain 
parenchyma is a limited distribution of the rAAV macromolecules to all brain 
regions where therapies may be needed.   Optimizing specific parameters of the 
administration techniques with the purpose of obtaining maximal gene 
distribution and gene uptake is an important obstacle to overcome for gene 
therapy studies.  Convection enhanced delivery (CED) is a method of delivering 
clinically relevant volumes of therapeutic agents to significantly larger areas of 
the brain.  The CED technique is designed to utilize the phenomenon of bulk flow 
and positive pressure to distribute macromolecules to a large area within solid 
tissue in a direct intracranial injection procedure.  In the present study the CED 
method using the step-design cannula (Krauze et al., 2005a) was used to deliver 
AAV vector serotype 5 expressing GFP into the hippocampus and cortical 
regions of the mouse brain.  Regions of the hippocampus and cortex receiving 
the CED injection showed significantly more robust expression of GFP and an 
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increased area of distribution than the simple diffusion method.  We also 
compare transduction efficiency of AAV serotypes 5, 8, and 9 using CED 
administration.  Following a single CED injection AAV 9 resulted in the largest 
area of distribution in the mouse CNS.  Moreover, the CED method, in addition to 
systemic administration of mannitol, was used to deliver rAAV vectors (serotypes 
5 and 9) expressing GFP into the hippocampus of 11 month old mice.  Mannitol 
is a blood brain barrier interruptive reagent which also induces hyperosmolarity 
thereby reducing intracranial pressure and facilitating the movement of particles 
through the interstitial space.  Mice were injected intracranially into the right 
hippocampus using the CED method with (n=8) or without (n=8) pre treatment 
with mannitol delivered intraperitoneally.  Animals receiving systemic injections of 
mannitol followed by the intracranial CED injection of rAAV into the hippocampus 
showed an increased area of distribution compared to animals that did not 
receive pre treatment with mannitol.  In addition, GFP expression was also 
detected in regions distant from the initial site of injection, in animals receiving 
the CED method with mannitol, including significant expression in the 
contralateral hemisphere to the injection site.  These data suggest that by 
optimizing injection techniques such as CED in addition to mannitol induced 
hyperosmolarity, provides an efficient means of increasing viral vector distribution 
and transgene uptake.    
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INTRODUCTION 
AAV (adeno associated viral) vectors have recently emerged as a 
promising and novel mean by which transgenes can be delivered to different 
tissue types successfully in a large range of animal species including humans.  
AAV have a unique profile with a number of advantageous characteristics which 
identify them as one of the most feasible gene transfer vectors in the treatment of 
a variety of diseases, including neurological diseases, compared to other viral 
vectors.  AAVs are one of the smallest viruses, approximately 25 nm in diameter, 
and their DNA genome is less than 5 kb which contains two large open reading 
frames with inverted terminals repeats located at either end Thomas (Berns, 
1990), (Thomas et al., 2003); (Wu et al., 2006).  The most attractive 
characteristics of AAV is their lack if pathogenicity, persistence of the transgene 
as an episome, and long term gene expression.  AAV vectors arrive in a variety 
of flavors otherwise known as serotypes.  The AAV serotype refers to the 
efficiency by which the specific AAV can infect a particular cell type through 
attachment to specific cell surface receptors.  A new AAV serotype is defined by 
the inability of an antibody that is reactive to the viral capsid protein of one 
serotype in neutralizing those of another serotype (Choi et al., 2005) .   The 
availability of different AAV serotypes is another major advantage that lends to its 
feasibility as a therapeutic in the treatment of neurodegenerative disease.  
Through the modification of serotype diversity, a variety different capsid proteins 
can be incorporated to create pseudotypes of recombinant AAV (mainly derived 
from AAV 2) which can ultimately mediate tropism and transduction efficiencies 
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targeted towards specified cell and tissue types throughout the body to optimize 
gene therapy (Choi et al., 2005), (Akache et al., 2006), (Cearley and Wolfe, 
2006), (Kwon and Schaffer, 2008).   
Unfortunately, one of the major disadvantages of a single intracranial 
injection of AAV vectors into the brain parenchyma using simple diffusion does 
not allow for efficient uptake of the transgene or significant distribution of the AAV 
macromolecules to significantly large areas of the affected regions within the 
brain.   Convection enhanced delivery (CED) is a method of delivering clinically 
relevant volumes of therapeutic agents to significantly larger areas of the brain in 
a direct intracranial injection procedure in comparison to simple diffusion 
methods.  The CED technique is designed to utilize the phenomenon of bulk flow 
and positive pressure to distribute macromolecules to a large area within solid 
tissue.  The CED technique was originally proposed by scientists in the early 
1990s as a method of delivering drugs, or macromolecules, directly to the 
parenchyma that would not normally cross the blood brain barrier (Raghavan et 
al., 2006).  Due to the lack of approved drugs that can be directly intracranially 
administered to the brain and the difficulty in predicting methods that ensure 
delivery of the therapeutic agent to its target site, CED remains an experimental 
procedure.  Furthermore, research of CED delivery devices is under current 
investigation by several researchers (Bankiewicz et al., 2000), (Raghavan et al., 
2006). 
This CED method has been investigated in gene therapy studies as a way 
to increase the distribution of AAV vectors in the brain.  Studies conducted by 
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Bankiewicz et. al. in 2000 revealed that CED can significantly increase gene 
transfer and distribution of AAV expressing AADC in the striatum of MPTP-
treated monkeys.  The AAV vector was found to be safely distributed throughout 
the entire region of the striatum compared to the simple injection method where 
the distribution was severely limited (Bankiewicz et al., 2000).  Similar results 
were replicated in the rat brain by Cunningham et. al. in 2000 with AAV2 
expressing thymidine kinase (TK) where the CED method showed robust gene 
transfer and increased distribution area within the putamen.  CED injections in 
the striatum were found distribute the AAV-TK throughout the striatum after a 
single injection into this region and TK immunoreactive cells were also found 
outside the striatum, in the globus pallidus, subthalamic nucleus, thalamus, and 
substantia nigra (Cunningham et al., 2000), (Hadaczek et al., 2006). 
One of the mechanistic limitations of the CED method as well as the 
simple injection method is the reflux of the injected material from the injection 
hole upon the removal of the cannula.  In 2002 Krauze et. al. developed a reflux 
free step cannula design which effectively eliminates reflux by placing silicone 
coated tubing within the cannula creating a step that prevents the backflow of 
fluid (Krauze et al., 2005a) .  The optimization of more efficient cannula designs 
coupled with the encouraging results from studies showing enhanced gene 
transfer and distribution emphasizes the therapeutic potential of the CED method 
in helping overcome some of the mechanical disadvantages of gene delivery in 
regards to gene therapy (Krauze et al., 2005b). 
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The use of osmotic agents such as mannitol is another method that can 
be used to increase the area of distribution of macromolecules throughout the 
CNS.  Mannitol is a blood brain barrier interruptive reagent and is also known to 
temporarily increase vascular pressure subsequently reducing intracranial 
pressure.  High concentrations of mannitol intravenously infused are currently 
used in patients with traumatic brain disease to reduce intracranial pressure.  
This osmotic agent pulls fluid from the CNS by increasing vascular osmotic 
pressure.  Several studies have also shown that with intra-arterial infusion of 
mannitol the blood brain barrier can be opened to enhance the distribution of 
chemotherapeutics throughout the CNS in both rats and humans (Nilaver et al., 
1995), (Rapoport, 2001), (Fu et al., 2003).  In this particular study we anticipate 
that by optimization of these mechanistic strategies in addition to AAV serotype 
tissue specificity we can optimize transduction efficiency and increase distribution 
area of AAV in the brain.   
 
MATERIALS AND METHODS 
Animals 
Non transgenic C57BL6 mice were acquired from the breeding colonies at 
the University of South Florida.  Multiple mice are housed together whenever 
possible until the time of use for the study; mice were then singly housed just 
before surgical procedures until the time of sacrifice.  Study animals were given 
water and food (ad libitum) and maintained on the twelve hour light/dark cycle 
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and standard vivarium conditions.  Mice aged 9 to 11 months were used for all 
experimental procedures with an n = 4 - 6 for each experimental group.   
Step Design Cannula 
 The step design cannula was used for all intracranial surgeries.  Fused silica 
tubing (polymicro technologies, Pheonix, AZ) was inserted into a 27 gauge 
Hamilton blunt ended needle and fixed in place with super glue (Krauze et al., 
2005a).  The end of the silica tubing was cut leaving 1mm of tubing protruding 
from the end of the Hamilton needle. 
GFP Expression Using CED 
Part A; animals were assigned to one of two cohorts, group one received 
AAV vector expressing GFP (n =6).  These animals received a single intracranial 
injection of the AAV-GFP vector using the CED injection method (5ul/min) or the 
traditional injection method (0.5ul/min) into either the right or left hippocampus 
and into the right or left frontal cortex.  Immediately before surgery mice were 
weighed then anesthetized using isoflurane.  Surgery was performed on animals 
using a stereotaxic apparatus, injections using the CED method were used to 
inject into hippocampus and frontal cortex at a flow rate of 5ul/min over a total 
period of 2 min. (infusion time of 0.4min) using the CED method described 
earlier.  The traditional injection method was used to inject into the hippocampus 
and frontal cortex at a flow rate of .5ul/min over a total period of 4 min. (infusion 
time of 2 min.) also described earlier.  The surgical procedure was performed by 
exposing the cranium using an incision through the skin along the median sagittal 
plane, and two holes were drilled through the cranium over the right frontal cortex 
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injection site and the right hippocampal injection site.  Previously determined 
coordinates for burr holes, taken from bregma were as follows; frontal cortex, 
anteroposterior, 1.5mm; lateral, -2.0mm, vertical, 3.0mm, hippocampus, 
anteroposterior, -2.7mm; lateral -2.5mm, vertical, 3.0mm.  Burr holes were drilled 
using a dental drill bit (SSW HP-3, SSWhite Burs Inc., Lakewood, NJ).  Each 
animal received both injection types in opposite hemispheres to control for 
mouse to mouse variability in gene uptake and expression.  Six weeks post 
surgery mice were weighed, overdosed with pentobarbital (200 mg/kg) and 
perfused with 25 ml of 0.9% normal saline solution then 50 ml of freshly prepared 
4% paraformaldehyde.  Brains were collected from the animals immediately 
following perfusion and immersion fixed in 4% paraformaldehyde for 24hrs.  
Mouse brains were cryoprotected in successive incubations in 10%, 20%, 30% 
solutions of sucrose; 24hrs in each solution.   Subsequently, brains were frozen 
on a cold stage and sectioned in the horizontal plane (25 μm thickness) on a 
sliding microtome and stored in Dulbecco’s phosphate buffered saline (DPBS) 
with 0.2% sodium azide solution at 4˚C. 
Six to eight sections 100 μm apart spanning the site of injection were 
chosen and free-floating immunochemical and histological analysis was 
performed to determine gene expression using an anti-GFP antibody at a 
concentration 1:3,000 (Chemicon; Temecula, CA).  Immunohistochemical 
procedural methods were analogous to those described by Gordon et al. 2002 for 
each marker.  Animal tissue was placed in multisample staining tray and 
endogenous peroxidase blocked (10% methanol, 30% H202, in PBS).  Tissue 
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samples were then permeabilized (with lysine 0.2%, 1% Triton X-100 in PBS 
solution), and incubated overnight in appropriate primary antibody.  Sections 
were washed in PBS then incubated in corresponding biotinylated secondary 
antibody (Vector Laboratories, Burlingame, CA).  The tissue was again washed 
after a 2hr. incubation period and incubated with Vectastin® Elite® ABC kit 
(Vector Laboratories, Burlingame, CA) for enzyme conjugation.  Finally, sections 
were stained using 0.05% diaminobenzidine and 0.3% H202 (for CD45 and FcγR 
0.5% nickelous ammonium sulfate was added for color enhancement).  Tissue 
sections were mounted onto slides, dehydrated, and coverslipped. 
Part B of the experiment was to access the safety profile of the CED 
injection method immediately following the injection procedure.  Animals received 
a single injection of saline (n =6) using either the CED method or the traditional 
injection method into the right or left hippocampus and frontal cortex.  Each 
animal received both injection methods into opposite hemispheres to control for 
variations between animals with regard to microglial activation and neurotoxicity 
to determine the safety profile of the CED technique.  Animals were sacrificed 4 
days post surgery as described earlier to determine whether the CED technique 
causes an acute significant increase in microglial activation or mechanical tissue 
damage using an immunohistochemical procedure described earlier.  Six 
sections 100 μm apart spanning the site of injection were chosen from each 
animal for part B of the experiment and free-floating immunochemical and 
histological analysis was performed for analysis of the safety profile of the CED 
method in comparison to the traditional injection method.  A series of sections 
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from experiment part B were immunostained for CD45 to determine relative 
microglial activation.  Each immunochemical assay omitted some sections from 
primary antibody incubation period to evaluate nonspecific reaction of the 
secondary antibody.  Another series of sections from part B were mounted on 
slides and stained with fluoro-jade stain (0.001%, Sigma Aldrich, St. Louis, MO) 
to assess the degree of neurotoxicity.  Fluoro-jade is an anionic fluorochrome 
that selectively stains degenerating neurons effectively detecting neuropathic 
lesions by fluorescent microscopy (Schmued et al., 1997).  A subsequent series 
of sections from part B (6 per animal) were mounted on slides and stained with 
the Cresyl Violet (Nissle) stain (0.05%, Sigma Aldrich, St. Louis, MO).  The cresyl 
violet stains all Nissl bodies of the rough endoplasmic reticulum and other acidic 
components in all neuronal cytoplasm therefore an absence of staining will 
indicate neuron loss.  For experiments which were analyzed to determine acute 
effects of the CED technique all immunohistochemical staining for CD45 and 
fluoro-jade and cresyl violet (Nissl) staining all procedures followed the same 
protocol aforementioned 4 days post surgery rather than six weeks post surgery.  
GFP Expression with Serotypes AAV 5, 8, and 9 
Study animals were assigned to one of three treatment groups receiving 
AAV serotype 5, 8, or 9.  All AAV vectors contain a coding sequence for green 
fluorescent protein (GFP).  All animals received an intracranial injection into the 
right hippocampus and all injections were performed using the CED technique 
described earlier.  Each group received a single intracranial injection of 2ul of an 
each respective AAV vector expressing GFP (1.5 x 1011vg/ul) into the right 
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hippocampus.  All intracranial surgeries were performed on a stereotaxic 
apparatus using predetermined hippocampal coordinates for the mouse 
hippocampus described earlier.  Six weeks post injection animals were sacrificed 
and brain tissue was collected as described earlier.   
GFP Expression with Serotypes AAV 5 or 9 and Mannitol 
Animals were assigned to one of four groups.  Group 1 and 2 received a 
single intracranial injection of 2ul of AAV serotypes 5 and 9 respectively 
expressing GFP (1.5 x 1011vg/ul concentration) into the right frontal cortex and 
right hippocampus using the CED injection method.  Group 3 and 4 also received 
a single intracranial 2ul injection of the AAV-GFP serotypes 5 and 9 (1.5 x 
1011vg/ul concentration) into the right frontal cortex and hippocampus in addition 
to a 200 ul single systemic intraperitoneal injection of 25% mannitol administered 
15 minutes before the intracranial injection.  The left untreated hemisphere in all 
animals remained untreated and used as an internal control.  Surgery was again 
performed on animals using a stereotaxic apparatus using burr hole coordinates 
previously described.  Six weeks post injection animals were sacrificed and brain 
tissue was collected as described earlier.  Sections were immunohistochemically 
stained using anti-GFP antibody (1:3000; Chemicon; Temecula, CA) to test for 
gene distribution and expression in addition to the markers listed in part A using 
tissue animals in each group.   
Quantification and Statistical Analysis 
All immunostained sections were imaged using an Evolution MP digital 
camera mounted on an Olympus BX51 microscope at 100X final magnification 
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(10 X objective).  Immunoflourescent double labeled images were taken using a 
confocal microscope.  Six to eight horizontal brain sections (100µm apart; every 
4th section) were taken from each animal and four nonoverlapping images near 
the site of injection from each of these sections were captured (24 
measurements per mouse).  All images were taken from the same location in all 
animals.  Quantification of positive staining surrounding and including the 
injection sites in the right frontal cortex and the right hippocampus and the 
corresponding regions in the left hemisphere were determined using Image-Pro® 
Plus (Media Cybernetics®, Silver Springs, MD).  ANOVA statistical analysis was 
performed using StatView® version 5.0.1 (SAS Institute, Raleigh, NC).    
 
RESULTS 
Non transgenic mice, 9 months old, were injected bilaterally into the 
hippocampus using either the CED injection method or the traditional injection 
method.  The CED injection method was performed as previously stated using 
the step design cannula with a flow rate of 5µl/min with a total injection time of 
approximately 2 min. including the time the cannula remained in the injection site 
to further prevent backflow of the AAV vector material.  The simple injection was 
done at a flow rate of 0.5µl/min with a total injection time of approximately 4 min.  
Each animal received both the CED method in one hemisphere and the 
traditional injection method in the opposite hemisphere to control for variations in 
gene uptake between individual animals.  The animals were survived 4 weeks 
post surgery and histology was performed to assess gene distribution and 
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expression.  Regions of the hippocampus and cortex receiving the CED injection 
showed more robust expression of GFP and an increased area of distribution 
than the traditional injection method (figure 1).    In addition, GFP expression was 
also detected in regions distant from the initial site of injection in the hemisphere 
which received the CED injection method.  Areas with positive GFP staining 
included the entorhinal cortex, as well as some neurons in the striatum and 
thalamus.  The striatum and entorrhinal cortex showed a significantly increased 
area of distribution in the animals receiving the CED injection as opposed to the 
traditional injection method.  The hippocampal and cortical regions in which the 
CED method was implemented also showed an increased intensity of staining 
immediately surrounding the cannula tip and in some distal areas in regions 
surrounding the injection site.  The difference in staining intensity appears to 
indicate an increase in gene product (GFP) and potentially indicate that the CED 
technique increases the transduction efficiency of the AAV vector by increasing 
the susceptibility of the cell to infection.  
Part B of the experiment was to determine if safety profile of the CED 
method on mechanical damage of parenchymal brain tissue.  Brain samples 
were analyzed for acute effects of the CED method in a second cohort of 
animals.  Non transgenic mice (n=6) were bilaterally injected in the same manner 
described above (injections were of PBS) using both the CED and traditional 
injection methods.  The mice were sacrificed and tissue was analyzed 4 days 
post injection and histology performed.  Neurotoxity was determined using the 
fluoro-jade stain which was only positive in a very small area in 2 animals which 
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was not significant.  Microglial expression was also analyzed to assess the 
increase in microglial activation due to the mechanical technique.  CD45 is a 
protein tyrosine phosphatase that is only expressed when microglial cells 
become activated, in this case, as a result of tissue damage (figure 2).  
Immunohistochemistry revealed that CD45 staining was increased but not 
significantly following the CED injections but this increase was limited to the area 
immediately surround the cannula tract (figure 2).  In addition the tissue was also 
stained for cresyl violet or Nissl.  The cresyl violet stains all Nissl bodies of the 
rough endoplasmic reticulum and other acidic components in all neuronal 
cytoplasm, therefore an absence of staining indicates neuron loss.  The results 
from the tissue did not reveal any significant areas devoid of Nissl staining 
signifying that there was no appreciable neuron loss (Figure 2). 
To examine whether AAV serotype was able to affect transduction 
efficiency as well as area of distribution three different vector serotypes were 
administered into right hippocampus of 11 month old non transgenic mice using 
the CED method.  A comparison of area of distribution as well as a comparison 
of transduced neurons in the hippocampus following administration of AAV 
serotypes 5, 8 and 9 each expressing GFP revealed that serotype 9 was 
distributed to a significantly greater area than either 8 or 5.  Six weeks post 
injection, serotypes 8 and 9 not only transduced neurons throughout a large 
region of the entire hippocampus but they were also successful in transducing 
neurons in the left hippocampus contralateral to the site of injection.  Conversely, 
AAV serotype 5 was primarily expressed in the neurons of the hippocampus 
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ipsilateral to the injection site.  GFP positive neurons were limited to the 
pyramidal and molecular cell layers dentate gyrus as well as cells in the hilus and 
CA1 regions.  A few GFP positive cells were observed in the entorhinal cortex in 
addition to a few GFP positive cells in the lateral thalamic region directly adjacent 
to the medial hippocampal regions but these were insignificant in comparison to 
serotypes 8 and 9.  AAV 8 and 9 serotypes revealed intense staining of GFP 
positive neurons in all three CA regions of the hippocampus as well as very 
intense staining of pyramidal cells in the molecular layer of the dentate gyurs and 
a large number of positive cells in the hilus in the ipsilateral hippocampus.  A 
large number of intensely stained cells can also be observed in the entorhinal 
cortex of the right hemisphere.  It appears that the majority of cells that have 
been transduced and are positive for GFP have intense staining not only of the 
cell body but the axonal and dendritic projections (although slightly less intense).  
These axonal projections are positive throughout the hippocampus and corpus 
callosum (which contains axonal connections between the right and left 
hemisphere).  The GFP positive axons are clearly stained at midbrain level 
ventral from the top of the cortex.  These axons are positive at the cells bodies 
from which they originate in the right contralateral hemisphere to the injections 
site, through the midline to the axonal termination site in the left hippocampus.  
Very few cells bodies were positively stained in the left uninjected hemispheres 
of mice receiving the AAV 8 and 9 serotypes.  Observations of the left 
hemisphere contralateral to the injections revealed positive staining of the axon 
terminals of neurons in the right dentate gyrus and CA regions.  Intensely stained 
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neurons can also be observed in the right entorhinal cortex for AAV 8 and 9 
treatment groups, while the left entorhinal cortex was less intense and as in the 
left hippocampus, only axons were positively stained for GFP.  Interestingly,  
GFP expression in animals receiving either AAV 8 or AAV 9 was observed not 
only in regions proximal to the right hippocampal injection site (as with AAV 5), or 
the left hippocampus resulting from retrograde axonal transport, but was also 
evident in neurons distal to the site of injection.  Following a single injection of 
AAV 8 or AAV9 GFP positive neurons in these groups were observed in the 
anterior cortex, thalamic nuclei, striatum, septal nuclei, superior colliculus, 
subiculum and cerebellum of the ipsilateral hemisphere.   
Quantification of the percent area of positive stain revealed that AAV9 
showed a 5 fold significant increase in the area of distribution in the right 
(ipsilateral) hippocampus with the left (contralateral) hippocampus showed an 
approximate 6 fold increase in the area of distribution (figure 3).  While, AAV 
serotype 8 was able to transduce a significantly greater area and number of 
neurons than AAV5, it was significantly less effective, therefore distributed to a 
significantly smaller region than AAV 9.    
Finally, we analyzed whether the osmotic agent, mannitol, could improve 
total area of distribution thus enhancing transduction efficiencies of the different 
AAV serotypes in addition to the utilization of the CED method for the intracranial 
administration.  AAV serotypes 5 and 9 (the highest and lowest transducing 
vectors in our study respectively) were given via direct intracranial injection using 
the CED method to 11 month old non transgenic animals with or without systemic 
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pre treatment with mannitol.   Animals receiving a systemic injection of 25% 
mannitol followed by CED administration into the right hippocampus of AAV 5 
showed significantly greater area of GFP expression 6 weeks post injection 
compared to animals only receiving AAV 5 administration alone.  GFP 
expression in animals receiving systemic mannitol was throughout the entire right 
hippocampal region and was also observed in the left (contralateral) 
hippocampus (figure 4).  All brain slices (25µm) in thickness through the 
hippocampus showed positive GFP staining in the mannitol treated group while 
the animals that did not receive mannitol did not have staining in the most ventral 
and dorsal portions of the hippocampus (Figure 4).  A 3 fold significant increase 
in the percent area of positive GFP stain in the right hippocampus was observed 
compared to animals that did not receive mannitol.  In the contralateral 
hemisphere we observed a 2 fold significant increase in GFP expression in 
mannitol treated animals compared to animals without mannitol pretreatment 
(figure 4).   
All animals receiving AAV 9 administered using CED with or without 
systemic mannitol showed much higher GFP expression than animals receiving 
AAV 5 similar to our previous findings.  In our comparison between animals 
receiving AAV 9 with systemic mannitol pretreatment and those that did not 
receive mannitol we did not observe significant differences of GFP expression in 
the right hippocampus (at the site of injection) or in the left hippocampus 
(contralateral to the injection site).  GFP expression in the right hemisphere was 
within the cell bodies of pyramidal neurons in the CA regions as well as granule 
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cells in the dentate gyrus, mossy fibers and cells within the hilus.  Axonal 
projections making up the perforant pathway of the hippocampus were also 
positive for GFP expression.  All cell bodies and axonal projections in these 
regions were intensely stained revealing a significant amount of GFP expression.  
GFP positive neurons were observed in the subiculum and entorhinal cortex 
which complete the hippocampal circuit.  GFP expression in the left hemisphere 
was limited to axonal projections which originate in the right hippocampal regions 
(the site of injection).  In the left hippocampus a few cells in the hilus were 
positive for GFP expression, but most staining was observed in mossy fibers as 
well as axonal projections of CA regions presumably of those originating in the 
right hippocampus.  The left entorhinal cortex was also positive for GFP 
expression but significantly less than the right entorhinal cortex (figure 5).  This 
was also true for cells within the thalamus (figure 5).  GFP positive neurons were 
also observed in the right thalamic nuclei which receives input from the 
subiculum of the hippocampus, and intense staining was observed in white 
matter tracts corpus collusum which connect the right and left hemispheres as 
well as the hippocampal commissure or commissure of fornix adjoining the right 
and left hippocampus.  Neurons positive for GFP expression were also observed 
in the anterior cortex, caudate putamen, striatum, lateral and dorsal septal nuclei, 
superior colliculus, and cerebellum of the ipsilateral hemisphere in both groups 
receiving AAV9 independent of whether they received mannitol pretreatment.   
To further characterize vector serotype tropism and whether tropism and 
transduction efficiency of AAV 5 and AAV9 was modified by mannitol the tissue 
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was double labeled using fluorescent immunostaining.  Our results, following 
injection with either AAV5  or AAV9, showed no co-localization of astrocytes 
(GFAP which stains astrocytes) and GFP positive labelling in the dentate gyrus 
of the hippocampus (or in any other regions in the brain) (figure 8).  This was 
noted in all animals receiving either serotype with or without mannitol 
pretreatment.  GFP labeled cells only co-localized with Neu-N (which stains 
neurons) positive staining (figure 8).  Positive labelling in the left uninjected 
hemisphere was in a few cells in the hilus of the DG but the majority of positive 
labelling was in the axons surrounding the cell bodies (figure 8, panel E-H).   
 
DISCUSSION 
The recent identification of different AAV serotypes has advanced the 
study of rAAV vectors which has quickly become a major dominant focus in the 
field of gene therapy.  There are a number of studies aimed at characterizing the 
different AAV serotypes with respect to transduction efficiency, tissue tropism, 
cell surface receptors, intracellular processing, and capsid structure.  AAV2 
serotype was the first to be cloned into bacterial plasmids by Samulski et. al. in 
1982 and to date it is the most characterized of all the serotypes of which a total 
of 11 have been discovered (Samulski et al., 1982).  AAV5 was originally 
discovered in a human clinical sample in 1984 as a contaminant in adenovirus 
stock and it contains ITRs that are not unlike the structures of AAV2 ITRs and is 
the most divergent of all of the serotypes (Choi et al., 2005), (Wu et al., 2007).  
AAV8 was originally isolated from rhesus monkey tissue in 2002 by Gao and 
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collegues (Gao et al., 2002).  AAV9, like AAV5, was originally discovered in 
human tissue, while AAV10 and AAV11 are the most recently identified 
serotypes, initially isolated from cynomolgus monkey tissue in 2004 by Mori et. 
al., to date have not been fully characterized (Mori et al., 2006), (Wu et al., 2006), 
(Wu et al., 2007).  Several recent studies have shown that different serotypes 
have distinct variations in their transduction efficiencies depending on the specific 
cell or tissue type, yet the molecular mechanisms which determine the preferred 
target cell for many serotypes remains unknown.  Despite what is currently 
known concerning different AAV transduction profiles, the data regarding AAV 
serotype specific tissue tropism is subject to different interpretation due to 
variations in vector titer, promoters, and transgenes between studies.  In the 
CNS, serotype characterization studies have revealed that AAV1, and 5 have 
higher transduction efficiencies than AAV2 throughout all the regions and cell 
types of the CNS (Alisky et al., 2000); (Burger et al., 2004), (Burger et al., 2005) 
while AAV4 will efficiently transduce specific cell types such as astrocytes within 
the subventricular zone (Davidson et al., 2000), (Weber et al., 2003), (Wu et al., 
2006).  Studies by Wolfe and collegues also reveal that AAV7, 8, 9 and Rh10 
expressing cDNA for lysosomal enzyme are also capable of transducing neurons 
within specific regions in the mouse brain.  AAV9 and AAVRh10 appeared to 
have the highest transduction efficiencies and were found to undergo vector 
genome transport through axonal transport pathways (Cearley and Wolfe, 2006, 
2007)(Cearley and Wolfe, 2006).  
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AAV2 vectors are the most extensively characterized and due to their well 
established safety profile and range of infectivity, approximately 20 clinical trails 
have been conducted using the AAV2 vector serotypes in numerous patients  
(Herzog and Hagstrom, 2001), (Grieger and Samulski, 2005b), (Wu et al., 2006), 
(Cai et al., 2009).  Phase I/II clinical trails have been initiated utilizing 
recombinant AAV 2 vectors for the treatment of human diseases such as cystic 
fibrosis, α-1 anti-trypsin deficiency, Parkinson’s disease, Batten’s disease, 
muscular dystrophy, hemophilia B, (Robbins and Ghivizzani, 1998) (Zhong et al., 
2008).  Unfortunately, one major disadvantage of using AAV in the treatment of 
brain disorders is the limitation in the dispersion of specific therapeutic gene or 
protein to relevant regions or the entire brain (Cearley and Wolfe, 2007).  In this 
particular study we aim to characterize and compare transduction efficiencies in 
the mouse CNS for AAV serotypes 5, 8, and 9 after a single intracranial 
administration and improve distribution of the AAV as well as increase gene 
expression in brain regions distal to the injection site using optimal injection 
techniques in an innovative manner.  Previous data from comparison studies of 
different AAV serotypes have shown AAV 2, 5, 7 ,8 and 9 efficiently transduce 
neurons in the murine CNS (Fu et al., 2003) (Burger et al., 2004) (Burger et al., 
2005) (Taymans et al., 2007).  We hypothesized that we would be able to 
sucessfully transduce neurons in the mouse brain after a single intracranial 
injection of AAV 5, 8, or 9 (that express GFP) and we will be able to increase the 
area of vector distribution using a CED administration technique in addition to 
systemic mannitol treatment in a novel combinatory fashion. 
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Following a single intracranial injection we successfully demonstrated that 
AAV9 was the most efficient serotype in transducing a larger number of neurons 
in a larger area of the brain than both AAV 5 and AAV 8.  AAV 8 was only slightly 
less efficient than AAV 9 and much more efficient that AAV5 at transducing 
neurons in the mouse CNS.  Our data in consistent with others who have also 
shown that both AAV 8 and 9 can more efficiently transduce a larger region of 
brain than AAV 5 in a murine animal model and yet others have shown this is 
pattern is consistent in other species as well  (Cearley and Wolfe, 2006).  AAV 9 
not only provides superior transduction compared to serotypes 5 and 8 in the 
CNS but in other organs such as heart, liver and lung as well as global 
transduction of several cell and tissue types in the periphery when systemically 
injected (Bish et al., 2008), (Zincarelli et al., 2008).  Furthermore, studies have 
clearly shown AAV serotype 8 to have significantly superior transduction 
efficiency than AAV2 or 5 in murine and nonhuman primate animal models which 
is also consistent with our data showing serotype 8 to be more efficient at 
transducing neurons in the mouse CNS than serotype 5 (Davidoff et al., 2005).  
There are several explanations which may account for the differences in 
transduction efficiencies between the different serotypes.  AAV must first bind to 
the cell surface receptor in order to successfully transduce the neurons once 
injected into the brain (Cearley and Wolfe, 2006), (Kwon and Schaffer, 2008), 
(Daya and Berns, 2008).  This is followed by a series of essential steps; viral 
uptake through endocytosis, intracellular trafficking and translocation of the 
particle to the nucleus, virion uncoating, synthesis of double stranded DNA and 
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finally viral gene expression (Rabinowitz et al., 2004), (Nash et al., 2007), (Kwon 
and Schaffer, 2008), (Nash et al., 2009); (Choi et al., 2005); (Cearley and Wolfe, 
2006), (Cearley et al., 2008); (Daya and Berns, 2008).  Each of these steps is 
essential to successful transgene expression and also determines the unique 
tropism of the AAV serotype.  Although the cell surface binding receptor for AAV 
1, 2, 3, 4, and 5 have been previously described, receptors for more recently 
discovered serotypes remains unclear.  In 1998 Samulski et al determined that 
AAV 2 utilizes the heparin sulfate proteoglycan receptor as its binding target and 
also uses secondary binding co- receptor targets (including the αVβ5 integrin and 
fibroblast growth factor receptor) which help stabilize viral binding thereby 
enhancing transduction efficiency (Summerford and Samulski, 1998), 
(Summerford et al., 1999), (Qiao et al., 2002), (Qing et al., 2003).  AAV 1 has 
been shown to bind to the same cell surface receptor and co-receptors as AAV 2, 
while AAV 5 has been shown to interact with the sailic acid receptor and platelet 
growth factor receptor and AAV 4, similar to AAV5, will bind to the sailic acid 
receptor but needs specific carbohydrate linkage to successfully bind to the cell 
surface (Walters et al., 2000), (Walters et al., 2001), (Kaludov et al., 2003), 
(Akache et al., 2006).  Most recently, Akache et al. have demonstrated that AAV 
8 uses the 37/67 kD laminin receptor (LamR) to bind to mammalian cells and 
overexpression of the LamR receptor results in increased binding of AAV 2,3 8 
and 9 (expressing GFP) in vitro and a 2.5 fold increase in GFP expression 
(Akache et al., 2006).  These data indicate that the differences in expression 
patterns between the different AAV serotypes used in the present study is 
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primarily mediated by the cells surface receptor that the AAV serotype binds to 
as well the co-receptors and the expression patterns of these receptors in the 
mouse CNS.  Other factors such as those previously mentioned (intracellular 
trafficking and translocation of the particle to the nucleus, virion uncoating, and 
synthesis of double stranded DNA and gene expression) may play a secondary 
role in transduction efficiencies.  Finally, the capacity to neutralize viral infection 
particles with neutralizing antibodies, generated from a previous exposure, also 
can affect the transduction profile of each serotype.  Our findings as well as 
others confirm that AAV 9 has significantly higher transduction efficiency in 
neurons in the CNS compared to AAV 8 and AAV 5.  The differences in cell 
specific transduction efficiencies are likely a consequence of the effective cellular 
entry through cell surface receptor modulation as well as un-packaging and post-
entry properties of each serotype (Hauck et al., 2004), (Wang et al., 2007).  We 
speculate that in this study AAV 9 was the most efficient likely due to its effective 
and stable binding to specific cell surface receptors possibly the LamR receptor 
or other potential receptors in addition to their expression profile within the 
murine CNS.  AAV 9 may be taken up by the cell more efficiently followed by 
more efficient translocation and viral uncoating and un-packaging within the 
nucleus of the neuronal cell and efficient DNA replication and expression 
properties.  The relative importance of each step in the process of transduction in 
the mouse CNS remains unclear and warrants more study which would lend to 
efforts in creating tailored recombinant AAV vectors with unique and disease 
modifying specificity.  
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Our next goal was to determine an optimal injection protocol aimed at 
improving distribution properties of the AAV vectors within the brain parenchyma.  
All of the intracranial injections into the hippocampus were performed using the 
CED technique with a modified version of the step design cannula (Bankiewicz et 
al., 2000) (Krauze et al., 2005a) which has previously been shown by us and 
others to further increase the area of distribution of material in the brain 
parenchyma in murine, canine, nonhuman primate as well as in humans 
(Bankiewicz et al., 2000), (Krauze et al., 2005b), (Szerlip et al., 2007), 
(Cunningham et al., 2008), (Dickinson et al., 2008), (Fiandaca et al., 2008).  In 
the present study we successfully further increase the area of distribution and 
gene expression by combining the CED method with administration of mannitol 
systemically approximately 15 min prior to the intracranial injection of AAV.  Our 
data are consistent with previous studies using AAV 2, in which mannitol further 
increased the area of distribution within the striatum of the rat brain (Burger et al., 
2004).  We clearly demonstrated that mannitol, by osmotically lowering 
intracranial pressure, could significantly increase the area of distribution of AAV 5 
after a single CED administration into the DG of the right hippocampus.  This 
distribution was evident throughout the entire right hippocampus allowing viral 
particles to travel to areas throughout the right hippocampus as well as other 
areas adjacent to the injection site such as the entorhinal cortex and thalamus 
(although the expression was limited to a few cells in these regions).  In addition 
a significant amount of GFP gene expression was noted in the left uninjected 
hemisphere most likely due to axonal retrograde transport which was not as 
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apparent without mannitol pretreatment.  The increase in GFP expression in the 
left hippocampus we attribute to greatly increasing the number of cells in the 
injected hemisphere that were exposed and therefore infected and expressing 
significantly more GFP that was then transported axonally to the left hemisphere.   
Mannitol also increased GFP gene expression in the AAV 9 treatment group in 
the entorhinal cortex and thalamus.  We did not see significant changes in the 
hippocampus due to the preexisting high transduction efficiency of AAV 9 
throughout the right and left hippocampi. 
Despite the rapidly growing popularity of AAV as a method of gene 
delivery, much remains unknown with regard to cellular mechanisms that are 
responsible for different AAV characteristics.  Although AAV demonstrate long-
term gene expression in vivo and a good safety profile, potential risks due to the 
host response to these vectors need further study.  Unlike adenovirus vectors 
which induce expression of chemokines and acute toxicity, AAV have not been 
previously associated with an inflammatory response or significant toxcity (Beuler 
et al., 1999), (Carter et al., 2000), (Muruve et al., 2004).  Some studies have 
shown repeated administration of AAV in the periphery results in a hummoral 
immune response, generated in the first administration, which dramatically 
lowers transduction efficiency upon second administration (Halbert et al., 
1997),(Halbert et al., 1998).  This problem can be overcome by host immuno-
suppression (Halbert et al., 1998), (Manning et al., 1998).  The majority of the 
human population (an estimated 80%) has been naturally previously exposed to 
wt AAV 2 and demonstrates presence of neutralizing anticapsid antibodies 
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(Chirmule et al., 1999), (Erles et al., 1999) which could be a potential problem for 
clinical success of AAV 2.  Recently studies have demonstrated that generating 
recombinant AAV can effectively overcome wt AAV neutralizing antibodies 
(Mandell et al., 2004).  Through modification of wt AAV and the creation of a 
variety of rAAV with uniquely tailored specificity, there is immeasurable potential 
for the use of AAV as a successful gene therapy technique. 
In the present study we investigate not only differences in transduction 
profiles of specific AAV serotypes but also optimization of administration 
techniques with regard to AAV in the CNS.  In recent years, scientists have 
conducted several studies aimed at improving transduction efficiencies of AAV 
vectors in different tissue types through modification of the AAV genome.  The 
utilization  of a “cross-packaging” strategy which essentially enables an unbiased 
direct comparison of the transduction rates without influence of ITRs on 
transgene expression has recently become a novel way to create recombinant 
AAV vectors (Rabinowitz and Samulski, 2000), (Rabinowitz et al., 2004), (Grieger 
and Samulski, 2005a), (Wu et al., 2006).  To accomplish this the Cap genes of 
different serotypes are placed downstream of the AAV2 Rep genes which 
ultimately allows the generation of serotypes specific capsids while the packaged 
genomes within the capsids are identical, these are also referred to as hybrid 
viruses (Rabinowitz et al., 2002), (Wu et al., 2006).  In addition to 
transcapsidation first described by Rabinowitz et. al. in 2002 there are several 
other techniques to accomplish the formation of a hybrid virus armed with 
specific modifications to enhance efficiency of gene uptake, transfer, and 
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expression in a specified therapeutic avenue.  These include absorption 
modifications where the capsid surface is modified to carry a foreign antibody 
that will bind to the cell surface receptor of interest to increase absorption 
efficiency.  Mosaic capsids are another method to increase transduction 
efficiency.  This technique involves creating a mixture of viral capsid proteins 
from different serotypes at various ratios in order to combine tissue tropisms of 
interest (Xiao et al., 1999), (Rabinowitz and Samulski, 2000), (Kruger et al., 
2008).  Finally, chimeric capsids can also provide a means of increasing 
transduction of a particular specificity and this technique involves the packaging 
of capsid proteins with foreign peptide sequences, such as a hemagglutinin (HA) 
tag fused at either the N or C terminus of the capsid coding sequence to alter 
tissue tropism (Yang et al., 1999), (Bowles et al., 2003), (Wu et al., 2006).  
Despite the rapidly growing body of knowledge in the field of AAV vector 
serology there is still much to be done.  In addition to the 11 AAV serotypes that 
have been found, over 100 AAV variants have also been discovered.  Delineating 
differences in transduction properties, and defining distinct characteristics of 
each virus is a burgeoning area of investigation.  The technological advances in 
recombinant molecular biology have permitted investigators to construct a myriad 
of recombinant AAV vectors that can be customized to take advantage of 
differences in transduction profiles which can be targeted for several different cell 
types. In addition, optimization of administration techniques that increase 
distributive properties of AAV such as CED and mannitol have improved gene 
delivery capacity of these vectors suggesting near limiteless potential they may 
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provide as a superior gene transfer vehicle through which to treat a variety of 
neurological diseases.  
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FIGURE 1: GFP EXPRESSION IS INCREASED FOLLOWING INTRACRANIAL 
ADMINISTRATION OF AAV5 USING CONVECTION ENHANCED DELIVERY. 
Percent positive area stained for anti-GFP is increased in the hippocampus, 
cortex and thalamus in 9 month old mice using CED method (5μl/min flow rate).  
The percent positive staining of GFP is significantly increased in the striatum and 
entorhinal cortex using the CED method compared to traditional injection 
method. The star (*) indicates significance with a p-value < 0.05.  Magnification 
100X on Olympus BX51. 
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FIGURE 2: CED METHOD DOES NOT RESULT IN NEURON LOSS OR 
SIGNIFICANT INCREASE IN CD45 EXPRESSION.   Nissl staining showed no 
obvious loss of neurons in the hippocampus following either the CED injection 
method (panel B) or the traditional injection method (panel A).  CD45 
immunostaining is increased (panel E) but not significantly in animals receiving 
the CED injection (panel D) compared to animals receiving the traditional 
injection (panel C).  Quantification of CD45 immunostaining is represented as % 
Area stain (panel E).   Magnification 40X on Olympus BX51. 
E
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FIGURE 3: COMPARISON OF AAV SEROTYPES 5, 8, AND 9 EXPRESSING 
GFP.   Expression of GFP in the right and left hippocampus following a single 
CED intracranial injection into the right hippocampus of AAV5, 8, and 9 
serotypes.  AAV 9 was distributed to a significantly larger area of the 
hippocampus in both the left and right hippocampus (panels A and B) following 
treatment than both AAV serotype 8 and 5 (panel C-F). The star (*) indicates 
significance with a p-value < 0.05.  Magnification 40X on Olympus BX51. 
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FIGURE 4: GFP EXPRESSION IS INCREASED FOLLOWING 
ADMINISTRATION OF AAV5 USING CED AND SYSTEMIC MANNITOL. 
Percent positive area stained for anti-GFP is significantly increased in the right 
and left hippocampus in 11 month old mice following CED delivery of AAV5 and 
systemic mannitol pretreatment (panel C and D) compared to animals injected 
with AAV 5 and did not receive systemic mannitol (panel A and B).  Panel E 
shows quantification of percent area positive stain for anti-GFP 
immunohistochemistry. The star (*) indicates significance with a p-value < 0.05.  
Magnification 40X on Olympus BX51 (panels A-D). 
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FIGURE 5:  GFP EXPRESSION IS INCREASED IN THE THALAMUS AND 
ENTORINAL CORTEX FOLLOWING ADMINISTRATION OF AAV9 USING 
CED AND SYSTEMIC MANNITOL.   Positive area stained for anti-GFP was 
intense throughout the entire hippocampus for all 11 month old mice following 
CED delivery of AAV9 with (panels A and B) or without systemic mannitol 
pretreatment (panels C and D).  A larger area of positive area staining was 
evident in the both the left and right entorhinal cortex and the right thalamus 
following CED delivery of AAV9 in animals pretreated with systemic mannitol 
(panels G and H) compared to animals that did not receive systemic mannitol 
(panels E and F).  Magnification 40X on Olympus BX51 (panels A-H). 
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FIGURE 6: QUANTIFICATION OF ANTI-GFP STAINING FOLLOWING AAV 9 
ADMINISTRATION.  Quantification of Percent positive area stained for anti-GFP 
is significantly increased in the thalamus and entorhinal cortex in 11 month old 
mice following CED delivery of AAV9 and systemic mannitol pretreatment (panel 
B)  No significant difference in anti-GFP staining was noted in the right or left 
hippocampus following AAV 9 administration and systemic mannitol 
pretreatment. The star (*) indicates significance with a p-value < 0.05.  
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FIGURE 7:  TRANSDUCTION EFFICIENCY IN HIPPOCAMPUS FOLLOWING 
AAV5 AND AAV9 ADMINISTRATION.  Transduction of GFP following AAV 5 
and AAV9 administration into the hippocampus.  GFP is expressed in the dentate 
gyrus granule and pyramidal cell bodies and axons in CA regions in the 
hippocampus primarily in the right hemisphere following a single intracranial 
injection of AAV 5 using CED method and systemic mannitol administration into 
the right hippocampus and in axonal projections in the left hippocampus (panels 
C and D; and E-H).  GFP is expressed in neuronal cell bodies and axonal 
projections in all regions of right hippocampus following AAV 9 injections using 
CED and systemic mannitol administration (panels A and B). GFP expression is 
primarily in axonal projections eminating from the right hippocampus as well as in 
some neuronal cell bodies in the hilus of the dentate gyrus (panels I-K).   
Magnification 40X panels A-D; magnification 100X panels E-K. 
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FIGURE 8:   TRANSDUCTION EFFICIENCY AND GFP EXRESSION IN CELL 
TYPES FOLLOWING AAV 5 AND AAV9 ADMINISTRATION INTO 
HIPPOCAMPUS.  GFP is expressed in the granule and pyramidal cell layers in 
the hippocampus as well as in neurons in entorhinal cortex primarily in the right 
hemisphere following a single intracranial injection into the right hippocampus.  
Panels A-D shows no co-localization (panel D) of astrocytic staining (GFAP) 
(panel B) and GFP positive labeling (panel A) in the dentate gyrus of the 
hippocampus (or in any other regions in the brain).  This was noted in all animals 
receiving either serotype.  Positive labelling in the left uninjected hemisphere was 
in a few cells in the hilus (panel E) of the DG.  Co-localization of NeuN and GFP 
positive staining indicate that mainly neurons were transfected in this region 
(panel E-H).  The majority of positive labelling was in the axons surrounding the 
cell bodies (panel E).  Panels I-L show staining of the entorhinal cortex ipsilateral 
to the injection site.  Co-localization of GFP positive cells and Neu-N (panel L) 
indicates that AAV transfect mainly neurons in this region.  Magnification 100X. 
 143
 
 
 
 
 
 
 
 
 
 
Injected Side Dentate Gyrus
GFP GFAP DAPI
DAPIGFP NeuN
MERGED
MERGEDE
I
F
B
J
C
G
K
D
H
L
Uninjected Side Dentate Gyrus 
Injected Side Entorhinal 
A
GFP NeuN DAPI MERGED
 144
REFERENCE LIST 
 
Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA (2006) The 37/67-
kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 
2, 3, and 9. J Virol 80:9831-9836. 
 
Alisky JM, Hughes SM, Sauter SL, Jolly D, Dubensky TW, Jr., Staber PD, 
Chiorini JA, Davidson BL (2000) Transduction of murine cerebellar neurons with 
recombinant FIV and AAV5 vectors. Neuroreport 11:2669-2673. 
 
Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, 
Cunningham J, Budinger TF, Harvey-White J (2000) Convection-enhanced 
delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene 
expression and restoration of dopaminergic function using pro-drug approach. 
ExpNeurol 164:2-14. 
 
Berns KI (1990) Parvovirus replication. Microbiol Rev 54:316-329. 
 
Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, Wilson JM, 
Sweeney L (2008) AAV9 Provides Global Cardiac Gene Transfer Superior to 
AAV1, AAV6, AAV7, and AAV8 in the Mouse and Rat. Hum Gene Ther. 
 
Bowles DE, Rabinowitz JE, Samulski RJ (2003) Marker rescue of adeno-
associated virus (AAV) capsid mutants: a novel approach for chimeric AAV 
production. JVirol 77:423-432. 
 
Burger C, Nash K, Mandel RJ (2005) Recombinant adeno-associated viral 
vectors in the nervous system. HumGene Ther 16:781-791. 
 
Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier 
PJ, Mandel RJ, Muzyczka N (2004) Recombinant AAV viral vectors pseudotyped 
with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell 
tropism after delivery to different regions of the central nervous system. MolTher 
10:302-317. 
 
Cai X, Conley SM, Naash MI (2009) RPE65: role in the visual cycle, human 
retinal disease, and gene therapy. Ophthalmic Genet 30:57-62. 
Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated 
virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. 
MolTher 13:528-537. 
 
Cearley CN, Wolfe JH (2007) A single injection of an adeno-associated virus 
vector into nuclei with divergent connections results in widespread vector 
distribution in the brain and global correction of a neurogenetic disease. J 
Neurosci 27:9928-9940. 
 145
 
Cearley CN, Vandenberghe LH, Parente MK, Carnish ER, Wilson JM, Wolfe JH 
(2008) Expanded repertoire of AAV vector serotypes mediate unique patterns of 
transduction in mouse brain. Mol Ther 16:1710-1718. 
 
Choi VW, McCarty DM, Samulski RJ (2005) AAV hybrid serotypes: improved 
vectors for gene delivery. CurrGene Ther 5:299-310. 
 
Cunningham J, Oiwa Y, Nagy D, Podsakoff G, Colosi P, Bankiewicz KS (2000) 
Distribution of AAV-TK following intracranial convection-enhanced delivery into 
rats. Cell Transplant 9:585-594. 
Cunningham J, Pivirotto P, Bringas J, Suzuki B, Vijay S, Sanftner L, Kitamura M, 
Chan C, Bankiewicz KS (2008) Biodistribution of adeno-associated virus type-2 
in nonhuman primates after convection-enhanced delivery to brain. Mol Ther 
16:1267-1275. 
 
Davidoff AM, Gray JT, Ng CY, Zhang Y, Zhou J, Spence Y, Bakar Y, Nathwani 
AC (2005) Comparison of the ability of adeno-associated viral vectors 
pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient 
transduction of the liver in murine and nonhuman primate models. Mol Ther 
11:875-888. 
 
Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, 
Ghodsi A, Chiorini JA (2000) Recombinant adeno-associated virus type 2, 4, and 
5 vectors: transduction of variant cell types and regions in the mammalian central 
nervous system. ProcNatlAcadSciUSA 97:3428-3432. 
Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. 
Clin Microbiol Rev 21:583-593. 
 
Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Roberts B, Larson RF, 
Yamashita Y, Krauze M, Noble CO, Drummond D, Kirpotin DB, Park JW, Berger 
MS, Bankiewicz KS (2008) Canine model of convection-enhanced delivery of 
liposomes containing CPT-11 monitored with real-time magnetic resonance 
imaging: laboratory investigation. J Neurosurg 108:989-998. 
 
Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS (2008) Image-guided 
convection-enhanced delivery platform in the treatment of neurological diseases. 
Neurotherapeutics 5:123-127. 
 
Fu H, Muenzer J, Samulski RJ, Breese G, Sifford J, Zeng X, McCarty DM (2003) 
Self-complementary adeno-associated virus serotype 2 vector: global distribution 
and broad dispersion of AAV-mediated transgene expression in mouse brain. 
MolTher 8:911-917. 
 
 146
Grieger JC, Samulski RJ (2005a) Adeno-associated virus as a gene therapy 
vector: vector development, production and clinical applications. AdvBiochemEng 
Biotechnol 99:119-45.:119-145. 
 
Grieger JC, Samulski RJ (2005b) Adeno-associated virus as a gene therapy 
vector: vector development, production and clinical applications. Adv Biochem 
Eng Biotechnol 99:119-145. 
 
Hadaczek P, Kohutnicka M, Krauze MT, Bringas J, Pivirotto P, Cunningham J, 
Bankiewicz K (2006) Convection-enhanced delivery of adeno-associated virus 
type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. 
HumGene Ther 17:291-302. 
 
Hauck B, Zhao W, High K, Xiao W (2004) Intracellular viral processing, not 
single-stranded DNA accumulation, is crucial for recombinant adeno-associated 
virus transduction. J Virol 78:13678-13686. 
 
Herzog RW, Hagstrom JN (2001) Gene therapy for hereditary hematological 
disorders. Am J Pharmacogenomics 1:137-144. 
 
Kaludov N, Padron E, Govindasamy L, McKenna R, Chiorini JA, Agbandje-
McKenna M (2003) Production, purification and preliminary X-ray crystallographic 
studies of adeno-associated virus serotype 4. Virology 306:1-6. 
 
Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, Berger MS, 
Bankiewicz K (2005a) Reflux-free cannula for convection-enhanced high-speed 
delivery of therapeutic agents. JNeurosurg 103:923-929. 
 
Krauze MT, McKnight TR, Yamashita Y, Bringas J, Noble CO, Saito R, 
Geletneky K, Forsayeth J, Berger MS, Jackson P, Park JW, Bankiewicz KS 
(2005b) Real-time visualization and characterization of liposomal delivery into the 
monkey brain by magnetic resonance imaging. Brain ResBrain ResProtoc 16:20-
26. 
 
Kruger L, Eskerski H, Dinsart C, Cornelis J, Rommelaere J, Haberkorn U, 
Kleinschmidt JA (2008) Augmented transgene expression in transformed cells 
using a parvoviral hybrid vector. Cancer Gene Ther 15:252-267. 
 
Kwon I, Schaffer DV (2008) Designer gene delivery vectors: molecular 
engineering and evolution of adeno-associated viral vectors for enhanced gene 
transfer. Pharm Res 25:489-499. 
 
Mori S, Takeuchi T, Enomoto Y, Kondo K, Sato K, Ono F, Iwata N, Sata T, 
Kanda T (2006) Biodistribution of a low dose of intravenously administered AAV-
2, 10, and 11 vectors to cynomolgus monkeys. JpnJInfectDis 59:285-293. 
 147
 
Nash K, Chen W, Salganik M, Muzyczka N (2009) Identification of cellular 
proteins that interact with the adeno-associated virus rep protein. J Virol 83:454-
469. 
 
Nash K, Chen W, McDonald WF, Zhou X, Muzyczka N (2007) Purification of host 
cell enzymes involved in adeno-associated virus DNA replication. J Virol 
81:5777-5787. 
 
Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, 
Neuwelt EA (1995) Delivery of herpesvirus and adenovirus to nude rat 
intracerebral tumors after osmotic blood-brain barrier disruption. 
ProcNatlAcadSciUSA 92:9829-9833. 
 
Qiao C, Li J, Skold A, Zhang X, Xiao X (2002) Feasibility of generating adeno-
associated virus packaging cell lines containing inducible adenovirus helper 
genes. J Virol 76:1904-1913. 
 
Qing K, Li W, Zhong L, Tan M, Hansen J, Weigel-Kelley KA, Chen L, Yoder MC, 
Srivastava A (2003) Adeno-associated virus type 2-mediated gene transfer: role 
of cellular T-cell protein tyrosine phosphatase in transgene expression in 
established cell lines in vitro and transgenic mice in vivo. J Virol 77:2741-2746. 
 
Rabinowitz JE, Samulski RJ (2000) Building a better vector: the manipulation of 
AAV virions. Virology %20;278:301-308. 
 
Rabinowitz JE, Bowles DE, Faust SM, Ledford JG, Cunningham SE, Samulski 
RJ (2004) Cross-dressing the virion: the transcapsidation of adeno-associated 
virus serotypes functionally defines subgroups. JVirol 78:4421-4432. 
 
Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ (2002) 
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome 
into multiple AAV serotypes enables transduction with broad specificity. JVirol 
76:791-801. 
 
Raghavan R, Brady ML, Rodriguez-Ponce MI, Hartlep A, Pedain C, Sampson JH 
(2006) Convection-enhanced delivery of therapeutics for brain disease, and its 
optimization. NeurosurgFocus 20:E12. 
 
Rapoport SI (2001) Advances in osmotic opening of the blood-brain barrier to 
enhance CNS chemotherapy. ExpertOpinInvestigDrugs 10:1809-1818. 
 
Robbins PD, Ghivizzani SC (1998) Viral vectors for gene therapy. Pharmacol 
Ther 80:35-47. 
 
 148
Samulski RJ, Berns KI, Tan M, Muzyczka N (1982) Cloning of adeno-associated 
virus into pBR322: rescue of intact virus from the recombinant plasmid in human 
cells. Proc Natl Acad Sci U S A 79:2077-2081. 
 
Schmued LC, Albertson C, Slikker W, Jr. (1997) Fluoro-Jade: a novel 
fluorochrome for the sensitive and reliable histochemical localization of neuronal 
degeneration. Brain Res 751:37-46. 
 
Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 
72:1438-1445. 
 
Summerford C, Bartlett JS, Samulski RJ (1999) AlphaVbeta5 integrin: a co-
receptor for adeno-associated virus type 2 infection. Nat Med 5:78-82. 
 
Szerlip NJ, Walbridge S, Yang L, Morrison PF, Degen JW, Jarrell ST, Kouri J, 
Kerr PB, Kotin R, Oldfield EH, Lonser RR (2007) Real-time imaging of 
convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg 
107:560-567. 
 
Taymans JM, Vandenberghe LH, Haute CV, Thiry I, Deroose CM, Mortelmans L, 
Wilson JM, Debyser Z, Baekelandt V (2007) Comparative analysis of adeno-
associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene 
Ther 18:195-206. 
 
Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of 
viral vectors for gene therapy. NatRevGenet 4:346-358. 
 
Walters RW, Duan D, Engelhardt JF, Welsh MJ (2000) Incorporation of adeno-
associated virus in a calcium phosphate coprecipitate improves gene transfer to 
airway epithelia in vitro and in vivo. J Virol 74:535-540. 
 
Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, Zabner J 
(2001) Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is 
required for gene transfer. J Biol Chem 276:20610-20616. 
 
Wang J, Xie J, Lu H, Chen L, Hauck B, Samulski RJ, Xiao W (2007) Existence of 
transient functional double-stranded DNA intermediates during recombinant AAV 
transduction. Proc Natl Acad Sci U S A 104:13104-13109. 
 
Weber M, Rabinowitz J, Provost N, Conrath H, Folliot S, Briot D, Cherel Y, 
Chenuaud P, Samulski J, Moullier P, Rolling F (2003) Recombinant adeno-
associated virus serotype 4 mediates unique and exclusive long-term 
transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate 
after subretinal delivery. Mol Ther 7:774-781. 
 149
 
Wu J, Zhao W, Zhong L, Han Z, Li B, Ma W, Weigel-Kelley KA, Warrington KH, 
Srivastava A (2007) Self-complementary recombinant adeno-associated viral 
vectors: packaging capacity and the role of rep proteins in vector purity. Hum 
Gene Ther 18:171-182. 
 
Wu Z, Asokan A, Samulski RJ (2006) Adeno-associated virus serotypes: vector 
toolkit for human gene therapy. MolTher 14:316-327. 
 
Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM (1999) Gene 
therapy vectors based on adeno-associated virus type 1. JVirol 73:3994-4003. 
 
Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF (1999) 
Concatamerization of adeno-associated virus circular genomes occurs through 
intermolecular recombination. JVirol 73:9468-9477. 
 
Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, 
Herzog RW, Zolotukhin I, Warrington KH, Jr., Weigel-Van Aken KA, Hobbs JA, 
Zolotukhin S, Muzyczka N, Srivastava A (2008) Next generation of adeno-
associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency 
transduction at lower doses. Proc Natl Acad Sci U S A 105:7827-7832. 
 
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE (2008) Analysis of AAV serotypes 
1-9 mediated gene expression and tropism in mice after systemic injection. Mol 
Ther 16:1073-1080. 
 
 
 
 
 
 
 
 
 
 
 
 150
 
 
CONCLUSIONS 
 
Alzheimer’s disease (AD) is the sixth leading cause of death in the United 
States and has been known as one of the most pervasive and devastating forms 
of dementia afflicting the aged population worldwide accounting for 70% of all 
dementia cases.   Although the pathological etiology which causes a slow 
progressive decline in normal brain function is well characterized, we have yet to 
identify novel therapeutics that result in the cessation of the disease process and 
a marked overall significant and longterm improvement in cognitive function.  
Unfortunately, with the steady increase in life expectancy of our aged population, 
the number of individuals over the age of 65 affected with this disease is rapidly 
increasing and will continue to increase by approximatly 50% over the next two 
decades.   Current estimations predict that 10 million baby boomers will develop 
AD in the coming years.  AD causes emotional trauma to family members and 
caregivers in addition to generating a growing economic burden as healthcare 
costs continue to rise in accordance with the increasing number of individuals 
who suffer from the disease.  Finding a novel therapeutic to delay onset of 
symptoms, improve cognitive function and potentially prevent further mental 
decline is essential to relieve both ecomonic and emotional burdens which may 
plague many individuals in the near future.     
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 The pathological disease process of AD that instigates the destruction of 
neurons in the CNS is thought to ultimately result in the progressive decline in 
mental function and cognitive abilities that manifest as a general loss of memory 
that is severe enough to interfere with daily life.  This decline in memory can be 
an early clinical symptom of AD.  Because there are several other types of 
dementia that have overlapping symptom patterns, a true diagnostic confirmation 
of AD is the presence of neuritic plaques composed of beta-amyloid (Aβ) and 
intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein 
identified in post-mortem brain tissue.     
 The Aβ peptide which was first discovered in 1984 has for decades been 
identified as the central pathological feature from which all other 
neuropathological insults that occur in AD disease progression stem (Glenner et 
al., 1984).  The Amyloid Cascade Hypothesis, first described by John Hardy and 
David Allsop circa 1991 suggests that it is the the overproduction and ensuing 
accumulation of Aβ peptides, resulting from the abberant processing of APP that 
is the fundamental event which then drives the formation of phosphorylated tau 
into neurofibrillary tangles which then result in disruption and disregulation of 
synaptic transmission, eventually causing the death of neurons and manifestation 
of dementia (Hardy and Allsop, 1991), (Selkoe, 1991a, 2001), (Tanzi, 2005).  
This theory has provided a roadmap of AD pathology for decades and is 
supported by a number of epidemiological genetic studies, molecular in vitro 
studies as well as in vivo studies using animal models of amyloid accumulation.     
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 The role of APP protein metabolism in AD pathogenesis has been 
extensively studied, although its native biological role is still only speculative.  
Some studies suggest that APP is involved in synaptic formation and repair as 
well as neuronal plasticity (Wang et al., 2006), (Priller et al., 2006).  Recent 
studies provide substantial evidence that APP expression is upregulated during 
neuronal differentiation following neural injury.  Additionally, APP has been 
implicated to participate in cell signaling, long-term potentiation, and cell 
adhesion but only a limited number of studies have been done in this area to 
date (Zheng et al., 2006), (Priller et al., 2006).  APP undergoes numerous post 
translation modifications (De Strooper et al., 2000) as well as many types of 
proteolyic processing.  A number of genetic studies clearly illustrate that 
mutations in APP can cause the over production of Aβ peptides resulting in an 
increased ratio of the more fibrillogenic Aβ1-42/1-40 (Wang et al., 1999), (Ling et 
al., 2003).  The APP gene has been localized to chromosome 21 and thus as a 
result AD-like neuropathology is consistently observed in Down’s syndrome or 
trisomy 21, due to the increased APP expression and thus higher Aβ levels 
(Glenner and Wong, 1984).    
 Unfortunately, the autosomal dominant genetic mutations that result in AD 
(originally identified during the 1990’s) which include the APP mutations and the 
presenilin mutations (PS1 and PS2), occur infrequently and account for a 
miniscule percentage of the current population (approximately 1-2 %) which 
suffers from the disease (Selkoe, 1991b), (Nunan and Small, 2002), (Saito et al., 
2003).  These FAD (familial AD) mutations also result in very aggressive disease 
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progression and clinical symptoms can become apparent as early as 30 to 40 
years of age but most commonly before the age of 65 (Selkoe, 1991c).  Thus the 
overwhelming majority of AD cases occur in an age dependent manner at a rate 
that increases exponentially with age.  Recently, a more thorough investigation 
into the cellular processes that mediate the sporadic late onset AD cases has 
become a dominant approach in the identification of specific targets in the 
treatment of AD.    
 The identification of the FAD mutations and the role they play in the 
production of the toxic Aβ peptides (due to abberant changes in APP processing) 
gave rise to the first generation of Aβ overexpressing mouse models of AD.  The 
PDAPP mouse model of AD was the first transgenic mouse containing the 
overexpressed mutant human APP and provided a new animal model through 
which to investigate mechanisms of amyloid deposition and removal (but did not 
contain tau pathology nor neuron loss) (Games et al., 1995).  Other transgenic 
mouse models followed including the Tg2576 which was the first mouse model to 
show learning memory deficits that were closely correlated with age dependent 
amyloid deposition in a reliable fashion (Hsiao et al., 1996), (Morgan et al., 
2000), (Ashe, 2006).  Additional transgenic mouse models of AD include the 
double transgenic APP + PS1 mutations that harbor an increased aggressive 
pathology that begins at a younger age than that of the afor-mentioned single 
transgenic animals.  These mice also show learning and memory deficits at an 
early age (which again correlated with paranchymal amyloid load) compared to 
 154
the mouse models with only the APP mutations  (Borchelt et al., 1997), (Citron et 
al., 1998), (Holcomb et al., 1998), (Gordon et al., 2002).   
The development of mouse models of Aβ accumulation and deposition 
paved the way for the development of several therapeutic target strategies that 
have evolved over recent years and yet unfortunately an effective therapeutic 
that can permanently reverse cognitive deficits suffered by AD patients remains 
elusive.   Currently, there are two types of medications approved for the 
treatment of AD which include cholinesterase inhibitors and N –methyl –D 
aspartate (NMDA) antagonist.  Although some patients respond initially to these 
drugs they do not modify the disease process, only having a transient moderate 
effect on clinical symptoms with a host of unappealing side effects.  The lack of 
disease modifying drugs for AD has fueled research efforts focused on 
development of novel therapeutics that have the potential to halt its progression 
and improve clinical symptoms. 
The supposition that Aβ is the primary toxic pathogenic agent that 
accumulates subsequently inducing a number of other pathogical abnormalities 
has provided the catalyst driving several therapeutic approaches aimed at 
lowering Aβ levels in the brain to treat AD (Hardy and Allsop, 1991), (Turner et 
al., 2004).  Although Aβ toxicity has been extensively studied and is generally 
accepted, the specific form of Aβ aggregate that is the primary caustic moiety 
contributing to neuron dysfunction is still debated.   Initial reports identified fibrillar 
Aβ as the major toxic species which subsequently resulted in decreased synaptic 
function and neuronal death.  Current reports have refuted these initial findings 
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revealing that large Aβ deposits or plaques may in fact play a neuroprotective 
role.  Their formation may provide a mechanism in which smaller soluble Aβ 
moieties are sequestered into larger insoluble aggregates preventing them from 
causing destruction.  Specifically, the soluble oligomeric Aβ assemblies have 
been implicated as the driving factor in AD pathogenesis as they exhibit potent 
toxicity in their capacity to significantly decrease long term potentiation (LTP), 
contribute to learning and memory deficits in vivo and induce neuronal cell death 
in vitro (Lambert et al., 1998), (Naslund et al., 2000), (Klein, 2002), (Glabe, 
2005), (Townsend et al., 2006), (Selkoe, 2008), (Varvel et al., 2008).  Under 
normal physiological conditions Aβ is constitutively produced and catabolized in 
the brain which suggests that it may have a role as a physiological metabolite of 
APP processing.  Furthermore, recent studies have shown that picomolar 
concentrations of Aβ containing both monomers and oligomers cause an 
increase in hippocampal long term potentiation and improved memory whereas 
higher concentrations in the nanomolar range, Aβ conversely causes a reduction 
in potentiation by modifiying the activity of voltage-dependent Ca + channels and 
GTPase activity in neurons (Cirrito et al., 2003), (Puzzo et al., 2008); (Koudinov 
and Berezov, 2004).  These results suggest the production of low levels of Aβ is 
a normal physiological process involved in modulating neurotransmission that 
occurs during learning and memory.  Conversely, high levels of Aβ leads to 
deficits in neurotransmission eventually leading cognitive deficits manifested as 
dementia (Cirrito et al., 2003), (Haass and Selkoe, 2007), (Puzzo et al., 2008).   
The link between Aβ levels and its influence on learning and memory has been 
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supported by several in vivo studies involving APP knockout mice that show 
impairments in memory and LTP (Seabrook et al., 1999).   These studies have 
provided one focus of disease modification strategies pertaining to drugs that can 
potentially inhibit Aβ formation, a process requiring β and γ secretase activity 
(Selkoe, 1991b), (Hardy and Selkoe, 2002).  The identification of the essential 
enzyme BACE 1, a transmembrane aspartyl protease that is believed to 
contribute to the majority of β-secretase activity, required for the production of Aβ 
in the brain initially provided a novel therapeutic target for the treatment of AD.  
Thus finding effective inhibitors of BACE 1 was an early disease modification 
approach in the development of AD drug targets.  The first BACE 1 knockout 
animal models were initially characterized in 2001, and fortuitously did not show 
any phenotypic deleterious consequence while showing a decrease in Aβ in the 
brain (Roberds et al., 2001), (Dominquez et al., 2001), (Turner et al., 2004).  
Unfortunately, BACE 1 inhibitors have shown little success which may be due to 
the fact that BACE 1 has recently been found to have several endogenous 
substrates.  Upon further investigation it has been revealed that BACE 1 
knockout mice have several deleterious phenotypes including premature death, 
cognitive deficits, and hypermyelination (Dominguez et al., 2001), (Turner et al., 
2004).   
Targeting γ-secretase activity provided yet another disease modifying 
therapeutic approach initially receiving a great deal of attention and support in 
the initial stages of developing drug targets for the treatment of AD.  In vivo 
studies involving γ-secretase and PS1 knockout models reveal the essential role 
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it plays Notch signaling (an important transmembrane protein that is essential 
during development) rendering these animals non viable (Shen, 1998).  Although 
γ-secretase inhibitors can successfully reduce Aβ synthesis, accumulation and 
deposition, they have also been shown to improve cognition.  Blocking BACE 1 
activity also prevents Notch signaling and chronic dosing of this class of inhibitors 
has been shown to have several deleterious effects including changes in the 
spleen, thymus, and gastrointestinal changes (Searfoss et al., 2003), (Milano et 
al., 2004), (Wong et al., 2004).  The expression of both β and γ-secretase is 
ubiquitous and evidence that they maintain important activity in several essential 
physiological processes has limited their potential as viable therapeutic targets 
for AD drug development.   
Another therapeutic strategy that has recently gained more momentum in 
the AD research community as a possible drug target aimed at modifying the AD 
disease process, involves modifying mechanisms of Aβ degradation (as opposed 
to targeting its synthesis through secretase inhibition).  The normal synthesis and 
catabolism of the Aβ peptide has been demonstrated to be a dynamic process 
involving several endogenous β-amyloid degrading enzymes and include a family 
of zinc metalloprotease expressed in the periphery and in the brain.   In contrast 
to inherited FAD, the accumulation of Aβ in late onset sporadic AD, has been 
implicated to be the result of an imbalance between Aβ production and removal. 
This deficiency in the removal process has been attributed to abnormal 
accumulation and formation of Aβ deposits in the brain (Selkoe, 2001), (Saito et 
al., 2003), (Turner et al., 2004).  Deficits in the normal Aβ removal is mediated 
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through several contributing cellular processes, including drainage by diffusion of 
Aβ into the extracellular matrix, low-density lipoprotein related receptor protein 1 
(LRP-1) mediated transport across blood vessels into the circulation acting as a 
peripheral sink (Sagare et al., 2007), (Deane et al., 2009), and enzymatic 
degradation through endogenously expressed proteases (Iwata et al., 2001), 
(Saito et al., 2001), (Saito et al., 2003).   Although a growing number of 
endogenous proteases have been implicated in several studies as having 
amyloid degrading capabilities in vitro, only a small minority of these have been 
identified as major contributing factors in the pathological accumulation of Aβ 
peptides in the brain.  Under normal physiologic conditions the catabolism of Aβ 
is mediated through the activation of neprilysin, endothelin converting enzyme, 
insulin degrading enzyme, angiotensin converting enzyme and matrix 
metalloproteases 2, 6 and 9, all of which belong to a family of zinc 
metalloproteinases (Mentlein et al., 1998), (Carson and Turner, 2002), 
(Mukherjee and Hersh, 2002), (Saito et al., 2003), (Turner et al., 2004), (Mouri et 
al., 2006), (Turner and Nalivaeva, 2007), (Miners et al., 2008).  More recently, 
additional proteases that have been shown to have several cleavage locations 
along the Aβ peptide thus may contribute to maintaining homeostatic Aβ levels, 
include plasmin, mitochondrial peptidasome (PreP) and cathepsins B and D 
(Turner and Nalivaeva, 2007).   
A growing body of evidence from both in vivo and in vitro data, including 
data presented in papers 1 and 2, support the importance of these proteases in 
preventing the aberrant accumulation of Aβ in the brain.  A series of in vitro 
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studies first identified insulin degrading enzyme and neutral endopeptidase (later 
recognized as neprilysin) as proteolytic enzymes capable of cleaving the Aβ 
peptide at multiple sites.  Subsequently, a series of studies published in 2001 
and 2002 by Saido and Iwata et al clearly established NEP as a major modulator 
of Aβ metabolism in the brain (Iwata et al., 2000), (Iwata et al., 2001), (Saito et 
al., 2001), (Iwata et al., 2002).  Furthermore, post mortem analysis of human AD 
brain tissue showed a distinct correlation between increases in Aβ deposition and 
decreases in NEP mRNA levels as well as NEP and IDE protein levels in a 
region specific manner compared to control individuals (Yasojima et al., 2001b), 
(Yasojima et al., 2001a), (Caccamo et al., 2005).   Further investigation into the 
link between NEP and Aβ under normal physiological conditions has attempted 
to identify cellular mechanisms that may modify NEP gene expression in the AD 
brain environment.  Pardossi-Piquard et al, in 2005, proposed that NEP gene 
transcription under normal physiological conditions can be upregulated by the 
βAPP intracellular domain (ACID), the cytosolic fragment generated following 
cleavage of APP by γ-secretase (Pardossi-Piquard et al., 2005).  These data 
support the speculation that Aβ production/degradation may be closely linked but 
does not explain decreased NEP expression in the post mortem AD tissue or the 
net accumulation and deposition of amyloid in late onset AD cases.  Interestingly, 
Jiang and collegues in 2008 provide additional molecular mechanisms that 
contribute to Aβ metabolism, reporting that ApoE, a known risk factor in late 
onset AD, can bind Aβ and promote its degradation (Jiang et al., 2008).  Once 
bound to Aβ it is postulated that the ApoE can acts as a chaperone allowing 
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efflux out of the brain across the blood brain barrier though specific receptors 
LRP1 or VLDL (Poirier, 2000), (Deane et al., 2004), (Zlokovic et al., 2005), 
(Deane and Zlokovic, 2007) or facilitate its degradation by NEP and IDE in the 
late endosome of microglia (Jiang et al., 2008).  The efficiency with which ApoE 
binds soluble Aβ, either facilitating or slowing its degradation, is dependent on 
the lipidation state and specific isoform.  Unfortunately the underlying molecular 
mechanisms modulating this process have yet to be clarified.  The overall 
accumulation and deposition of Aβ, particularly in late onset sporadic AD, is likely 
the result of the additive effects of multiple deleterious events occurring over time 
which influence production, accumulation and fibrillogenesis, and degradation.   
These data are supported by a large number of in vivo studies with 
transgenic animal models to further understand the roles of specific enzymes in 
the catabolism of Aβ.  Initial reports of mice deficient of these enzymes, 
specifically NEP, ECE, and IDE demonstrated significant increases in steady 
state levels of Aβ in the brain.  Eckman and collegues reported that the dual 
knockdown of NEP and ECE resulted in an additive cumulative effect on amyloid 
load in the brain (Eckman et al., 2006).   Additional studies using the direct 
transduction of neurons resulting in the increased expression in a variety of β-
amyloid degrading enzymes including NEP, ECE, IDE, MMP-2 and 9, plasmin 
and cathepsin B were accompanied by the significant reductions in the overall Aβ 
in vitro (Marr et al., 2004), (Mueller-Steiner et al., 2006), (Yan et al., 2006).  In 
vivo studies involving gene transfer methods for the treatment of Alzheimer’s 
pathology using viral vectors have had some success in reducing Aβ deposition 
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by overexpressing Aβ degrading enzymes, including NEP, ECE and IDE and 
more recently Cathepsin B, a cysteine protease also implicated in the lysosomal 
degratory pathway of Aβ peptides (Marr et al., 2004), (Mueller-Steiner et al., 
2006).  The degree to which each enzyme contributes to the overall catabolism 
of Aβ is not entirely delineated.  Some reports identify neprilysin as having the 
most pronounced effect on plaque load in the brain, while others identify MMP-9 
as the most efficient proteolytic enzyme in the degradation of Aβ, compared to 
others, due to its ability to degrade both fibrillar and monomeric forms of Aβ in 
vitro (Eckman et al., 2003), (Yan et al., 2006), (Farris et al., 2007), (Hersh and 
Rodgers, 2008), (Spencer et al., 2008).   
In paper 1 we investigate the effectiveness of overexpessing ECE on 
amyloid load in the more aggressive model of Aβ deposition double transgenic 
APP+PS1 mice using rAAV vectors as a method of gene therapy.  Recombinant 
AAV has become widely used for the transduction of neuronal cells.   AAV is 
nonpathogenic, has low immunogenicity, lacks all viral genes and is capable of 
long term expression in neurons. Thus making rAAV an attractive method for the 
use as a gene therapy vector for neurological disorders (Burger et al., 2005),  
(Mandel et al., 2006).  Moreover, rAAV is currently being examined in a number 
of neurological clinical trials (Mandel and Burger, 2004).  Six weeks post 
intracranial injection of rAAV-ECEHA serotype 5, into the right hippocampus and 
anterior cortical regions, we demonstrated successful transduction of several 
different neuronal cell types in the mouse CNS including CA4 neurons in the 
hilus and CA3 neurons of the hippocampus pyramidal cell layer (paper 1, figure 
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3) .  We also were able to show transduction of neurons in the dentate molecular 
layer, as well as a number of round cells possibly oligodendrocytes.  The positive 
transduction of cells in the CNS although concentrated at the injection sites was 
also evident in regions distal from these regions and was detected in the 
striatum, entorhinal cortex, subiculum, and corpus callosum along the midline of 
the ipsilateral hemisphere.  Additionally, some positive neurons in the 
contralateral left hippocampus were also detected.  These findings are consistent 
with Burger and collegues, and are believed to result from retrograde transport of 
the virus along axonal projections originating in the right hippocampus and 
synapsing in the left hippocampus (Burger et al., 2004).  Positive transduction of 
neurons expressing ECE were evidenced by anti HA immunohistochemistry.  Not 
only were we able to show an increase ECE expression following rAAV 
treatment, but were successfully demonstrate that the transduced neurons show 
a 70% increase in ECE activity compared to control rAAV-GFP animals.  
Furthermore, this increase in ECE activity resulted in significant decreases in 
total amyloid load and congophilic plaque load in these regions (paper 1, figure 5 
and 6).  Our data are consistent with reports that ECE can degrade Aβ in vitro, 
and that partial knockdown of the ECE gene leads to more rapid accumulation of 
Aß in transgenic mouse models (Eckman and Eckman, 2005).   
Our results from paper 1 showed that modification of ECE expression 
through the use of rAAV vectors contributes to degradation of Aβ, ultimately 
decreasing both total Aβ and congophilic load in the brain.  In paper 2 we 
investigate whether overexpression of neprilysin will have an equal or greater 
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effect on Aβ levels.  In vivo data demonstrating NEP contributes to Aβ 
degradation, has been proven by results that show an increase in endogenous 
Aβ levels in a gene dose dependent manner.  Decreased NEP protein 
expression thus contributes to plaque formation and increase CAA levels in NEP 
knockout animal studies (Farris et al., 2007).  Similar results were obtained with 
NEP specific inhibitors that dramatically decrease NEP activity also resulting in 
significant increases in endogenous Aβ levels in mice (Iwata et al., 2001), 
(Eckman and Eckman, 2005), (Iwata et al. 2001), ( Eckman et al. 2005).   
Previously reported gene transfer studies demonstrated that treatment of amyloid 
depositing APP transgenic mice using lenti virus and AAV to overexpress NEP 
could significantly decelerate/decrease amyloid accumulation (Marr et al., 2003), 
(Iwata et al., 2004); (Iwata et al 2004), (Marr et al 2003).  
In Paper 2 we investigate both the effectiveness of rAAV to deliver NEP to 
neurons in the mouse brain as well as novel means of increasing dispersion of 
the virus and gene product to therapeutically relevent regions within the mouse 
CNS.  Specifically, we examine transduction efficiency and area of distribution of 
two different NEP constructs (a membrane bound or an engineered secreted 
form; NEP-n and NEP-s respectively) in the hippocampus and anterior cortex.   
Conclusively, we compared the effects of overexpression of both NEP enzymes 
on amyloid burden.  Unlike previous gene transfer studies aimed at modification 
of AD pathology, we administered rAAV by convection enhanced delivery 
method, initially described by Krauze and collegues, in an effort to increase the 
dispersion of the rAAV to larger regions in the brain parenchyma to improve gene 
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transduction efficiency and increase levels of NEP protein expression to obtain a 
larger global effect on total amyloid burden.    
Six weeks post injections of rAAV vectors administration into the right 
hippocampal and anterior cortical regions, we were able to obtain successful 
gene transfer NEP constructs which include those previously mentioned, NEP-n 
and NEP-s as well as an inactive mutant NEP (NEP-m) construct.  We were able 
to transduce a variety of neuronal cell types similar to those reported in paper 1 
due to the fact that we used the same AAV serotype 5.  Positive NEP expression 
revealed by anti-HA immunohistochemistry showed staining concentrated in 
areas at the site of injection in the hippocampus and anterior cortex as well as in 
sites distal from the injection site.  NEP protein expression was evident 
thoughout the entire hippocampus and some staining was observed in the 
entorhinal cortex in the right hemisphere (ipsilateral to the injection site).  Miminal 
staining was also observed in the contralateral hippocampus of animals receiving 
the NEP-n and NEP-m rAAV.  Staining was also seen in the striatum and corpus 
callosum and to small extent in the ipsilateral hemisphere along the midline.   
The staining for NEP-n and NEP-m was greater in intensity covering a larger 
region both in the hippocampus and anterior cortex compared to the staining for 
NEP-s (Paper 2, Fig. 2A and 2C).  The NEP-s construct was engineered, through 
modification of the membrane binding sequence to instead encoding a signal 
peptide sequence in the hopes of creating a nucleus from which the expressed 
protein could diffuse to greater regions of the brain; thus eliminating the 
requirement for a large number of injections.  The NEP-s expression profile 
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revealed less intensity of HA staining when compared to the NEP-m and NEP-n 
staining patterns.  Cells within the hilus of the molecular layer were stained as 
were as cells in the CA3 region of the hippocampus.  Although the NEP-s 
showed less intense staining this may have been due to the diffusion of the NEP 
protease throughout the extracellular matrix.   Diffuse secreted NEP protein may 
not be concentrated in a specified region, making it more difficult to detect using 
anti-HA immunohistochemisty compared to the membrane bound NEP-n 
protease.  An alternative explanation for the NEP-s staining pattern may be that 
once the NEP-s is secreted the NEP protein or possibly the HA-tag is more prone 
to degradation by other extracellular proteases that is would not otherwise be 
exposed to upon secretion not necessarily that this vector had lower transduction 
efficiency.   
Although NEP-s staining was significantly less intense (compared to the 
other constructs), the anterior cortex showed significantly more intense staining 
compared to the hippocampus.   This result may indicate that the signal peptide 
is processed more effectively in the cortex compared to the hippocampus.  
Despite the differences in staining intensity of the different NEP proteins, in vitro 
data confirmed that both NEP-n and NEP-s proteases showed significant levels 
of enzyme activity in the cell pellet, while the NEP-m version did not.  
Additionally, only the media from NEP-s transfected cells showed significant 
enzyme activity.  The in vitro activity data was further corroborated with results 
from our examination of amyloid burden in APP+PS1 mice following treatment 
with the rAAV NEP constructs.  NEP-n and NEP-s were able to significantly 
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reduce total Aβ deposition and congophilic deposits in the anterior cortex and 
hippocampus at the site of injection.    Examination of Aβ staining in the 
contralateral hemisphere revealed that NEP-s rAAV significantly decreased total 
Aβ load in hippocampus and cortex compared to the control group.  NEP-n 
treated animals showed significant decreases in total Aβ in the contralateral 
anterior cortex but not the hippocampus.  More, interestingly, examination of 
congophilic staining on the contralateral hippocampal side revealed there was 
approximately 40% and 50% reductions with the NEP-n and NEP-s treatments 
respectively, but only the reduction with NEP-s was statistically significant 
compared to the control group.  No reductions in congophilic staining were 
observed in the contralateral anterior cortex with either NEP constructs. The 
reduction on the contralateral hemisphere observed here is likely due to 
retrograde transport of the rAAV which has been previously reported (Burger et 
al., 2004; Iwata et al., 2004) and anterograde transport of the NEP protein.  No 
expression was detected in the contralateral cortex which may be due a 
decreased number of neuronal connections between the right and left cortices 
compared to those in the hippocampus.  This may explain our results which show 
a reduction in congophilic staining in the contralateral hippocampus and not the 
contralateral anterior cortex.  We were also able to demonstrate decreases in 
amyloid load in aged 20 month old APP+PS1 mice following overexpression of 
NEP-s for five months (injections were administered bilaterally at 15 months).  
Total Aβ was reduced significantly in the left anterior cortex as well as in the left 
and right hippocampus following treatment with the NEP-s vector compared to 
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control untreated animals.  Total congophilic staining was also significantly 
reduced in both contralateral and ipsilateral hemisphere in the hippocampi and 
cortices following intracranial administration of rAAV-NEP-s.  Our results reported 
here in paper 2 are consistent with data previously reported by Iwata et al in 
2004 using rAAV to overexpress NEP in young and old APP transgenic mice 
(Iwata et al., 2004).  Our results also revealed that we were able to show more 
substaintial decreases in Aβ load in both the ispilateral and contralateral 
hemisphere’s following NEP overexpression in the more aggressive amyloid 
depositing double transgenic mouse model in both young and old animals.  
Additionally, we demonstrate reductions were not limited to soluble forms of Aβ 
but signifcant reductions in congophilic load as well.  An explanation for 
decreases in congophilic staining may be that NEP degrades oligomeric and 
monomeric soluble Aβ aggregates (Kanemitsu et al., 2003), (Yan et al., 2006), 
generally believed to be the toxic precursors to fibrillar insoluble aggregates 
preventing accumulation rather than actively degrading existing deposits.  
Ultimately, the engineered NEP-s construct was more efficient in decreasing 
fibrillar Aβ load in the contralateral hemisphere compared to the NEP-n and 
control vectors, while the NEP-n more efficiently decreased total Aβ load, in the 
ipsilateral hemisphere.  As previously mentioned our findings showed that by 
implementing the use of a secreted form of the NEP protease in addition to using 
the CED method for intracranial administration, we were able to successfully 
improve the area of gene expression and further reduce amyloid load in the 
brain.  We speculate that these findings result from the ability of NEP-s to diffuse 
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readily throughout the extracellular matrix upon secretion therefore obtaining 
access (more readily than membrane bound NEP-n) to both intracellular and 
extracellular pools of Aβ aggregates.       
The AAV 5 serotype has previously been shown to effectively transduce 
non-dividing neuronal cells as well as glial cells in the mouse brain.  Our data 
support this finding, demonstrating that by using rAAV serotype 5 expressing 
different human gene constructs of NEP or ECE; we can transduce several 
different neuronal and glial cell types.   The expression profiles for the gene 
transfer experiments in papers 1 and 2 are also consistent with the previously 
published serological specificity of the AAV vectors (Alisky et al., 2000), (Burger 
et al., 2004), (Choi et al., 2005).  Although the transduction of specific cell types 
were similar between study animals receiving ECE constructs and NEP 
constructs the staining patterns within the neurons were different.   Unlike ECE, 
staining patterns for NEP revealed less intense staining in the cell bodies in the 
dentate molecular layer compared to the corresponding axonal projections of 
these cells which were very darkly stained.  These results are consistent with 
data published by Huang et al. and Iwata et al., describing the normal neuronal 
metabolism of NEP processing first in the endoplasmic reticulum then in golgi 
apparatus of the cell body and finally transported along the axon via vesicles to 
the synaptic terminal (Iwata et al., 2004); (Iwata et al 2004), (Huang et al., 2006).  
Although we demonstrate that both ECE and NEP significantly decrease amyloid, 
due to the differences in injection methods we cannot directly compare the 
efficiency by which ECE and NEP decrease Aβ load in the APP+PS1 aminal 
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model.  Despite this caveat, we can conclude that by implementing novel the 
CED delivery method in addition to modification of the NEP construct directing its 
secretion allowed significantly increased area of vector distribution thus exposing 
more cells to viral infection and ultimately enhancing gene expression levels 
following a single intracranial injection.  Due to the differences in localization of 
endogenous amyloid degrading enzymes, a list which is continually growing, it is 
likely that they each contribute to the normal catabolism of Aβ maintaining its 
basal levels in the brain.  In vitro studies have identified that each of the 
proteases have distinctive Aβ cleavage sites that yield unique fragments (Iwata 
et al., 2001)(Yan et al., 2006), (Nalivaeva et al., 2008).  Additionally, some 
proteases, including NEP, IDE, ECE and ACE have been shown to only degrade 
monomeric soluble Aβ.  NEP can also degrade toxic oligomer forms and still 
others including plasmin and MMP-9 have been shown to degrade fibrillar Aβ.  It 
is therefore likely that the different proteases play an additive role in maintaining 
homeostatic endogenous levels of Aβ in the brain degrading different pools of Aβ 
aggregates ultimately preventing deposition.    
Although we have identified rAAV as a potential gene transfer method 
through which we can upregulate amyloid degrading enzymes to modify AD 
pathology in vivo, there are limitations and obstacle that must be overcome to 
make gene therapy a more attractive therapeutic approach in the clinic.  One of 
the current limitations of gene therapy is obtaining reliable gene transfer 
techniques that will provide therapeutically relevant levels of gene product.  
Specifically, with the treatment of neurological disorders, methods involving a 
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direct intracranial injection are limited due to gene transduction and expression 
being confined to a very small region primarily at the site of injection.  This 
limitation would require numerous injections to overcome the site specific 
expression of the gene of interest adding to potential complications.  We address 
this issue in paper 3 through the investigation of several novel mechanisms 
aimed at enhancing gene transduction efficiency and improving distribution of 
viral vectors within the parachyma to increase gene product.  Specifically, we 
investigated the different transduction characteristics of three different serotypes, 
AAV5, AAV8, and AAV 9 each of which express GFP (green fluorescent protein) 
in the mouse CNS.  Additionally, we implemented a novel “convection enhanced 
delivery technique” using a slightly modified reflux free cannula design (Krauze et 
al., 2005a) to dispense AAV directly into the brain parenchyma.  Finally, we 
attempt to optimize the CED injection method and distribution parameters by 
using a reflux free cannula design in addition to pre-treatment with hyperosmotic 
mannitol, an agent that decreases intracranial pressure, administered by 
intraperitoneal injection.   Previous reports have demonstrated CED, which 
employs positive pressure and a high flow rate, to dramatically facilitate 
widespread distribution of AAV within the parachyma following a single 
intracranial injection (Bankiewicz et al., 2000), (Cunningham et al., 2000).  In 
addition we have modified the CED cannula using a step design (Krauze et al., 
2005a) which we have customized to provide a more efficient method to prevent 
reflux of AAV suspension following administration (paper 3, materials and 
methods).  A comparison of AAV vectors revealed that each AAV serotype 
 171
showed distinctly different transduction patterns with AAV 9 being the most 
efficient transducer of neurons in several brain regions in the ipsilateral 
hemisphere as well as the contralateral hemisphere (paper 3; figure 2).  AAV 5 
was the least efficient and showed the smallest region of vector distribution and 
GFP expression, while AAV 8 showed similar patterns of transduction to AAV 9 
but showed a decreased amount of GFP expression.  Our findings as well as 
others confirm that AAV 9 has significantly higher transduction efficiency in 
neurons in the CNS compared to AAV 8 and AAV 5 (Cearley and Wolfe, 2006).  
The differences in transduction patterns may be a result of different binding 
affinity to specific cell surface receptors as well as un-packaging and post-entry 
properties of each serotype (Hauck et al., 2004), (Wang et al., 2007).  We 
speculate that in this study the efficiency of AAV 9 transduction of neurons may 
be due to its effective and stable binding to cell surface receptors possibly the 
LamR receptor or other potential receptors.  It may also be that specific capsid 
proteins allow AAV 9 to be taken up by the cell more efficiently followed by more 
efficient translocation and viral uncoating and un-packaging within the nucleus of 
the neuronal cell and efficient DNA replication and expression properties.  
Additionally, anti-GFP immunohistochemistry revealed that AAV 9 treated 
animals had the most intense darkly stained pattern of both cell bodies and 
axonal projections, compared to animals treated with AAV 5 or 8.  These results 
may indictate that cells tranduced with AAV9 may be producing more GFP which 
is later transported via vesicles within the cell body and along axons to regions 
that have connectivity with the injection site in both the ipsilateral and 
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contralateral hemispheres.  Another possible explanation for the high 
transduction efficiency of AAV 9 recently proposed by several research groups, 
may be that more than one AAV 9 virion can transduce a single cell and that 
once a viral particle gains entry into the cell it may be easily transported axonally 
to other regions of the brain (Passini et al., 2002), (Burger et al., 2004), (Cearley 
and Wolfe, 2006).  Despite differences in vector distribution and GFP expression, 
all three serotypes appear to primarily transduce neurons, which was proven by 
co-localization of double labeled NeuN, a neuronal marker, and GFP in the 
mouse CNS.  Double labeling of GFP and GFAP, a marker for astrocytes, 
showed no co-localization of the two proteins indicating that AAV did not 
tranduce astrocytes.  These data are consistent with previous reports of AAV 5, 8 
and 9, transduction patterns in the murine CNS (Burger et al., 2004), (Davidoff et 
al., 2005), (Broekman et al., 2006), (Cearley and Wolfe, 2006).  A clear 
understanding of AAV characteristics that mediate cellular mechanisms 
underlying viral infectivity of specific cell and tissue type would advance efforts to 
create tailored recombinant AAV vectors with disease modifying specificity.  
 Once AAV 9 was identified in our study as having the highest transduction 
efficiency in the mouse CNS following a single CED intracranial injection, we 
investigated the effects that mannitol had on vector distribution.  We determined 
that systemic pre-treatment with hyperosmotic mannitol significantly improved 
vector distribution of AAV.   Previous reports have demonstrated improved 
distribution of AAV 2 following direct intracranial injection into the striatum 
(Burger et al., 2004) and thalamus (Fu et al., 2003) with intravascular 
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administration of mannitol or co- administration with rAAV into the parachyma 
(Mastakov et al., 2002).  The effects of hyperosmotic mannitol in previous studies 
has been reported to cause an efflux of water out of surrounding tissue or brain 
cells and increasing the porosity of the extracellular matrix (Rapoport, 2001), 
(Neeves et al., 2007).   Additionally, in 2002, Sandberg and collegues 
investigated the affects of mannitol administration on CED delivery in the rat 
brain stem and did not find significant differences or improved distribution 
parameters for CED with either systemic administration or co-administration of 
mannitol.  We assert that this may have been due to the slow infusion rate, 
0.1µl/min, or the large molecula size of the molecule delivered (FITC-dextran) 
(Sandberg et al., 2002).  In contrast, we use a high flow rate (2.5 µl/min) to 
administer very small AAV vector particles to the hippocampus resulting in 
widespread distribution of AAV throughout the entire hippocampal region and to 
regions distal to the site of injection in both the ipsilateral and contralateral 
hemispheres (paper 3; figures 3 & 4).   
The efficacy and safety profile of the CED technique has been well 
established in both animal studies and in human trials (Laske et al., 1997), (Chen 
et al., 1999), (Bankiewicz et al., 2000).   In recent years the CED method has 
gained acceptance and popularity as an extremely effective method to enhance 
delivery of an expanding list of different molecules with wide range molecular 
sizes including therapeutics agents, proteins, macromolecules, viral vectors, and 
nanoparticles in the brain (Cunningham et al., 2008), (Kikuchi et al., 2008), 
(Perlstein et al., 2008), (Song and Lonser, 2008), (Patel et al., 2009).  Most 
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recently, this novel technique has been implemented in several clinical trials to 
delivery therapeutics agents for the treatment of Parkinson’s disease and 
glioblastoma multiform (Lopez et al., 2006), (Vogelbaum, 2007), (Vogelbaum et 
al., 2007).   Despite its clinical efficacy, the parameters under which CED can be 
optimized providing further distribution are still under investigation.  Our data are 
consistent with previous reports describing significantly improved distribution of 
rAAV in the parenchyma.  We also demonstrate that by combining the CED with 
mannitol further enhanced distribution parameters for CED administration of AAV 
particles.  In addition to CED and mannitol, investigators have used co-infusions 
of heparin with rAAV 2 (Mastakov et al., 2002) (Nguyen et al., 2001)  (Hadaczek 
et al., 2006) or bFGF (basic fibroblast growth factor) (Hadaczek et al., 2004) to 
significantly increase viral distribution in the CNS.   Presumably, these molecules 
increase viral spread by preventing or limiting the interaction between the virion 
particle and its cellular receptor or co-receptor thus masking the a significant 
portion of the potential viral receptors, thereby increasing the number of cells that 
can potentially be infected by decreasing the cells that undergo infection by 
multiple virion particles (Mastakov et al., 2002).  Unfortunately, due to the 
potential risks of these agents they may have little clinical appeal but identifying 
an alternative method of improving viral spread in the CNS by mediating cell 
surface receptor interactions is a viable approach to improving rAAV efficiency.     
 Overall we provide convincing evidence that Aβ levels can be modified 
through regulation of endogenous β-amyloid degrading enzymes in the brain, 
which suggests that these enzymes contribute to the normal catabolism of Aβ 
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peptides preventing its accumulation and deposition.  Moreover, we show that 
significant up-regulation of these enzymes specifically NEP and ECE can be 
achieved through gene therapy using rAAV vectors that provide reliable, stable 
gene expression and viable gene product with significant enzyme activity.  
Furthermore, we demonstrate the potential for the use of rAAV as a clinical 
therapeutic in the treatment of AD by providing novel methods that improve viral 
distribution to larger regions of the brain parenchyma, a major obstacle that must 
be overcome in the field of gene therapy.  We demonstrate that optimal injection 
techniques in addition to serotype specific AAV characteristics can significantly 
enhance transduction efficacy and overall disease modifying capacity.  Further 
investigation must be done to fully understand and characterize cellular 
mechanisms underlying viral infectivity of AAV thus unlocking the true potential of 
their use in the treatment of neurological diseases. 
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